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Abstract 
Cardiovascular disease (CVD) remains the leading cause of death in the United Kingdom and is 
associated with a huge burden of morbidity. Within the group of cardiovascular diseases 
coronary artery disease (CAD) is the single largest cause of death. Death rates from CAD have 
been falling since the 1970s predominantly due to a reduction in the prevalence in major risk 
factors such as cigarette smoking. Type 2 diabetes mellitus (DM) is an important risk factor for 
CVD. Type 2 DM is increasing in prevalence and there is concern that this will contribute to an 
increase in the burden of CVD. Reducing cardiovascular risk in patients with type 2 DM has to 
date focussed on tight blood pressure and glycaemic control together with statin therapy to 
achieve tight low density lipoprotein cholesterol (LDL) targets. Recent studies such as 
ADVANCE and ACCORD have highlighted some of the limitations with this approach. 
Important vascular abnormalities underlying the development of CAD include endothelial 
dysfunction and increased arterial stiffness. Some of the mechanisms underlying these 
abnormalities are thought to include increased oxidative stress, inflammation, insulin resistance 
and dyslipidaemia. These processes in patients with type 2 DM are currently not fully 
understood. It is hoped that through increased understanding of these processes new strategies 
for reducing cardiovascular risk in patients with type 2 DM can be identified. 
This study aimed to investigate some of the processes thought to underlie CVD in patients with 
type 2 DM namely endothelial dysfunction, arterial stiffness, oxidative stress and dyslipidaemia. 
Finally this study aimed to assess the impact of two cardiovascular prevention strategies (statin 
therapy and increased physical activity) on these processes believed to underlie the development 
of CVD. 
One hundred and twenty six patients with CAD (36 patients with type 2 DM, 90 patients without 
diabetes) and 80 controls (64 healthy controls and 16 varicose vein controls) were recruited as 
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part of the VASCAB study. In these patients in vivo and ex vivo endothelial function studies 
were performed. Indicators of arterial stiffness were measured using pulse wave velocity and 
pulse wave analysis techniques. Superoxide levels were assessed in vascular tissue, 
mononuclear cells and whole blood. LDL and high density lipoprotein cholesterol (HDL) 
subfractions were analysed in patients with CAD. To assess the impact of intensive statin 
therapy and tight LDL targets, endothelial function and vascular superoxide levels were 
compared in patients recruited as part of the VASCAB study (2007 cohort) to a group of patients 
recruited in 2003. Finally patients attending the cardiac rehabilitation programme following 
surgical revascularisation were recruited to assess the impact of increased physical activity on 
endothelial function and oxidative stress. 
Endothelial function was impaired in patients with CAD compared to controls. In patients with 
CAD, type 2 DM was associated with greater impairment of endothelial function compared to 
patients with CAD alone. Superoxide levels in the vasculature, mononuclear cells and whole 
blood were similar in patients with and without type 2 DM. Type 2 DM was associated with 
significantly lower HDL levels and a preponderance to small dense LDL compared to patients 
without diabetes. Arterial stiffness was increased in patients with CAD compared to controls. 
There was however no significant difference in arterial stiffness in patients with type 2 DM and 
CAD compared to patients with CAD alone. Intensive statin therapy was associated with lower 
LDL levels and improved endothelial function but no change in vascular superoxide levels. 
Following the cardiac rehabilitation programme endothelial function was improved and HDL 
levels increased. There were no changes in levels of oxidative stress. 
Endothelial dysfunction in patients with type 2 DM may partly account for the increased 
cardiovascular risk and worse cardiovascular outcomes seen in this group of patients. Increased 
oxidative stress did not explain the endothelial dysfunction associated with type 2 DM. The 
dyslipidaemia that was associated with type 2 DM (low HLD and small dense LDL levels) may 
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partly explain the increased endothelial dysfunction observed. Targeting endothelial dysfunction 
may therefore be a strategy for reducing cardiovascular risk in patients with type 2 DM. 
Intensive statin therapy and increased physical activity were both associated with improvements 
in endothelial function. The lack of evidence for increased arterial stiffness in patients with type 
2 DM may reflect deficiencies in the methods used for assessing arterial stiffness. However this 
study highlights the difficulties of assessing arterial stiffness clinically and raises questions 
regarding the impact of type 2 DM on commonly used measures of arterial stiffness. 
Future prospective studies assessing the impact of improving endothelial function in patients 
with type 2 DM on cardiovascular outcomes are required.  
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1 Introduction 
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1.1 The clinical context 
1.1.1 Cardiovascular disease  
Cardiovascular disease (CVD) remains the leading cause of death in the United Kingdom and is 
associated with a huge burden of morbidity. The term CVD covers stroke, peripheral vascular 
disease and coronary artery disease (CAD) all of which have the same underlying 
pathophysiology; atherosclerosis. Within the group of CVD, CAD is the single largest cause of 
death. CAD causes over 90,000 deaths a year in the UK; approximately 20% of deaths in men 
and 14% death in women 
1
. CAD is also the most common cause of premature death (death in 
the under 75s) in both men and women 
1
. 
The most important modifiable risk factors for CVD are cigarette smoking and cholesterol levels 
followed by hypertension, diabetes mellitus, abdominal obesity and psychosocial factors. The 
INTERHEART study showed that these risk factors together with dietary factors, levels of 
physical activity and alcohol consumption accounted for 90% of the risk for acute myocardial 
infarction
2
. 
Death rates from CVD have been falling since the 1970s. Over half of this reduction (58%) is 
the consequence of a reduction in cardiovascular risk factors, most notably cigarette smoking
1
. 
The remainder of the reduction can be attributed to improvements in medical management of 
CVD 
1
. The role of diabetes mellitus (DM) in the development of CVD and CAD is of particular 
interest as rates of this condition are dramatically increasing throughout the world. There is 
concern that the increase in type 2 DM may contribute to an increase in prevalence of CVD. 
1.1.2 Type 2 DM  
DM is diagnosed on the basis of elevated blood glucose levels. The current WHO guidelines are 
a fasting glucose level of greater than 7mmol/L or random glucose greater than 11.1 mmol/L
3
. 
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These levels were set based on the levels of hyperglycaemia above which microvascular 
complications specific to diabetes occur (e.g. retinopathy). 
Type 2 DM is the commonest type of diabetes accounting for between 80 and 95% of cases of 
diabetes. Classifying an individual as having type 2 DM remains a predominantly clinical 
diagnosis. Type 2 DM is diagnosed in a patient with hyperglycaemia, no evidence of significant 
insulin deficiency and no evidence of secondary causes of diabetes (e.g. pancreatic 
insufficiency).  
The pathogenesis of type 2 DM is complex but involves both insulin resistance and inadequate 
insulin secretion. Obesity, in particular abdominal obesity is central to the development of type 2 
DM; over 80% of patients with type 2 DM are obese. Blood glucose levels are normally kept 
within tight control. Oral intake is balanced against insulin dependent glucose uptake by muscle, 
adipose tissue and the liver, and glucose production by the liver. Obesity and inactivity reduce 
insulin sensitivity. Increased insulin production by the β-cells of the pancreas are able to 
compensate for this initially, however eventually this is insufficient and blood glucose levels 
start to rise 
4
.  
Type 2 DM therefore develops over many years. It is preceded by a pre-diabetic state that starts 
with abdominal obesity and insulin resistance, followed by marginally elevated blood glucose 
levels, termed impaired glucose tolerance and impaired fasting glucose. Over time if nothing is 
done to halt the process a significant proportion of these patients will go on to develop type 2 
DM 
4
.  
The prevalence of type 2 DM is increasing dramatically, fuelled both by the obesity epidemic 
and the aging population. In 2000 the prevalence of diabetes was estimated to be 171 million 
worldwide (2.8%). Based purely on demographic data and in particular the aging population it is 
projected that by 2030, 366 million people worldwide will have diabetes (4.4%) 
5;6
. This is 
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likely to be an underestimate as the calculations are based on the assumption that current levels 
of obesity remains constant which is unlikely 
6
. The 2009 Scottish diabetes survey reported the 
prevalence of diabetes at 4.3% with 87.4% of people having type 2 DM. Once again this has 
been increasing over the recent years 
7
.  
Type 2 DM is associated with a number of long term complications in the vasculature which are 
divided into microvascular (retinopathy, neuropathy and nephropathy) and macrovascular 
(CAD, stroke and peripheral vascular disease) complications.  
1.1.3 Type 2 DM and CVD  
CVD is the leading cause of death in patients with Type 2 DM accounting for 50-70% of all 
deaths 
8
. Indeed patients with Type 2 DM have the same risk of myocardial infarction as patients 
who have already suffered a heart attack, leading many clinicians to consider type 2 DM to be a 
cardiovascular equivalent 
9
. Similar to the situation in the general population there is evidence 
death rates from CAD in patients with type 2 DM are also falling 
10
. However the prevalence of 
Type 2 DM is increasing rapidly and the concern is that the prevalence of CAD may also start 
increasing in unison with this. Tackling CAD aggressively in patients with Type 2 DM is 
therefore essential. CAD is not only more prevalent in patients with Type 2 DM but when it 
does occur the atherosclerotic lesions are more severe and diffuse 
11;12
.  
Hyperglycaemia partly explains the increased cardiovascular risk associated with type 2 DM. 
however the risk associated with hyperglycaemia is modest compared to the overall 
cardiovascular risk associated with type 2 DM. A 1% increase in HbA1c is associated with 18% 
increase in cardiovascular events 
13
.Other cardiovascular risk factors associated with type 2 DM 
such as hypertension and dyslipidaemia are as, if not more important in the development of 
CVD in type 2 DM. For example blood pressure shows a stronger association with CVD in 
patients with type 2 DM compared to blood glucose levels 
14
. 
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Insulin resistance is also an important cardiovascular risk factor independent of diabetes status 
15-17
. Insulin resistance is associated with a characteristic dyslipidaemia (high triglycerides, low 
HDL and preponderance of small dense LDL particles), hypertension and obesity 
18
. A number 
of interventions can improve insulin sensitivity including pharmacological agents such as 
metformin, increased physical activity and weight loss 
4
. Measures of insulin sensitivity are not 
currently assessed in routine clinical practice, and targeting insulin resistance in the prevention 
of CVD is not currently a clinical priority.  
Current strategies for reducing cardiovascular risk in patients with type 2 DM predominantly 
focus on blood pressure and lipid management together with glycaemic control. The evidence 
behind these strategies will be discussed below. 
1.1.3.1 Hyperglycaemia  
Hyperglycaemia can be assessed by blood glucose levels or glycated haemoglobin (HbA1c). 
HbA1c gives an indication of blood glucose levels over the preceding 6-8 weeks. 
Epidemiological studies have shown that hyperglycaemia, assessed by either HbA1c or blood 
glucose levels, are an important risk factor for CVD 
19;20
. Previous studies had found a linear 
relationship between levels of glycaemia and cardiovascular risk 
20
. A recent large meta-analysis 
however found a non-linear relationship between fasting blood glucose levels and 
cardiovascular risk 
21
. For fasting blood glucose levels between 3.9 and 5.59 there was no longer 
a significant association with cardiovascular risk 
21
. Optimal blood glucose targets for the 
prevention of CVD are not clear. Based on the earlier epidemiological studies it was assumed 
that achieving tight glycaemic control with the aim of near normal blood glucose levels would 
lead to a reduction in CVD in patients with type 2 DM. Many cardiovascular prevention 
guidelines therefore recommend target HbA1c levels of 7% or less 
22-24
. Evidence from a number 
of randomised controlled trials has however questioned this strategy. 
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Managing hyperglycaemia 
Managing hyperglycaemia usually begins with lifestyle interventions such as dietary 
modification and the recommendation to increase physical activity. This is then followed by oral 
agents; three main drug classes of which are currently in widespread clinical use (biguanides, 
thiazolidinediones and sulphonylureas). These can be divided into insulin sensitizers, biguanides 
(metformin) and thiazolidinediones, and insulin secretogogues such as sulphonylureas. Insulin is 
usually added once oral agents fail. 
Based on the epidemiological evidence it was hypothesised that improving glycaemic control in 
patients with type 2 DM would reduce cardiovascular events. A number of randomised 
controlled trials have aimed to test this hypothesis; 4 of the key studies will be discussed below. 
The UKPDS (UK Prospective diabetes study) study began in 1977 and reported in 1998 
compared intensive glucose control compared to conventional treatment in 3867 patients with 
newly diagnosed type 2 DM 
25
. Intensive blood glucose control was achieved with increased use 
of sulphonylureas and insulin compared to conventional treatment. The difference in HbA1c was 
7.0% in the intensive group compared to 7.9% in conventional group. There was no reduction in 
macrovascular disease in the intensive group compared to conventional group. Weight gain was 
higher in the intensive group and episodes of hypoglycaemia more common.  
The ADVANCE study (Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation study) looked at intensive blood glucose control and 
vascular outcomes in approximately 11,000 patients with type 2 DM. Patients were randomised 
to standard glucose control or intensive glucose control 
26
. All patients in the intensive group 
were prescribed the sulphonylurea, gliclazide together with other drugs as necessary to achieve 
an HbA1c of 6.5% or less. The primary endpoint was the combined outcome of major 
macrovascular and microvascular events. After 5 years of follow-up the average HbA1c level in 
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the intensive group was 6.5% compared to 7.3% in the standard group. There was a 10% 
reduction in the combined primary endpoint but this was achieved through a 21% relative 
reduction in nephropathy. There was no reduction in macrovascular events in the intensive 
group. All cause mortality was similar between the two groups. Severe hypoglycaemia occurred 
more frequently in the intensive group. At the end of follow-up mean weight was 0.7kg greater 
in the intensive group compared to standard.  
The ACCORD study (Action to Control Cardiovascular Risk in Diabetes study) also aimed to 
test whether intensive glucose control would reduce macrovascular disease in patients with type 
2 DM 
27
. The study also randomised patients to aggressive blood pressure and lipid control in a 
double two-by-two factorial design. All ten thousand patients were randomised to either 
intensive or standard blood glucose control with the primary outcome non-fatal myocardial 
infarction or stroke or death from any cardiovascular cause. Blood glucose control was achieved 
in both groups through the combination of oral agents together with insulin. Within the intensive 
group there was higher prescription of all blood glucose lowering therapies but in particular the 
use of 3 or more agents, insulin and thiazolidinediones. The study was terminated by the safety 
monitoring committee 17 months early due to the finding of increased mortality in the intensive 
group. At the time the study ended HbA1c levels were 6.4% in the intensive group compared to 
7.5% in the standard group. All cause mortality was significantly increased in the intensive 
group with no reduction in major cardiovascular events. Hypogylcaemia and weight gain was 
more common in the intensive group. 
Finally VADT (Veterans Affairs Diabetes Trial) assessed intensive versus standard control in 
1791 military veterans and once again found no significant effect on cardiovascular death or all 
cause mortality in the intensive group 
28
. The HbA1c was 8.4% in the standard group compared 
to 6.9% in the intensive group. 
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In these studies improved glycaemic control did not result in a reduction in cardiovascular 
mortality and morbidity. Given the epidemiological evidence linking hyperglycaemia and CVD 
these findings are somewhat unexpected and the reasons for this discrepancy are not clear. The 
studies may have been underpowered since in all studies cardiovascular event rates were lower 
than expected. A recent meta-analysis published looking at 33 000 patients in 5 randomised 
controlled trials suggested that improved glycaemic control, as assessed by HbA1c, is associated 
with a reduction in cardiovascular events without an increase in all cause mortality 
29
.  
The increased weight gain and episodes of hypoglycaemia found in the intensive groups may 
also be important. The ACCORD study which found increased mortality in the intensive group 
achieved tight glycaemic control rapidly in patients with long standing diabetes. The risk of 
severe hypoglycaemia was therefore greatest in this study with rates of 24.1% in the intensive 
group compared to 17.6% in the standard group 
27
. Hypoglycaemia is postulated as a cause of 
sudden death in patients with type 1 DM and may be a precipitant for cardiac arrhythmias 
through QT prolongation 
30
. 
The method by which glycaemic control is achieved may be important. Clearly in the 
epidemiological studies low blood glucose levels occur via very different processes to those 
induced during the management of patients with type 2 DM. All the discussed studies used a 
combination of various oral agents with the addition of insulin as necessary. Within the UKPDS 
study a subgroup of overweight patients with intensive blood glucose control using metformin 
showed a reduction in all cause mortality compared to obese patients receiving conventional 
treatment
31
. The metformin group had significantly fewer myocardial infarctions compared to 
obese group receiving conventional management however rates of myocardial infarct did not 
differ from the other intensive therapy groups.
31
. In the more recent studies thiazolidinediones 
were commonly prescribed, particularly in the ACCORD trial 
26
. Recently there has been 
increasing concern with possible increased risk of CVD associated with thiazolidinediones 
32
.  
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At present there is insufficient evidence from randomised control trials to advocate attempting to 
achieve near normal blood glucose levels specifically for the prevention of CV disease in 
patients with type 2 DM. Furthermore in some circumstances tight glycaemic control may 
actually be harmful. 
1.1.3.2 Hypertension  
Hypertension is an important risk factor for CVD and is more prevalent in patients with type 2 
DM. In the general population reducing blood pressure by an average of 12/6mmHg reduces the 
incidence of CAD by 20% with comparable reductions in patients with and without type 2 DM 
33
. The relationship between blood pressure and incidence of macrovascular disease in patients 
with type 2 DM is stronger than the relationship with hyperglycaemia 
34
 Controlling blood 
pressure is therefore one of the cornerstones in preventing CVD in patients with type 2 DM.  
The majority of studies have shown blood pressure to be a continuous risk factor for CVD. With 
the lower the blood pressure the lower the cardiovascular risk and with no level of blood 
pressure which is not associated with further risk reduction
33;34
. When to introduce 
antihypertensive therapy is therefore a balance between benefit and adverse effects of treatment 
and dependant on overall cardiovascular risk. In high risk patients such as those with type 2 DM 
and established CVD lower blood pressure targets are therefore recommended 
22-24
. There was 
until very recently little evidence from randomised controlled trials to support this strategy of 
intensive blood pressure lowering in patients with type 2 DM. The blood pressure arm of the 
ACCORD study aimed to address whether very tight blood pressure targets would reduce CVD 
in patients with type 2 DM
35
. The results of the ACCORD trial showed no benefit with targeting 
systolic blood pressure to less than 120mmHg compared to 140mmHg
35
. In addition, patients in 
the intensive group experienced more adverse events attributed to antihypertensive therapy 
35
. 
The optimal blood pressure target for the reduction of cardiovascular events in patients with type 
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2 DM is therefore not clear however based on the evidence there appears to be little addition 
benefit from tighter blood pressure control.  
Achieving blood pressure control appears to be the more important factor than choice of 
antihypertensive therapy. Meta analysis has failed to show any class of anti-hypertensive to be 
superior in preventing CVD 
33
. There is however a disparity between the expected reduction in 
CVD with blood pressure lowering based on epidemiology evidence and the actual reduction 
achieved in randomised controlled trials 
36
. Much of this evidence comes from early trials that 
used beta-blockers and diuretics raising the question whether newer agents would be superior. 
The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) suggested increased benefit from 
the combination of calcium channel blocker (CCB) with angiotensin converting enzyme 
inhibitor (ACEi) compared to β-blocker and diuretic in a population of patients with 
hypertension and at least 3 other cardiovascular risk factors including type 2 DM 
37
. This 
difference may simply reflect slightly (although not significant) lower blood pressure in the 
CCB/ACEi group. Other possible explanations are improved metabolic profile or differences in 
central pressures with ACEi and CCB combination 
37;38
. What is known is that ACEi and ARBs 
significantly reduce progression of kidney disease in patients with DM 
39
. For this reason 
ACEi/ARBs are commonly used as first line antihypertensives in patients with type 2 DM. 
1.1.3.3 Dyslipidaemia  
Type 2 DM and other insulin resistant states are associated with a typical pattern of lipid 
abnormalities that is characterised by low HDL levels and elevated triglyceride levels LDL 
levels are comparable to those in the general population 
40
. 
LDL cholesterol 
Epidemiological studies have shown increasing prevalence of CVD with increasing levels of 
LDL 
41
. Lowering cholesterol by any means, diet, drugs or even ileal bypass, significantly 
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reduces rates of cardiovascular disease 
42;43
. The majority of the evidence for lowering LDL 
however comes from the numerous “statin” trials. HMG-COA reductase inhibitors or “statins” 
are a safe and well tolerated class of medication that lower cholesterol levels by inhibiting 
HMG-CoA reductase which is the rate limiting step in the production of cholesterol. The meta-
analysis by the Cholesterol Trialists Collaboration, looked at 90 056 participants in 14 statin 
trials
44
. This analysis showed that the 5 year incidence of coronary events, revascularization and 
stroke was reduced by approximately 20% for every 1 mmol reduction in LDL. Importantly this 
reduction in cardiovascular disease was seen irrespective of starting levels of LDL with benefit 
continued to be seen in patients with normal and even low LDL levels. These results were seen 
both in patients with and without diabetes. Increasingly guidelines are therefore recommending 
ever lower targets for LDL levels in patients at high risk of CVD. This includes patients with 
established CVD and patients with type 2 DM (table 1.1). 
Table 1.1. LDL targets for patients at high risk of CVD 
Organisation Most recent LDL 
target 
Previous LDL target 
JBS* <2mmol/L (2005) <3mmol/L (2000) 
Joint Task Force**  <2mmol/L (2007) <3mmol/L (2003) 
AHA/ACC*** <1.8 (2006) <2.6 (2001) 
*JBS; Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical 
practice 2005 
22
 2000 
45
 **Joint task force; Joint Task Force of European and other Societies 
European task force on cardiovascular disease prevention in clinical practice 2007 
24
 2003 
46
. 
***AHA/ACC, American Heart Association, American College of Cardiology Guidelines for 
Secondary Prevention for Patients with coronary and Other Atherosclerotic Vascular Disease 
2006 
23
 2001
47
. 
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Levels of LDL are not higher in patients with type 2 DM compared to the general population. In 
the Framingham Heart Study the prevalence of high LDL levels in men and women with DM 
was 9% and 15% respectively compared to 11% and 16% in men and women without DM 
40
. 
However as LDL is such a strong risk factor for CVD and statins are so efficient and well 
tolerated lowering LDL in patients with diabetes has been a major target for reducing CVD. 
HDL cholesterol  
Low HDL levels are a feature of the dyslipidemia associated with type 2 DM and other insulin 
resistant states. Low HDL levels are an important risk factor for CVD. This relationship was 
first identified in the 1970s through the Framingham heart study and a number of subsequent 
studies since 
48-50
. HDL can be raised by lifestyle factors including weight loss, dietary 
manipulation and increased physical activity 
51-53
. There is currently no pharmacological agent 
available that raises HDL alone. The cholesterol ester transfer protein (CETP) inhibitor 
torcetrapib which specifically raised HDL has been withdrawn due to increased cardiovascular 
events 
54
. Statins have very minor effect on HDL levels
44
. Fibrates, thiazolidinediones and niacin 
can increase HDL to varying degrees but all also have a number of other effects 
55-57
. In 
summary although low HDL is an important risk factor for CVD it is probably one that is not at 
present being adequately addressed in clinical practice.  
1.1.3.4 Other strategies: lifestyle factors: obesity and physical activity 
Lifestyle modification is an important part of the management of type 2 DM. Modifying oral 
intake and levels of physical activity are usually the initial steps recommended for improving 
glycaemic control. Obesity and levels of physical activity are also risk factors for CVD so 
important targets in the quest to reduce CVD 
2;58
. 
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Obesity 
Obesity is defined by a body mass index (BMI) of 30kg/m
2
 or greater
59
. Waist circumference is 
clinically the best method for detecting increased visceral fat
59
. The prevalence of obesity is 
increasing rapidly throughout the world 
60
. Obesity, particularly central obesity is pivotal in the 
development of type 2 DM and is also an important risk factor for CVD 
2;61
. Hypertension, 
dyslipidaemia and type 2 DM are all more prevalent in people who are obese 
60
. 
The driving force behind the obesity epidemic is a combination of reduced physical activity and 
the greater availability of energy rich foods. This can be illustrated by the dramatic increases in 
prevalence of type 2 DM seen when rural communities migrate to cities and adopt western style 
diets 
62;63
. It therefore follows that the management of obesity should focus on increasing 
physical activity and reducing energy consumption. Studies show that weight loss of only 5%-
10% result in improvements in blood glucose levels, lipids and blood pressure
64
. Even modest 
weight reduction can be extremely difficult to achieve
65
. There is therefore interest in the 
development of pharmacological agents to augment the weight loss that can be achieved with 
lifestyle modification. To date pharmacological agents had little success with rimonabant and 
sibutramine both being withdrawn due to safety concerns
66;67
. The only pharmacological agent 
currently available specifically aimed at tackling obesity is orlistat. Orlistat impairs the 
absorption of fat and only has modest effects on weight loss
68
. Obesity is a cardiovascular risk 
factor that is probably not adequately addressed in the management of patients with type 2 DM. 
Sedentary lifestyles  
For over 50 years it has been recognised that sedentary lifestyles are an important risk factor for 
CVD. In 1953 the now classic epidemiological study by Morris et al.
58
 showed that the 
conductors compared to bus drivers had lower rates of CAD. Furthermore when conductors 
were diagnosed with CAD it tended to be later in life with a lower mortality. This difference was 
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partly attributed to the conductors being more physically active at work compared to bus drivers. 
Since then numerous studies have confirmed a reduction in levels of CVD with increased levels 
of physical activity 
69-71
. Physical activity reduces blood pressure increases HDL and reduces 
risk of type 2 DM, however there also appears to be an independent effect of physical activity 
69
. 
For the prevention of CVD it is recommended that individuals take 30 minutes of regular 
physical activity most days of the week 
22
. The 2008 Scottish health survey estimates only 39% 
of adults met these recommendations
72
.  
1.1.4 Summary 
Type 2 DM is associated with increased risk of CVD. Tackling the traditional risk factors such 
as LDL and hypertension can partly reduce this risk. Hyperglycaemia is an important risk factor 
for CVD but current evidence does not support strict blood glucose lowering for the prevention 
of CVD. Lifestyle factors such as obesity and sedentary lifestyles are important risk factors for 
both type 2 DM and CVD and are therefore attractive targets although ones that are often 
difficult to modify. In view of these difficulties novel strategies for reducing CVD in patients 
with DM are required. 
1.2 Mechanisms underlying CVD: the cardiovascular continuum 
A greater understanding of the mechanisms underlying the development of CVD in patients with 
type 2 DM may help identify novel cardiovascular management strategies. CVD can be viewed 
as a continuum that spans from patients with cardiovascular risk factors, through vascular 
abnormalities such as endothelial dysfunction and arterial stiffness, to the development of 
atherosclerotic lesions and eventually established end stage disease (figure 1.1) 
73
..  
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Figure 1.1 The cardiovascular continuum. (Adapted from Dzau et al. 
73
) 
 
1.2.1 The atherosclerotic lesion 
The underlying pathological abnormality in CVD is the atherosclerotic lesion. Atherosclerotic 
lesions occur in the arterial system predominantly at the sites of bifurcations. Atherosclerotic 
lesions develop slowly over many years, with the initial abnormality; fatty streaks developing in 
adolescence 
74
 . Extracellular deposition of lipids is followed by an inflammatory infiltrate of 
monocytes and T lymphocytes to form fatty streaks 
74
. Monocytes develop in to macrophages 
and scavenge modified lipids to form foam cells 
75
. The inflammatory infiltrate and foam cells 
secrete inflammatory mediators and produce reactive oxidative species resulting in the migration 
and proliferation of vascular smooth muscle cells
76
. This process continues with further lipid 
deposition, inflammatory infiltration and vascular smooth muscle cell proliferation. As the 
lesion develops focal necrosis occurs at the centre; attracting further inflammatory cells and 
formation of fibrous tissue
74
. The lesion is now termed a complex lesion consisting of a fibrous 
cap overlying a core of lipid and necrotic tissue. The lesion may continue to expand producing 
clinical symptoms secondary to gradual reduction in arterial flow. The plaque may also rupture 
with thrombus forming lending to acute occlusion of the vessel
74-77
. 
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Multiple processes are involved in the initial development and progression of atherosclerotic 
plaques. Important processes in the development of atherosclerosis are endothelial dysfunction, 
oxidative stress, inflammation and increased arterial stiffness
74;76;78-80
. Cardiovascular risk 
factors such as dyslipidemia, hyperglycaemia and hypertension are understood to act through 
these processes to contribute to the development of atherosclerosis and CVD
78;79;81
. 
  
 43 
Figure 1.2 The atherosclerotic process (Adapted from Ross
74
). 
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1.2.2 Endothelial dysfunction 
Disruption of the normal endothelial function or endothelial dysfunction is one of the earliest 
steps in the development of atherosclerosis
82;83
. The basic structure of the human vasculature 
consists of adventitial tissue, vascular smooth muscle cells and finally the endothelium. The 
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endothelium is composed of a single layer of endothelial cells and is pivotal in maintaining 
normal vascular function. In health the endothelium maintains the balance between vasodilation 
and vasoconstriction, pro-thrombotic and anti-thrombotic, inflammatory and anti-inflammatory 
processes
82;83
. Production of nitric oxide (NO) is one of the key mediators of these processes. 
NO is produced by endothelial nitric oxide synthase (eNOS) through the conversion of L-
arginine to L-citrulline
78
. NO is a potent vasodilator and the balance between production of NO 
and vasoconstrictors such as endothelin maintains vascular tone. In the vascular smooth muscle 
cells (VSMC) NO activates guanylate cyclase resulting in cGMP mediated vasodilation
78
. In 
addition NO reduces platelet adhesion, leukocyte migration and proliferation of VSMC
78;84
. In 
health these processes are balanced and produce a vascular phenotype that prevents the 
development of atherosclerosis. 
Endothelial dysfunction describes a pathological state in which many of the normal functions of 
the endothelium are disrupted. Impairment of normal endothelial function therefore results in a 
complex array of abnormalities including disruption of normal vaso-regulation, increased 
adhesion and migration of leukocytes, platelet aggregation and vascular smooth muscle cell 
proliferation
83
. All of which as discussed are key steps in the development of atherosclerotic 
plaques. Reduced NO bioavailability is fundamental to the development of endothelial 
dysfunction
84
. The hallmark of endothelial dysfunction is therefore attenuated NO dependent 
vasodilation
85
.  
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Figure 1.3 Endothelial dysfunction (Adapted from Hamilton et al.
79
) 
 
1.2.3 Oxidative stress 
Reactive oxygen species (ROS) are a group of highly oxidative molecules and are produced in 
all cells. They include superoxide (O2
-
), hydroxyl radical (HO
∙
) hydrogen peroxide (H2O2), 
peroxynitrite (ONOO
-
) and lipid radicals among others
84;86
. Of these O2
-
 is one of the most 
important ROS. O2
-
 is the principle ROS produced by the vasculature and inflammatory 
cells
86;87
. In addition O2
-
 produces further ROS through chain reactions. For example, O2
-
 rapidly 
scavenges NO to produce peroxynitrite
84
 Not only does this reduce the bioavailability of NO but 
peroxynitrite itself is highly oxidative
84
. ROS are produced during normal cellular function and 
play a physiological role in intracellular signalling
88
. However due to the highly reactive nature 
of ROS complex antioxidant scavenging systems are in place to keep levels in balance. For 
example O2
-
 is converted by superoxide dismutase to H2O2
88
. H2O2 is converted to water by 
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catalase and glutathione peroxidase
88
. Increased oxidative stress occurs when there is an 
imbalance between the production of ROS and the antioxidant systems that scavenge these 
molecules. Increased oxidative stress can therefore result from either increased production of 
ROS or impaired scavenging systems or a combination of both.  
Increased oxidative stress and ROS exacerbate many of the proatherogenic processes underlying 
the development of CVD. Oxidative stress contributes to the development of endothelial 
dysfunction. ROS such as O2
-
 react rapidly with NO
84;89
. Reduced bioavailability of NO results 
in impaired endothelial function manifested by loss of vasodilation, platelet aggregation and 
inflammation
90
. Increased levels of ROS also potentiate the formation of oxidized LDL a key 
substance in the formation and maintenance of atherosclerotic lesions
91
. Furthermore oxidized 
LDL can itself increase levels of oxidative stress 
91
. ROS exacerbate inflammation in the vessel 
wall through the increased adhesion and migration of monocytes 
92
. Increased oxidative stress 
can contribute to proliferation and migration of vascular smooth muscle cells
90
. 
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Figure 1.4 Oxidative stress (Adapted from Hamilton et al.
79
). 
 
1.2.4 Arterial stiffness 
As part of the aging process vessels become increasingly stiff and this process can be 
accelerated by the presence of cardiovascular risk factors such as hypertension, hyperlipidaemia 
and diabetes
80;93
. The mechanical properties of arteries are complex however in simple terms 
normal arterial physiology protects the microcirculation from pressure-induced damage and 
ensures adequate perfusion of the coronary vessels during diastole
94
. Increased arterial stiffness 
can alter these normal processes and contribute to the development of cardiovascular disease. 
Under normal conditions the aorta transforms the pulsatile on-off blood flow of the left ventricle 
in to less pulsatile flow in distal vessels and smooth non pulsatile flow in capillaries
94
. This 
system protects the microcirculation from damage due to high pressures and ensures the 
coronary arteries have sufficient blood flow in diastole to meet metabolic requirements of the 
heart. The ability of the aorta and proximal arteries to buffer the pulsatile flow during systole 
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depends in part on the compliance of these vessels
94
. The phenomenon of wave reflection also 
plays a role in normal arterial function. Changes in vessel diameter and stiffness occur as the 
arterial tree branches and tapers. This results in reflection of a proportion of the propagating 
pressure wave
95
. In ideal circumstances the reflected wave returns to the central aorta in diastole 
enhancing coronary perfusion. Furthermore wave reflection reduces the transmission of pulsatile 
energy to the microcirculation
96
. Increased arterial stiffness reduces compliance of aorta and 
proximal vessels. This results in a reduction in the buffering properties of these vessels and early 
return of the reflected wave
97
. Reflected waves arriving in late systole increase or augment 
central systolic pressure increasing left ventricular afterload and altering coronary artery 
perfusion
95
. These changes contribute to left ventricular hypertrophy, worsening of coronary 
ischaemia, and increased vessel wall stress with risk of atherosclerotic plaque rupture
96
.  
1.3 CAD and the role of surgical revascularisation 
As discussed CVD encompasses stroke, peripheral vascular disease and CAD all of which have 
the same underlying pathogenesis. The focus of this study will be patients with CAD undergoing 
elective surgical revascularisation or coronary artery bypass grafting (CABG). Patients 
undergoing CABG are an attractive study group for a number of reasons. Firstly they represent a 
group of patients with severe atherosclerotic disease. Secondly they are well phenotyped with all 
patients having undergone thorough investigation including diagnostic angiography to confirm 
the diagnosis of severe CAD prior to surgery. Thirdly there is the opportunity to obtain samples 
of the by-pass grafts for ex vivo studies that are surplus to clinical requirements.  
Revascularisation techniques, either percutaneous or surgical, for patients with established CAD 
have become an important and effective management option. For most patients with left main 
stem coronary artery lesions or triple vessel CAD surgical revascularisation is the treatment of 
choice
98
. Approximately 1600 patients undergo CABG in Scotland annually. In 2009, 45.7% of 
 50 
patients undergoing CABG had triple vessel disease and 42.1% had left main stem lesions. 
Approximately 24% of these patients had diabetes
99
. Overall short and long term outcomes 
following CABG are good. In patients undergoing CABG in Scotland in patient mortality is 
2.3%, with 10 year survival of 26.3%
99
. These rates are similar to those reported in other 
studies
100;101
. Both short and long term outcomes are worse in patients with diabetes compared to 
patients without diabetes
101-103
. CABG in patients with diabetes is however associated with 
improved long term survival compared to percutaneous intervention
101;103
. CABG is therefore 
the management of choice for patients with diabetes and multivessel CAD
104
. 
1.4 Study aims and objectives 
Type 2 DM is associated with increased cardiovascular risk. Recent studies such as ACCORD 
and ADVANCE have highlighted some of the limitations with current cardiovascular prevention 
strategies for patients with type 2 DM. This study has three broad aims. By studying patients 
with severe CAD undergoing CABG this study firstly aims to investigate some of the 
mechanisms underlying cardiovascular disease and secondly to assess the impact of type 2 DM. 
Finally the effect of two CV prevention strategies on these mechanisms will be evaluated. 
Chapter 3 focuses on the assessment of arterial stiffness. Arterial stiffness is understood to play 
an important role in the development of CVD. Clinical assessment of arterial stiffness may assist 
in the management and prevention of CVD. The hypothesis was that patients with CAD would 
have increased arterial stiffness compared to healthy controls. Secondly patients with CAD and 
type 2 DM would have increased arterial stiffness compared patients with CAD alone. 
The aims of chapter 3 were therefore: 
1. To use pulse wave velocity (PWV) and pulse wave analysis (PWA) techniques to assess 
indicators of arterial stiffness in patients with CAD compared to healthy controls. 
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2. To use PWV and PWA techniques to assess indicators of arterial stiffness in patients 
with CAD and type 2 DM compared to patients with CAD alone. 
3. To investigate the use of simpler indicators of arterial stiffness such as augmentation 
index compared to aortic PWV (current gold standard for assessing arterial stiffness). 
Since endothelial dysfunction is understood to be a pivotal process underlying the development 
of cardiovascular disease this is the focus of chapter 4. The hypothesis was to confirm that 
patients with CVD would have impaired endothelial function compared to healthy controls and 
secondly to confirm that patients with type 2 DM and CAD would have greater impairment of 
endothelial function compared to patients with CAD alone. 
The aims of chapter 4 were therefore to: 
1) Investigate endothelial function using ex vivo and in vivo techniques in patients with 
CAD compared to healthy controls 
2) In patients with CAD assess the impact of type 2 DM on endothelial function. 
3) To evaluate the use of a non-invasive PWA based technique for assessing endothelial 
function in vivo. 
Chapter 5 focuses on oxidative stress as this is understood to be one of the major mechanisms 
underlying both endothelial function and CV disease. The hypothesis was that patients with 
CAD would have increased oxidative stress compared to healthy controls. Furthermore that 
patients with CAD and type 2 DM would have increased levels of oxidative stress compared to 
patients with CAD alone. 
The aims of chapter 5 were therefore to:  
1) Measure superoxide levels in vascular tissue, mononuclear cells and whole blood as an 
indicator of levels of oxidative stress. 
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2) Compare levels of oxidative stress in patients with CAD compared to healthy controls. 
3) Measure levels of oxidative stress in patients with CAD and type 2 DM compared to 
patients with CAD alone 
4) Evaluate the use of whole blood superoxide as a simple direct measure of reactive 
oxygen species and an indicator of levels of oxidative stress. 
Chapter 6 aims to investigate whether dyslipidaemia in patients with type 2 DM and CAD might 
partially account for the impaired endothelial function found in patients with type 2 DM. The 
hypothesis was that patients with type 2 DM would have lower HDL levels and increased 
triglyceride levels and small dense LDL particles compared to patients without diabetes. 
Furthermore that these abnormalities may partially explain the endothelial dysfunction 
associated with type 2 DM described in chapter 4.  
The aims of chapter 6 were therefore to assess triglyceride, HDL and LDL levels in patients 
with type 2 DM and CAD compared to patients with CAD alone. Furthermore to investigate 
LDL and HDL particle size in patients with CAD and type 2 DM compared to patients with 
CAD alone. 
LDL reduction by statin therapy is a major strategy for management of CVD in patients with 
and without DM; this is the focus of chapter 7. LDL levels are an important risk factor for CVD 
and determinant of endothelial function. Over the years guidelines have recommended 
increasingly tight LDL targets. The hypothesis was that patients managed under these newer 
guidelines would have lower LDL levels, reduced oxidative stress and improved endothelial 
function compared to patients managed during older guidelines. Furthermore that this effect 
would be greater in patients with type 2 DM and CAD who are understood to have greater 
impairment of endothelial function and increased oxidative stress compared to patients without 
DM. 
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The aims of chapter 7 were to assess LDL levels, oxidative stress and endothelial function in 
patients with CAD undergoing CABG in 2007 compared to a group of patients investigated in 
2003. 
Levels of physical activity are low in the general population. Sedentary lifestyles are an 
important risk factor for CVD and type 2 DM. The focus of chapter 8 is therefore the effect of 
increased physical activity on processes underlying CVD. The hypothesis was that in patients 
who attended exercise classes as part of cardiac rehabilitation would have improved endothelial 
function and reduced oxidative stress compared to patients who elected not to attend exercise 
classes. 
The aims of chapter 8 were firstly to assess endothelial function and oxidative stress in patients 
before and after 12 weeks of exercise classes that form part of the cardiac rehabilitation 
programme. Secondly to assess the impact of number of classes attended on these variables.  
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2 Methods 
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2.1 Participants 
2.1.1 VASCAB study 
The CAD group consisted of patients with stable coronary artery disease attending for elective 
CABG. Volunteers were recruited at preoperative assessment clinic at the Western Infirmary, 
Glasgow between October 2006 and February 2008. This clinic took place on a Wednesday 
afternoon and included patients from across the West of Scotland. Patients were recruited the 
week preceding by-pass surgery. Recruits were examined in the clinical research facility at the 
BHF Glasgow Cardiovascular Research Centre (BHF GCRC) the afternoon prior to surgery (the 
day of hospital admission). Patients were asked to avoid large meals for 3 hours prior to 
assessment and to avoid smoking. Patients were asked to take their medication as usual. 
Exclusion criteria were atrial fibrillation, co-existing valvular heart disease, type 1 DM and 
previous CABG. Classification of diabetes was made following case note review and history 
using the WHO guidelines for classification of diabetes
3
. This was done to ensure that patients 
treated with insulin only were not misclassified. 
Two hundred and sixteen patients undergoing CABG were eligible for recruitment into the 
study. Thirty (14%) patients declined to be part of the study upon initial approach in the pre-
operative clinic. Sixty (28%) further patients did not attend the initial appointment at the BHF 
GCRC. Cancellation of appointments was usually the consequence of either a change in the date 
or location for the patients operation. 
The control group consisted of both patients attending for elective VV removal and participants 
recruited from local health clubs. 
Control (or healthy) saphenous veins were obtained from patients attending for elective VV 
removal who were recruited from the vascular surgery unit at Gartnavel hospital during pre-
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operative assessment by the surgical team. Exclusion criteria were previous history of CAD 
(including angina, myocardial infarction and CABG), type 1 or type 2 DM, hypertension 
requiring two or more antihypertensive agents and untreated hypercholesterolaemia. Patients 
were examined 8 weeks after surgery in clinical research facility at the BHF GCRC. 
Patients undergoing surgery for VV tend to be younger with a higher proportion of females 
compared to CABG patients. In view of this a further group of healthy controls were recruited. 
This group were age and sex matched to the CABG patients and recruited from local health 
clubs in response to advertisements. Exclusion criteria were previous history of CAD (including 
angina, myocardial infarction and CABG), type 1 or type 2 DM, hypertension requiring two or 
more antihypertensive agents and untreated hypercholesterolaemia.  
2.1.2 2003 cohort 
The 2003 group consists of patients with CAD and controls attending for VV surgery that were 
studied between February 2003 and February 2004. Detailed history and clinical examination 
was taken between 1 and 7 days prior to surgery. The control groups were used to confirm 
consistency of vascular function and O2
-
 studies between 2003 and 2007.  
2.1.3 Exercise study  
Patients attending cardiac rehabilitation following coronary artery bypass grafting were 
recruited. The rehabilitation assessment clinic was held in the Western Infirmary, Glasgow on 
Friday mornings and run by the cardiac rehabilitation nurses and physiotherapists. Patients were 
assessed in the clinic approximately 6 weeks after discharge following CABG. Detailed 
assessment of the patient’s recovery from surgery was evaluated by the cardiac rehabilitation 
team. Exercise tolerance was then assessed by the physiotherapists using a validated step test or 
shuttle walk test 
105;106
. Cardiac rehabilitation consists of a 10 week programme which includes 
twice weekly exercise classes. The exercise classes are adapted to an individual’s exercise 
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capacity and consist of 15 minutes warning up and down and 30 minutes cardiovascular 
training. Patients are asked to work at 65-80% of age predicted maximal heart rate based on self 
assessment of pulse rate and use of the Borg scale (Borg’s perceived exertion scale).  
Seventy seven patients were eligible for recruitment in to the exercise study. Thirty four patients 
agreed to participate in the study. 
Patients were assessed at BHF GCRC centre prior to commencing cardiac rehabilitation and 
then 12 weeks later. Patients attended the research centre in the morning following an overnight 
fast. 
Assessment of physical activity and functional capacity 
Levels of physical activity were assessed before and after cardiac rehabilitation programme 
using Scottish physical activity questionnaire (SPAQ see figure 10.2 in supplementary data). 
This is based on the more widely used Stanford 7 day recall questionnaire. In the SPAQ the 
language has been modified for use with a Scottish population and to enable the questionnaire to 
be self reported rather than interviewer based. SPAQ has been validated and shown to be a good 
estimate of levels of physical activity compared to objective measures using accelerometers 
107
. 
Functional capacity before and after cardiac rehabilitation was assessed by physiotherapists 
using the shuttle walk test or chester step test
105;106
.  
2.2 Ethics 
All studies were performed to comply with the declaration of Helsinki. All studies were 
approved by the local ethics committee and approval letters are enclosed in section 10. All 
participants gave informed written consent.  
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2.3 Clinical examination  
All clinical studies were performed in the clinical research facility at the BHF GCRC except for 
the 2003 cohort. Details for the clinical examination in the 2003 cohort are provided separately 
below.  
All participants completed questionnaires (see section 10.1 in supplementary data) providing 
detailed information on lifestyle and medical history. Blood pressure was measured according to 
current WHO guidelines. Participants were seated for 5 minutes prior to blood pressure 
measurement. The arm was supported at the level of the heart. Any tight clothing was removed. 
Blood pressure was measured three times using a calibrated oscillometric device (Omron HEM-
750CP). The appropriate cuff size was used to ensure that the bladder encircled at least 80% of 
the arm. The first recording was discarded. The average of the second and third recordings was 
used in subsequent analysis. 
Height was measured with the patient barefoot and to the nearest millimetre. Tanita Body 
Composition Analyzer BC-418MA (Tanita UK limited) was used to measure weight. 
Participants were weighed fully clothed with an appropriate clothing allowance subtracted 
(0.5kg for light summer clothes, 1kg for normal indoor wear). Waist and hip measurements were 
measured using an anthropometric tape measure. Waist circumference was taken as the smallest 
circumference around the abdomen with the participant relaxed. Hip circumference was 
measured as the largest measured circumference at the level of the buttocks. 
In the 2003 cohort detailed history and clinical examination was taken between 1 and 7 days 
prior to surgery. 
2.4 Routine biochemistry 
Venous blood samples were taken using Vacutainer® system. Plasma samples were centrifuged 
and stored at -70
o 
C. Cholesterol, triglyceride, HDL and high-sensitivity C-reactive protein 
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(CRP) assays were performed by the staff (Professor Naved Sattar, Dr Lynne Cherry and Miss 
Christine Gourlay) of the routine lipids section of Glasgow Royal Infirmary. Cholesterol and 
triglycerides were measured using enzymatic colorimetric methods in Roche/Hitachi modular P 
analyser. Very low density lipoprotein (VLDL) and LDL cholesterol results were calculated 
using Friedewald equation (LDL= [total cholesterol]-[HDL]-[Triglyceride]/2.19). VLDL= [total 
cholesterol-LDL]. CRP was measured using particle-enhanced immunoturbidimetric assay 
(Roche diagnostics). 
Glycated haemoglobin (HbA1c) and urinary albumin:creatinine ratio (ACR) were assessed by a 
latex immunoagglutination inhibition method using the Bayer DCA 2000® (Bayer Diagnostics) 
Venous blood glucose was obtained using Accu-Chek® Advantage (Roche Diagnostics). 
2.5 Pulse wave analysis 
Pulse wave analysis (PWA) was performed using the SphygmoCor® device (AtCor medical). 
This system uses a tonometer connected to an electronics module to non-invasively record a 
peripheral pressure waveform. All PWA measurements were performed at the right radial artery. 
The wrist was slightly dorsiflexed and supported, the maximal pulsation of the radial artery was 
located. The tonometer was then placed over the site of maximal pulsation and gentle pressure 
applied. The position of the tonometer was adjusted until good quality pressure pulse tracings 
were obtained. Ten seconds of good quality pulse pressure tracings were then captured using the 
SphygmoCor® software.  
The shape of the tracing was inspected. The shape will change according to the age of the 
patient and cardiovascular risk factors; however the basic features should remain constant 
(figure 2.1). The following were checked in all tracings; an initial sharp upstroke rising to an 
initial peak (T1) followed by a second shoulder (T2) and finally a notch marking closure of the 
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aortic valve. Waveforms lacking these features usually reflect incorrect placement of the 
tonometer and were therefore repeated following repositioning. 
Figure 2.1 Typical Pulse wave tracing (from Williams et al.
38
). 
 
1 
 
 
 
As well as the shape the recording was checked for quality. Quality control indices check pulse 
wave variables are within limits set using the configuration settings and include average pulse 
height, pulse height variation, diastolic variation. The quality index is an indicator of the overall 
quality of the captured data and was calculated by the software by assigning a weighting to each 
of the quality control indices. Recordings with a quality index of 80% or greater were accepted. 
Overlaid recorded data was also checked. This area displays a visual guide to how well 
individual pulses can be overlaid to form an average pulse. This is visually checked to ensure 
little variability. Baseline PWA recordings were made in duplicate. 
T0, time at the start of the waveform. T1, time from start of waveform to first peak. 
T2, time from start of waveform to second peak. ED ejection duration i.e. time form 
start of waveform to closure of aortic valve (incisura) SP, systolic pressure. DP, 
diastolic pressure, PP pulse pressure (SP-DP). P1, difference between the minimum 
pressure and the pressure at T1. ∆ P, Augmented pressure, difference between SP and 
P1. AIx ,Augmentation index, Augmented pressure divided by PP expressed as a 
percentage.  
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For each patient where the PWA tracings were of an acceptable quality the following variables 
from the aortic pressure waveforms were recorded; Time to the peak/shoulder of the first and 
second pressure wave components (T1, T2). The pressure at T1 (P1 height). The pressure 
difference between P1 and the maximal pressure during systole (ΔP or augmentation). AIx; 
augmented pressure as a percentage of pulse pressure (ΔP/PP) x100. Time to reflected wave 
(TR) and ejection duration time from start of waveform to closure of aortic valve. 
2.6 Pulse wave velocity 
Pulse wave velocity (PWV) was measured non-invasively using SphygmoCor® device (AtCor 
medical, model SCOR_Vx, NSW, Australia). The system uses a high-fidelity tonometer (SPC-
301, Millar Instruments) and ECG leads connected to an electronics module to non-invasively 
record a peripheral artery pressure and ECG waveforms. PWV is determined from the distance 
between artery sites and the delay between the R wave in the ECG and the sharp systolic up-
stroke of the pulse wave. 
Measurements were recording in a quiet room at 20
o
C. Participants were asked not to smoke or 
take caffeinated drinks for 3 hours prior to study. Participants were rested for 10minutes supine 
prior to recording commencing. Participants were asked to lie still and refrain from talking 
during the study. The ECG leads were connected and ECG tracing inspected to confirm sinus 
rhythm. Supine blood pressure was measured using a calibrated oscillometric device (Omron 
HEM-750CP).  
2.6.1  Brachial PWV  
The participant’s wrist was slightly dorsiflexed and the radial pulse located. The distance from 
the maximal pulsation of the radial artery to the suprasternal notch was measured. The patient 
was asked to slightly extend their neck and the carotid pulse was located. The distance from the 
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most prominent pulsation of the carotid artery to the suprasternal notch was recorded. All 
measurements were in millimetres (mm) to the nearest mm.  
Pulse pressure wave forms were initially recorded at the radial artery in the right arm using the 
tonometer. Once again the participant’s wrist was slightly dorsiflexed and the maximum 
pulsation of the radial artery located. The tonometer was placed over the maximal pulsation of 
the radial artery and the position adjusted until a good quality waveform was obtained. Pulse 
pressure recordings were then obtained for the carotid artery. With the patients neck slightly 
extended maximal pulsation of the carotid artery was located and pulse pressure tracings 
recorded. Capture time was set at 10 seconds. The Intersecting tangent method was used to 
identify the onset of the pressure pulse. This algorithm uses the point formed by the intersection 
of a line tangent to the initial systolic upstroke of the pressure waveform and a horizontal line 
through the minimum point. Brachial PWV were recorded in duplicate. 
2.6.2 Aortic PWV 
The above method was then employed to obtain aortic PWV readings. The distance from the 
maximal pulsation of the femoral artery to the umbilicus and then to the suprasternal notch was 
recorded. Maximum pulsation of the femoral artery was located and pressure tracings recorded. 
Pressure tracings were then captured from the carotid artery. Aortic PWV readings were also 
recorded in duplicate. 
2.7 Assessment of endothelial function 
2.7.1 Ex vivo assessment of endothelial function; organ bath studies 
Residual segments of saphenous veins were obtained during CABG surgery of patients with 
CAD. Control saphenous veins were obtained from patients undergoing elective VV surgery. In 
the operating theatre vessels were immediately stored in sterile saline solution before being 
transferred to the research laboratories at BHF GCRC. On arrival the vessels were then 
 63 
transferred into Krebs HEPES solution (10mmol) and stored under refrigeration until the 
following day. Directly prior to the experiment, vessels were cleaned of adherent fat and 
connective tissue, and then sliced into rings of 2-3mm length. The rings were transferred onto 
metal hooks and suspended in organ chambers filled with 10ml oxygenated Krebs buffer 
solution (37°; 7.4 pH), containing indomethacin (0.02 mmol/L) to inhibit prostanoid-mediated 
vasoactive
 
effects. The isometric tension studies were performed using a Grass FT03 force 
transducer and displayed using a MacLab dedicated computer. 
After stabilisation at a resting tension for approximately 1 hour, the vessels were activated with 
potassium chloride (KCl) 0.1M. Vessels were then washed out for 30 minutes and the KCl 
repeated. After activation, the vessels were washed out and allowed to rest for 30 minutes before 
any vasoactive agents were added. Resting tension was adjusted to 1g. 
To assess endothelium dependent vasodilation the vessels were pre-contracted with 
phenylephrine 3x10
-6
M before measurement of relaxation to calcium ionophore A23187. The 
dose-response curve to calcium ionophore was then carried out from concentrations 10
-8
 to 10
-
5
M. Calcium ionophore stimulates the synthesis and release of nitric oxide by increasing 
intracellular calcium, and is therefore an endothelium dependent vasodilator.  
To assess endothelium independent vasodilation a dose-response curve to sodium nitroprusside 
(10
-8
 to 3x10
-6
M; David Bull Laboratories, UK) was carried out. Vessels were preconstricted 
with phenylephrine 3x10
-6
M before measurement of relaxation to sodium nitroprusside (SNP). 
SNP acts as a NO donor therefore causing endothelium independent vasodilation. 
Endothelial function studies in both the 2003 cohort and the VASCAB study (2007 cohort) were 
performed under the supervision of the same experienced researcher Dr Carlene Hamilton. 
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2.7.2 In vivo assessment of endothelial function 
In vivo assessment of endothelial function was performed using the methods described by 
Wilkinson et al.
108
 and Hayward et al.
109
. This method uses PWA to assess change in AIx 
following administration of salbutamol (endothelial dependent vasodilation) and GTN 
(endothelial independent vasodilation). Within observer variability of AIx measurement was 
assessed in 10 healthy volunteers. AIx was measured twice on day 1 and then measurements 
repeated 24-48 hours later, to check for validity of repeated AIx measurements.  
Measurements were recording in a quiet room at 20
o
C. Participants were rested for 10 minutes 
supine prior to the recording commencing. Participants were asked to remain still and to refrain 
from talking throughout the test. Supine blood pressure was measured using a calibrated 
oscillometric device (Omron HEM-750CP).  
Basal PWA recordings were made in triplicate according to the methods described in section 
2.1.4. Following the capture of basal PWA recordings 400µg of inhaled salbutamol (Salamol®; 
IVAX, UK) was administered via volumatic spacer device (Allen and Hanburys, Middlesex, 
UK). Salbutamol was administered via the use of a spacer device with assistance from the 
researcher to ensure reliable drug delivery as inhaler devices can be difficult to use without 
practice. 
Salbutamol causes reduced pulse wave reflection
110
. These effects appear to be due to 
endothelial dependent NO release as they are ameliorated with the infusion of the eNOS 
inhibitor L-NMMA
111
. It is likely that salbutamol simulates NO release through the L-arginine 
NO pathway
111
. 
PWA recordings were obtained in triplicate at 5, 10, 15 and 20 minutes following salbutamol. 
These timings are based on the findings by Wilkinson et al.
108
 that the maximal change in AIx to 
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salbutamol occurred at 12±3 and 11±3 minutes in patients with hypercholesterolaemia and 
healthy controls respectively. 
The average peripheral AIx was calculated at each time point. Peripheral AIx was used since it 
was felt to be preferable to use the raw readings rather than central recordings calculated using a 
generalised transfer function. Change in peripheral AIx from baseline was calculated for each 
time point. The maximum change in peripheral AIx from baseline was used as a measure of 
endothelium dependent vasodilation. 
Following salbutamol administration participants were then rested for 5 minutes. A further 3 
PWA recordings were performed. 400µl sublingual GTN (Nitrolingual®, Lipha, UK) was 
administered. GTN is an NO donor resulting in endothelium independent vasodilation 
112
. PWA 
was recorded in triplicate 5 minutes later. The change in peripheral AIx from baseline was then 
calculated. This was used as a measure of endothelial independent vasodilatation. 
2.8 Oxidative stress studies 
2.8.1  Vascular O2- measurement  
Vascular O2
-
 studies in both 2003 and VASCAB study (2007) group were performed under the 
supervision of the same experienced researcher Dr Carlene Hamilton. 
Residual segments of saphenous veins were obtained during CABG surgery of patients with 
CAD. Control saphenous veins were obtained from patients undergoing elective VV surgery. In 
the operating theatre vessels were immediately stored in sterile saline solution before being 
transferred to the research laboratories at BHF GCRC. On arrival the vessels were then 
transferred into Krebs HEPES solution (10mmol) and stored under refrigeration until the 
following day.  
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The following morning blood vessels were carefully dissected
 
free of loose connective tissue, 
divided into 3-4 mm segments,
 
and weighed. The vessels were then incubated in Krebs buffer
 
at 
pH 7.4±0.02.
  
Vascular·O2
-
 was measured by lucigenin-enhanced chemiluminescence. Lucigenin-enhanced 
chemiluminescence is the most commonly used chemiluminescence technique for the detection 
of O2
-113
. When O2
-
 reacts with lucigenin a series of reactions occur culminating in the release of 
a photon. The photon release can then be detected using a scintillation counter. Lucigenin based 
techniques are specific for O2
-
 and have been widely used. One of the major concerns is that 
lucigenin can itself react with oxygen to produce O2
-
 and therefore levels may be overestimated. 
This phenomenon can be partly overcome by using low doses of lucigenin 
114
. Vascular O2
- 
was 
measured
 
in a liquid scintillation counter (Hewlett Packard model Tricarb
 
2100TR) in out of 
coincidence mode with a single active photomultiplier tube. Low dose lucigenin (5µmol/L) was 
used as described by Berry et al.
114
. Counts were obtained at 2 minute intervals and quantified 
with a xanthine/xanthine
 
oxidase calibration curve for·O2
-
 generation. Results were reported
 
as 
pmol min
-1
 mg tissue
-1
. In all experiments, O2
- 
production was measured in paired samples. 
2.8.2 Electron paramagnetic resonance spectroscopy studies  
Electron paramagnetic resonance (EPR) spectroscopy measures the absorption of microwave 
radiation by molecules such as free radicals following stimulation by an electromagnetic field. 
The amplitude of the EPR signal is proportional to the numbers of free radicals in the sample. 
Interactions between the nuclei and unpaired electrons contribute to the magnetic field applied 
by the spectrometer. This results in several peaks being detected by the spectrometer. Since most 
ROS are short lived, compounds that form stable adducts with free radicals have been 
developed. These compounds are specific to one ROS species and produce a characteristic EPR 
spectrum
113;115
. 
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2.8.2.1 Mononuclear cell O2- measurement 
Venous blood was collected using the vacutainer
®
 system in to ethylenediaminetetraacetic acid 
(EDTA) tubes. Samples were kept at room temperature and processing begun within 30 minutes 
of venesection. Total white cell count and differential white cell count were obtained using 
coulter®A
c
·T diff 2
TM 
Analyser (Beckman coulter).  
Mononuclear cells were isolated from venous blood using a Ficoll gradient as described by 
Fortuno et al.
116
. Ten ml of venous blood was diluted with 10ml of 0.9% saline. This diluted 
blood was carefully layered on top of 10ml of lymphoprep
TM
 The sample was centrifuged for 
25minutes at 20
o
C and 800g so as to produce a buffy coat of mononuclear cells between the 
plasma and erythrocytes. The buffy coat was carefully removed and 50ml of phosphate buffered 
saline (PBS) added. The isolated mononuclear cells were washed twice in PBS, through 
centrifugion for 10min at room temperature and 300g. Finally the pellet containing the isolated 
mononuclear cells was re-suspended in 1ml of PBS. For the duration of the study the isolated 
mononuclear cells were kept under soft agitation at 37
o
C using a thermomixer to prevent cell 
aggregation. Total white cell count and differential white cell count were again obtained using 
coulter®A
c
·T diff 2
TM 
Analyser (Beckman coulter). The isolated white cells were then diluted to 
give a final concentration of 5x10
6 
cells/ml. 
Mononuclear O2
-
 levels were detected by electron paramagnetic resonance (Bruker BioSpin e-
scan R, Bruker Corporation) with the spin probe 1-Hydroxy-3-carboxy- 2,2,5,5-
tetramethylpyrrolidine (CPH, Noxygen). CPH reacts with O2
-
 to produce a stable nitroxide 
radical with half life of several hours
115
.  
Basal mononuclear cell O2
- 
levels were recorded initially. 3µl of CPH (final concentration 
500uM) and 2µl of PBS were added to 55µl of the isolated mononuclear cells. The sample was 
mixed and immediately transferred to a thin glass capillary and placed in EPR machine. 
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Instrument settings used were: centre field of 3375G, modulation amplitude of 2.27G, sweep 
time of 5.24s, sweep width of 60G and 10 scans. Counts were recorded once a minute for 10 
minutes and the rate of O2
-
 anion production (counts/minute) was calculated by means of a 
standard curve. Basal O2
-
 levels were recorded in duplicate and the mean of recordings taken. 
Stimulated O2
-
 release was measured using the protein kinase C activator Phorbol 12-myristate 
13-acetate (PMA Sigma-Aldrich Company Ltd). PMA causes NAD(P)H oxidase-dependant O2
-
 
release from mononuclear cells 
116
. 3µl of CPH and 2µl of PMA (Final concentration 3.2uM) 
was added to 55µl of isolated mononuclear cells. The sample was mixed and immediately 
transferred to glass capillary for EPR O2
-
 measurement. Stimulated O2
-
 release was recorded in 
duplicate and the mean of recordings taken. To adjust for slight variations in capillary diameter, 
a note was made of capillary batch number used and result adjusted against standard. Intra assay 
variability, assessed in 3 independent experiments, performing 5 measurements within 90 
minutes after blood collection, was 10%. Inter assay variability, as analyzed in 7 independent 
experiments performing 3 measurements, was 10%. 
2.8.2.2 Whole blood O2-measurement 
Venous blood was collected via the Vacutainer
®
 system in to lithium-heparin tubes and placed 
immediately on ice. Samples were analysed within 30 minutes of venesection. 475µl of whole 
blood was added to 25µl of CPH (final concentration 500uM). Sample was transferred to a glass 
capillary and placed in EPR machine for O2
-
 measurement. Machine settings were: centre field 
of 3375G, modulation amplitude of 2.27G; sweep time of 5.24s; sweep width of 60G and 10 
scans. Whole blood O2
-
 measurements were recorded in duplicate and the mean of readings 
taken. To adjust for slight variations in capillary diameter, a note was made of capillary batch 
number used and result adjusted against standard. 
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2.9 Detailed lipid profiles 
LDL and HDL size and relative proportions in plasma were determined using non-denaturing 
gradient gel electrophoresis using 2-16% polyacrilamide gels (Alamo Gels, San Antonio, TX) as 
previously described 
117
. Using in house standards prepared by density gradient 
ultracentrifugation LDL was divided in to three fractions; LDL I (28.92-31.38nm), LDL II 
(25.88-27.06nm) and LDL III (24.5-25.5nm). The gels were stained with comassie blue and 
scanned using an imaging densitometer (Model GS-700, Biorad, Hemel Hempstead). LDL 
subfraction is reported as a percentage of total LDL. LDL peak particle diameter (PPD) was 
reported as the size of the major LDL subfraction. HDL mean particle diameter (MPD) and 
LDL-MPD were calculated to give the mean diameter across the entire HDL or LDL profile. 
2.10 Statistical analysis  
Statistical analyses were performed using SPSS (version 15; SPSS Inc.,Chicago,IL,USA) 
software. In text and tables, data are expressed as mean ± standard deviation or median 
[interquartile range] as appropriate. Normal distribution of data was examined by the 
Kolmogorov-Smirnov test and by visual inspection of Q-Q plots. Unpaired Student’s t-tests 
were performed for comparison of normally distributed data. Wilcoxon test was used for 
comparison of data that were not normally distributed. Fisher’s exact test was used for 
comparison of categorical data. 95% confidence intervals were calculated for the difference 
between means where appropriate. Paired t-tests were used for repeated measurements in the 
exercise study. Pearson’s correlation coefficients were been calculated where indicated. Multiple 
linear regression analysis was used to investigate determinants of endothelial function in 
chapters 4 and 6. In the full model all variables were forced into the model. In the stepwise 
model variables with a significance of ≥0.1 were removed. A P-value of less than 0.05 (two-
sided) was considered significant. 
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3 Arterial Stiffness 
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3.1 Introduction  
Arterial stiffness refers to important changes in the mechanical properties of arteries that 
contribute to the development of cardiovascular disease (CVD). The ability to assess these 
changes is of interest to help stratify cardiovascular risk and as a therapeutic target. 
3.1.1 Mechanisms underlying increased arterial stiffness 
As the structure of the vasculature changes the mechanisms underlying increased arterial 
stiffness alter. In the walls of the aorta and large arteries varying amounts of elastin and collagen 
are the main determinants of compliance
94
. Alterations in the proportion and composition of 
elastin and collagen that occur with aging and disease contribute to increased arterial stiffness in 
these vessels 
93;118
. In medium size conduit arteries and the microcirculation vascular smooth 
muscle quantity and function is important in determining the compliance and calibre of vessels 
94
. Endothelial function in these vessels therefore may contribute to arterial stiffness 
119
.  
3.1.2 Assessing arterial stiffness 
Arterial stiffness is a concept, a descriptive term, which cannot be absolutely quantified by one 
single measure. There are a number of different variables that can be measured as indicators of 
degree of arterial stiffening. As discussed the causes and underlying mechanisms of arterial 
stiffness vary according to the vessel being studied and this needs to be taken into account when 
interpreting studies. Incorporating simple non-invasive methods of assessing arterial stiffness 
into clinical practice is of interest for quantifying cardiac risk and making arterial stiffness a 
therapeutic target. Indeed the 2007 European Society of Hypertension guidelines recommend the 
use of arterial stiffness measures, aortic pulse wave velocity (PWV), in the assessment of 
patients with hypertension 
120
. The guidelines do however acknowledge that methods for 
assessing arterial stiffness are currently not widely available outside the research setting. For 
assessment of arterial stiffness to become a routine part of clinical practice tests need to be non-
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invasive and easy to perform. Furthermore the tests need to provide valuable prognostic 
information independent of currently available risk factors. The use of PWV, augmentation 
index (AIx) and central pulse pressure (PP) will be discussed below as methods for assessing 
aspects of arterial stiffness in clinical practice. 
3.1.3 PWV 
3.1.3.1 Basic principles and measurement of PWV 
The speed at which a pulse wave travels in a vessel is related to distensibility of the vessel, the 
stiffer the vessel the faster the pulse wave will travel. The velocity or speed off a pulse wave is 
therefore an indicator of arterial stiffness. PWV is obtained by measuring the time for a pulse 
wave to travel a specified distance. In the SphygmoCor® system the pulse wave is captured 
noninvasively using applantation tonometry at a proximal site and a distal site. Time to the foot 
of the wave is measured and gated against the R wave in an ECG recorded simultaneously. The 
distance is then measured and the PWV in m/s can be calculated. Aortic PWV is measured from 
carotid to femoral artery. Peripheral PWV can be measured from carotid to radial or brachial 
arteries or femoral to dorsalis pedis or posterior tibial arteries. Aortic PWV has recently been 
recognised as the gold standard measurement of arterial stiffness 
121
. The utility of peripheral 
measurement of PWV is currently uncertain 
121
. 
3.1.3.2 Aortic PWV and CVD 
Age and hypertension are the most important determinants of aortic PWV 
122
. Aortic PWV is 
increased in patients with cardiovascular risk factors and established CVD 
123
. Other factors 
associated with increased aortic PWV include hypercholesterolaemia, diabetes mellitus (DM), 
endothelial dysfunction and sedentary lifestyles 
124-128
. However the relative contribution of 
these other factors in determining aortic PWV is unclear. Indeed a recent meta-analysis has 
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suggested that other cardiovascular risk factors in addition to age and hypertension only make a 
small contribution to aortic PWV 
122
. 
As discussed the compliance of large vessels such as aorta is principally determined by elastin 
and collagen. Aging is associated with a reduction in both function and quantities of elastin in 
the walls of the aorta 
93
. It is thought that cardiovascular risk factors such as hypertension and 
DM accelerate this process; however the underlying mechanisms are not fully understood. 
Mechanisms thought to be involved include Angiotensin II stimulated collagen formation, 
advanced glycation end products (AGE) and inflammation 
80
. Acute changes in blood pressure 
can also affect aortic stiffness. As blood pressure increases the aorta becomes stiffer due to 
recruitment of collagen fibres 
118
. Short term changes in blood pressure therefore need to be 
taken into consideration when interpreting studies assessing PWV.  
Aortic PWV is a predictor of future cardiovascular events in a number of different patient 
groups including patients with end stage renal failure, essential hypertension and type 2 DM 
129-
132
. Strategies to reduce aortic PWV are therefore a possible therapeutic target in the 
management and prevention of CVD.  
3.1.3.3 Strategies to reduce PWV 
There are limited studies assessing the effect of interventions on aortic PWV and no long term 
outcome studies. Endurance trained male athletes have lower aortic PWV compared to less 
active aged matched men 
126
 The effects of exercise training programmes on aortic PWV are 
however not known. The effect of antihypertensive agents on aortic PWV is also unclear. 
McKenzie et al.
133
 showed no effect on aortic PWV with either angiotenisn-converting enzyme 
inhibitors (ACEi), diuretics, beta blockers or calcium channel blockers (CCB), however this was 
a short term study. In patients with type 2 DM Angiotensin-receptor blockers (ARBs) decreased 
aortic PWV more than CCB and this effect was independent of blood pressure lowering 
134
. 
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Novel agents such as inhibitors of AGE formation and agents that break down AGE cross links 
are of interest although development of these agents has been slow 
135
. 
3.1.3.4 Limitations of aortic PWV 
Aortic PWV is considered the gold standard for assessment of arterial stiffness and is 
recommended in 2007 ESH guidelines for the assessment of patients with hypertension 
121
. 
Aortic PWV is in theory easy to perform but there can be a number of difficulties in certain 
patient groups 
121
. The accuracy of the PWV result is dependent on the accuracy of the distances 
measured 
136
. In the calculation of aortic PWV this can be difficult for a number of reasons. 
Measuring the distances between the femoral pulsation and the sternum may be inaccurate 
particularly in obese patients. In addition the surface measurement that aim to estimate the 
length of the aorta may be inaccurate in more elderly individuals with tortuous aortas. Obtaining 
pulse wave recordings at the femoral artery may also be difficult particularly in overweight 
patients. They are also more intrusive due to the intimate nature of recording femoral 
waveforms. Simpler methods for assessing arterial stiffness are therefore attractive. It is possible 
to calculate brachial PWV by recording the pulse wave at the radial and carotid artery. Certainly 
this would resolve a number of problems seen with aortic PWV, as the distance measurements 
are simpler and recording pulse wave at the radial less technically challenging compared to 
recording femoral waveforms. However in patients with end stage renal failure PWV in 
peripheral arteries had no prognostic value 
137
. In addition it is not clear whether brachial PWV 
correlates well with aortic PWV. Cameron found that only Aortic PWV and not brachial PWV 
correlated with age in patients with type 2 DM 
138
. It is possible that since the brachial artery is 
not affected by CVD to the same degree as the aorta, PWV measurements in this artery do not 
reflect the degree of CVD. Finally PWV gives information only on the speed of pulse wave 
travel and no information on the consequences of this, i.e. no indication of changes in wave 
reflection/central pressures 
118
.  
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3.1.4 Pulse wave analysis 
In addition to measuring the speed of flow in vessels the shape of the pulse wave can give 
information on vascular function and degree of arterial stiffness 
97
. Pulse wave analysis (PWA) 
can be performed through applantation tonometry at the radial artery. A transfer factor can then 
be applied to generate the aortic or central pulse wave 
139
. Alternately waveforms can be 
captured directly at the carotid artery without the need for a transfer function. A number of 
parameters can then be calculated including central blood pressure measurements and AIx 
97
.A 
typical pulse wave tracing using the SphygmoCor® system is shown in figure 3.1. 
Figure 3.1 Typical pulse wave tracing produced by the SphymoCor® system 
 
Sp, systolic pressure, Dp diastolic pressure, Mp, mean arterial pressure, PP, pulse pressure.ms, 
milliseconds. T1 time from start of waveform to first peak. T2 time from start of waveform to 
second peak. TR time to start of reflected wave. P1, difference between the minimum pressure 
and the pressure at T1 AP, Augmentation difference between central Sp and P1. AIx 
augmentation index (AP pressure divided by PP expressed as a percentage).SEVR, 
subendocardial viability ratio. 
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3.1.4.1 AIx 
A number of variables can be obtained from analysis of the waveform however the AIx has been 
proposed as a single reading that provides an assessment of wave reflection and a surrogate 
marker of arterial stiffness 
97
. 
3.1.4.2 Basic principles and assessment of AIx 
AIx is defined as the difference between the second and the first systolic peaks expressed as a 
percentage of the pulse pressure 
97
. In other words AIx is the percentage of the systolic pressure 
wave attributable to wave reflection. AIx depends on the shape of the forward wave and the 
timing of the reflected wave 
118
. The shape of the forward wave is determined by left ventricular 
outflow and elasticity of aorta 
118
. The timing of the reflected wave is influenced by a number of 
factors including gender, height, reflected wave amplitude and vessel stiffness 
96
. So although 
AIx is determined in part by arterial stiffness other factors are also important. AIx has been 
advocated by some to be suitable as a surrogate marker for arterial stiffness 
140
. Whereas others 
advise that AIx has a role in complementing PWV recordings to provide information on the 
consequences of increased PWV on wave reflections and central blood pressures
121
. The use of 
AIx has been much debated and its usefulness in the clinical assessment of cardiovascular risk is 
far from certain 
141
.  
Central blood pressure readings and AIx can be obtained directly from the carotid artery or from 
reading taken at the radial artery with central recordings calculated using a transfer function 
139;142
. Recording good quality waveforms at the carotid artery is difficult and it has been shown 
that the correlation between central AIx obtained from carotid and radial arteries is relatively 
poor 
143
. Most studies therefore use radial measurements and a generalised transfer function to 
produce central readings. The use of a generalised transfer factor to generate central pressure 
readings from peripheral pulse waves was investigated by Chen et al.
139
 in 24 patients 
undergoing cardiac catherization using non-invasive measures at the radial artery and invasive 
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measures in the aorta. These recordings were used to generate a generalised transfer function 
that was able to calculate central aortic pressures from the radial waveform. This generalised 
transfer function was subsequently validated in 400 subjects by Gallagher etc al.
142
. There are 
concerns that this generalised transfer function may not be applicable to all patient groups. Hope 
et al.
144
 showed there was significant error when the transfer function was used to generate 
central pressures compared to invasive measures and this was particularly marked in patients 
with type 2 DM. It was advocated that a specific diabetes transfer function should be used. This 
may also be important in other groups of patients. 
3.1.4.3 Determinants of AIx 
Age, gender, height and heart rate are all important determinants of AIx and need to be taken 
into consideration when comparing AIx between groups 
143;145-147
. Age is a key determinant of 
AIx however this relationship is not linear. AIx increases more in younger individuals 
145
. Some 
studies have shown a plateau in older patients whereas others have reported a decline 
145;148
. This 
is different to the relationship seen with PWV and age in which the increase is more prominent 
in older individuals 
145
. Gender is also an important determinant of AIx with women having 
higher AIx at all ages. 
147
. Part of this difference can be explained by height. Body height is 
important factor determining AIx as with taller statue, wave reflections occur later due to 
increased aortic length 
149
. However height does not fully explain the differences in AIx between 
men and women and the underlying mechanisms are not fully understood 
146
.Heart rate is also an 
important determinant of AIx. There is a significant inverse relationship with AIx with an 
increase of 10 beats per minute being associated with approximately a 4% decrease in AIx 
140
.  
3.1.4.4 AIx and CVD 
The data surrounding the significance of AIx in the assessment of CVD is mixed. AIx has been 
found to be correlated with cardiovascular risk factors 
150
. It is also increased in patients with 
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hypercholesterolaemia 
151
 and inversely related to endothelial function 
128
. Weber et al.
152
 found 
that in patients undergoing diagnostic angiography AIx is correlated with coronary artery plaque 
load. This relationship however was only seen in younger individuals; in patients over 60 years 
this relationship was no longer observed 
152
.The prognostic significance of AIx for the prediction 
of future cardiovascular events is unclear. Increased AIx has been shown to be an independent 
predictor of all cause mortality and cardiovascular mortality in patients with end stage renal 
failure 
153
. In a further study by Weber et al.
154
 AIx adjusted for heart rate was also an 
independent predictor of cardiovascular events in patients undergoing percutaneous coronary 
interventions. However in a substudy of the Australian Blood Pressure trial (ANBP2) Dart et 
al.
155
 found carotid arterial waveforms were not predictive of cardiovascular events in elderly 
women with hypertension whereas brachial pressures were. Chirinos et al.
156
 showed that in 
patients with established coronary artery disease (CAD) augmented pressure was predicted of all 
cause mortality but not AIx. Most recently the Conduit Artery Function Evaluation (CAFE) 
study also found augmented pressure but not AIx was significantly associated with the 
composite clinical endpoint of all cardiovascular events and renal failure 
38
. 
3.1.4.5 AIx and type 2 DM 
There is also a great deal of debate surrounding the use of AIx in patients with DM. The 
presence of increased arterial stiffness as assessed by a number of methods in patients with type 
2 DM is supported by a wealth of data 
157-160
 . In view of the difficulties discussed early with 
measuring aortic PWV particularly in obese individuals it is clear why a simpler method such as 
AIx would be attractive in patients with type 2 DM. The utility of AIx in patients with type 2 
DM is far from clear however. Some groups have found increased AIx in patients with type 2 
DM while others have not. Brooks et al.
161
 found elevated AIx in patients with type 2 DM. 
Whereas Lacy et al.
127
 found no increase in AIx in a group of patients with type 2 DM despite an 
increase in aortic PWV. These findings have been reported by other groups although the reasons 
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underlying this discrepancy are uncertain. Maple-Brown et al.
162
 found no increase in AIx in 
patients with type 2 DM compared to obese individuals without type 2 DM. In this study AIx 
was found to be inversely related to obesity. One mechanism may be dampening of the reflected 
wave through fat, similar to the observation that wave reflection can be reduced by applying 
external pressure to the arm 
163
. Whether this explanation is correct is unclear and whether it is 
part of the explanation for the findings in patients with type 2 DM (the majority of who are 
obese) is uncertain.  
3.1.4.6 AIx and PWV  
Although AIx is partly determined by PWV the relationship between AIx and PWV is not 
straightforward. As already discussed AIx is determined by a number of factors in addition to 
PWV. Yasmin et al.
164
 showed that brachial PWV was weakly correlated with AIx (R=0.29) 
although this relationship was stronger when men and women were analysed separately. A 
number of studies have however shown no correlation between AIx and aortic PWV. Kelly et 
al.
165
 showed that aortic PWV was correlated with AIx but this relationship was no longer seen 
after adjusting for age. Lemogoun et al.
166
 also found no correlation between aortic PWV and 
AIx in healthy men. These findings call in to question the use of AIx as a surrogate for arterial 
stiffness.  
3.1.4.7 Strategies to reduce AIx 
Vasodilator drugs such as ACEi, ARBs and CCB can reduce AIx index to a greater degree than 
other antihypertensive agents
38;167;168. ACEi and β blocker have similar effects on brachial blood 
pressure but ACEi decrease AIx to a greater extent 
167. β blockers have little effect on wave 
reflection but can increase augmented outgoing pressure wave during systole as a result of heart 
rate and timing of systolic ejection 
168
. A sub study of the ASCOT trial, the CAFE study showed 
combination of amlodipine and perindopril was associated with a significantly greater reduction 
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in AIx compared to atenolol and thiazide regime despite similar effects on brachial cuff blood 
pressure 
38
. The combination of ACEi and CCB in the ascot study was associated with improved 
cardiovascular outcomes compared to a β blocker/thiazide based regime 37. In the CAFE study 
although central pulse pressure was significantly associated with cardiovascular events and 
procedures augmentation index was not 
38
.  
3.1.4.8 Limitations of AIx 
Radial artery tonometry is less technically demanding than pulse wave capture at femoral or 
carotid arteries. This is the major advantage of AIx over aortic PWV. In addition AIx provides 
information on wave reflection, an important consequence of increased arterial stiffness. 
However as discussed there are a number of concerns regarding the use of AIx for the 
assessment of arterial stiffness, including the effect of age, heart rate, height and gender, the 
applicability of a generalised transfer function, and the use of AIx in certain groups of patients. 
AIx needs further assessment to determine whether it provides useful information in the 
assessment of CVD.  
3.1.5 Central blood pressure readings; Pulse Pressure 
3.1.5.1 The theory and assessment 
PP is the difference between systolic blood pressure and diastolic blood pressure. PP measures 
the impairment of the buffering function of larger arteries. In addition early return of the 
reflected wave will contribute to increased PP 
169
. PP calculated from cuff measurements taken 
at the brachial artery is the simplest available marker for assessing arterial stiffness 
169
. There is 
however increasing interest in the use of central pressure measurements calculated from non-
invasive pulse wave recordings taken at the radial artery using applantation tonometry as 
discussed above. 
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3.1.5.2 PP and CVD 
Brachial PP is predictive of CVD in healthy individuals , untreated and treated hypertension and 
in patients with type 2 DM 
170-172
. Central PP may be a better assessment of cardiovascular risk 
as brachial PP tends to overestimate central PP in the young and underestimate in the elderly 
169
. 
This is supported by the finding that central PP was a better predictor of carotid intima media 
thickness than brachial PP 
173
. Carotid PP has also been shown to predicted CAD severity more 
accurately than brachial pressure 
174
. Central PP was also a predictor of cardiovascular mortality 
in patients with end stage renal failure 
175
. However Dart et al.
155
 found that central pressures 
were not predictive of cardiovascular events in hypertensive women whereas brachial readings 
were. There is little evidence to support that reducing PP reduces cardiovascular events 
independently of systolic blood pressure
169
.  
3.1.6 Summary 
Arterial stiffness is an important step in the cardiovascular continuum. PWV is the gold standard 
measurement of arterial stiffness and is an important prognostic indicator in patients with CVD 
and is increased in patients with type 2 DM. There a number of technical difficulties with 
measuring aortic-PWV and simpler methods are therefore attractive clinical tools. Two such 
methods are brachial PWV and AIx. The value of these two simpler techniques is as yet not 
clear and further evaluation of these techniques is required. 
3.2 Aims and objectives 
The hypotheses were that patients with CAD would have increased arterial stiffness (as assessed 
by aortic PWV and AIx) compared to controls. Furthermore in a subgroup of patients with type 
2 DM and CAD these markers of arterial stiffness would be increased compared to patients with 
CAD alone. 
The aims of this study were: 
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1. To investigate aortic PWV in healthy controls and patients with CAD with and without 
type 2 DM. 
2. To investigate the correlation between brachial and aortic PWV. 
3. To investigate the use of AIx in patients with CAD with and without type 2 DM.  
3.3 Methods 
PWA and PWV measurement were performed in patients with CAD and healthy controls 
recruited as part of the VASCB study. Detailed descriptions of the methods used are provided in 
chapter 2. 
3.4 Results 
3.4.1 PWA  
Seventy four patients with CAD and 70 healthy controls attended for pulse wave recordings. In 
13 patients with CAD and 7 healthy controls the quality of recordings was inadequate for 
analysis. Demographics and clinical characteristics are shown in table 3.1. Patients with CAD 
were older and the group contained a higher proportion of males compared to controls. 
Prevalence of hypertension was significantly higher in the CAD group although brachial systolic 
and diastolic blood pressure recordings were not significantly different. Patients with CAD were 
more overweight compared to controls as illustrated by higher body mass index. There was 
significant usage of statins, ACEi/ARB, CCB and nitrates in the CAD group compared to 
controls. Biochemistry results are shown in table 3.2. Participants that attended for PWA studies 
were not significantly different from those who did not attend. Demographics, clinical 
characteristics and basic biochemistry for all patients recruited are available in the 
supplementary tables (chapter 10). 
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PWA results are shown in table 3.3. Both brachial and central pulse pressure was higher in 
patients with CAD compared to controls. Heart was slower in patients with CAD compared to 
controls. Time to reflected wave was shorter in CAD patients compared to controls. Augmented 
pressure was higher in CAD group compared to controls. There was no significant difference in 
peripheral AIx, central AIx or central AIx corrected for heart rate between controls and CAD 
(figure 3.2). 
Since the control group contained more women than CAD and sex is an important determinant 
of AIx males were analysed separately (table 3.4). When males were analysed alone there was a 
trend to higher peripheral, central and central AIx corrected for heart rate but this was not 
significant. The male CAD patients had a significantly lower heart rate compared to healthy 
controls and shorter time to first reflected wave. 
PWA results for patients with and without type 2 DM are shown in table 3.5. Once again there 
was no significant difference in peripheral AIx, central AIx or central AIx corrected for heart 
rate. There was no difference in time to start of reflected wave between the two groups. 
3.4.2 PWV  
Of the 74 CAD patients attending for pulse wave recordings brachial PWV results were 
available for 60 patients and aortic PWV for 16 patients. Fourteen brachial PWV recordings and 
18 aortic PWV recordings were rejected due to poor quality. In a further 26 CAD patients there 
was insufficient time for aortic PWV measurements. Fourteen patients with CAD declined to 
have recordings performed at groin. Of 70 controls attending for pulse wave studies, 57 brachial 
PWV were available for analysis (13 rejected due to poor quality) Forty two aortic PWV 
recordings from controls were available for analysis (18 rejected due to poor quality, 10 
participants declined to have recordings performed at groin). Demographics and clinical 
characteristics are shown in table 3.6. Biochemistry results are shown in table 3.7. 
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Aortic PWV was significantly faster in CAD compared to controls (10.16±2.17 vs. 8.42±1.75, 
P=0.003) (figure 3.5). Brachial PWV was significantly slower in patients with CAD compared 
to controls (8.22±1.43 m/s vs. 9.05±1.41m/s P=0.002, figure 3.6). 
In patient with CAD with and without type 2 DM there was no difference in brachial PWV 
8.14±1.67 (n=16), vs.8.25±1.67 (n=44), P=NS. Due to the small number of aortic PWV results 
in patients with CAD it was not possible to compare these groups. 
There was a significant correlation between brachial PWV and aortic PWV (R=0.399, P=0.005) 
When the two groups were analysed separately this relationship only remained in the control 
group (r=0.527, P=0.001). In patients with CAD there was no correlation between aortic and 
brachial PWV (figure 3.7). 
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Table 3.1 Demographics and clinical characteristics for patients with CAD and controls 
undergoing PWA studies 
 CAD (n=61) Control (n=63) P-value 
Age (years) 66.8±9.3 60.0±10.2 <0.0001 
Male (%) 48(78.7) 38 (60.3) <0.0001 
Systolic BP, mm Hg 142.1±20.2 137.8±19.4 NS 
Diastolic BP, mm Hg 78.3±10.4 81.7±10.5 NS 
Heart rate (beats/min) 63.1±9.3 68.3±12.4 0.01 
BMI, kg/m
2
 29.0±4.1 26.1±3.5 <0.0001 
Current smokers (%) 4 (6.6) 3(4.8) NS 
Type 2 DM (%) 17(27.9) 0 n/a 
Hypertension (%) 35(57.4) 16(25.4) 0.002 
Myocardial Infarction (%) 33 (54.1) 0 n/a 
TIA/CVA (%) 3(4.9) 1 (1.6) NS 
Chronic renal failure (%) 3 (4.9) 0 NS 
Heart failure (%) 7 (11.5) 0 n/a 
Aspirin (%) 56 (91.8) 6(9.5) <0.0001 
Other antiplatelet agent (%) 18 (29.5) 1 (1.6) <0.0001 
Statin (%) 56 (91.8) 9 (14.3) <0.0001 
ACEi/ARB (%) 35 (57.4) 6(9.5) <0.0001 
Beta-blocker (%) 47 (77) 4 (6.3) <0.0001 
Calcium channel blocker (%) 25 (41) 3 (4.8) <0.0001 
Nitrate (%) 41 (67.2) 0 <0.0001 
Diuretic (%) 11(18) 5 (7.9) NS 
Oral hypoglycaemic agent (%) 10 (16.4) 0 n/a 
Insulin (%) 4 (6.6) 0 n/a 
Continuous variables are mean± standard deviation. Discrete variables are absolute numbers and 
percentage (%) BP, blood pressure, TIA; transient ischaemic attack, CVA, cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 3.2 Biochemistry results for patients with CAD and controls undergoing PWA 
studies 
 CAD (n=61) Control (n=63) P-value 
Cholesterol (mmol/L) 4.01±0.91 5.71±1.17 <0.0001 
Triglycerides (mmol/L) 1.88±0.91 1.54±0.79 0.026 
LDL(mmol/L) 1.97±0.70 3.50±1.07 <0.0001 
HDL(mmol/L) 1.17±0.27 1.50±0.35 <0.0001 
CRP (mg/L) 4.76±10.74 2.12±2.46 0.036 
HbA1c (%) 6.13±1.12 5.50±0.29 <0.0001 
Urinary ACR (mg/mmol) 3.05±6.79 1.33±0.97 0.045 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C-reactive protein; HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio. 
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Table 3.3 Pulse wave analysis results in patients with CAD and Controls 
 CAD (n=61) Control (n=63) P-value 
Brachial Systolic BP, mm Hg 135.5±17.6 131.7±18.0 NS 
Brachial Diastolic BP, mmHg 74.5±9.5 77.5±10.4 NS 
Brachial Pulse Pressure, mm Hg 61.1+14.2 54.2+12.6  0.011 
Brachial Mean Arterial Pressure, mmHg 94.8±11.7 96.8+12.5 NS 
Peripheral AIx 88.5±12.5 84.6±16.5 NS 
Heart rate, bpm 57.3±7.3  60.6±9.6 0.031 
Central Systolic BP, mm Hg 126.4±17.4 122.8±18.1 NS 
Central Diastolic BP, mm Hg 75.1±9.6 78.5±10.4 NS 
Central Pulse pressure 51.3±13.5 44.3±12.5 0.003 
Central AIx (%) 31.5±7.7 29.0±11.0 NS 
Central AIx corrected for HR (%) 23.1±7.0 22.1±10.8 NS 
Augmentation, mm Hg 16.7±7.6  13.7±7.6 0.036 
P1 height, mm Hg 34.6±7.8 30.6±7.0 0.003 
T1, ms 108.2 ±9.8 112.2±9.9 0.025 
T2, ms 236.6±18.1 240.7±18.9 NS 
TR, ms 140.1±10.7 147.7±15.6 0.004 
ED, ms 338.8±23.8 337.6±21.4 NS 
HR heart rate. T1 time from start of waveform to first peak. T2 time from start of waveform to 
second peak. TR time to start of reflected wave. ED ejection duration ie time from start of 
waveform to closure of aortic valve. Augmentation difference between central SBP and P1. AIx 
augmentation index (Augmented pressure divided by pulse pressure expressed as a percentage). 
  
 88 
Table 3.4 PWA results for males only 
 CAD males only 
(n=47) 
Healthy controls 
males only (n=27) 
Brachial SBP, mm Hg 135.1 ±16.9 136.4±19.0 
Brachial DBP, mm Hg 74.7 ±9.1 78.9± 9.1 
Brachial PP, mm Hg 60.4 ±13.1 57.6± 14.7 
Brachial MAP, mmHg 94.9 ±11.4 99± 11.9 
Peripheral AIx 89.1±13.5 83.7± 15.3 
Heart rate, bpm 56.2 ±6.5* 60.2±6.5 
Central SBP, mm Hg 126.2 ±17.4 126.9 ±19.1 
Central DBP 75.4 ±9.1 79.7 ±9.3 
Central PP 50.8 ±13.3 47.2 ±10.7 
Central AIx (%) 31.6 ±8.3 27.9± 10.7 
Central AIx corrected for 
HR (%) 
22.8 ±7.5 20.9 ±10.0 
Augmentation, mm Hg 16.7 ±8.2 14.0 ±8.2 
P1height, mm Hg 109.5±12.3 113.0 ±14.0 
T1, ms 108.5 ±10.2 112.7 ±10.5 
T2, ms 237.5± 17.9 237.6± 17.4 
TR, ms 140.5 ±11.0** 146.7 ±12.7 
ED, ms 340.1± 24.3 333.2 ±18.7 
*P=0.027 **P=0.031. SBP, systolic blood pressure, DBP diastolic blood pressure, PP, pulse 
pressure, MAP, mean arterial pressure, HR heart rate. T1 time from start of waveform to first 
peak. T2 time from start of waveform to second peak. TR time to start of reflected wave. ED 
ejection duration ie time from start of waveform to closure of aortic valve. Augmentation 
difference between central SBP and P1. AIx augmentation index (Augmented pressure divided 
by pulse pressure expressed as a percentage). 
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Table 3.5 PWA results for patients with CAD with and without type 2 DM 
 CAD and 
T2DM (n=17) 
CAD alone 
(n=44) 
Brachial SBP, mm Hg 135.7±10.8 135.4±19.7 
Brachial DBP, mm Hg 71.5±9.6 75.5±9.3 
Brachial PP, mm Hg 64.1±13.8 59.9±14.4 
Brachial MAP, mmHg 91.8±8.5 95.9±12.6 
Peripheral AIx (%) 85.8±11.8 89.5±12.8 
Heart rate, bpm 59.9±6.5 56.3±7.4 
Central SBP, mm Hg 124.6±9.1 127.1±19.8 
Central DBP, mm Hg 72.1±9.6 76.3±9.5 
Central PP, mm Hg 52.4±11.1 50.9±14.4 
Central AIx (%) 29.7±7.2 32.2±7.8 
Central AIx corrected for HR (%) 22.6±6.8 23.3±7.2 
Augmentation, mm Hg 15.6±5.1 17.1±8.4 
P1 height, mm Hg 36.8±8.7 33.8±7.3 
T1, ms 108.7±9.6 108.0±10.0 
T2, ms 228.5±14.7 239.8±18.5* 
TR, ms 139.9±10.0 140.2±11.1 
ED, ms 332.4±22.4 341.3±24.2 
*P=0.028. T1 time from start of waveform to first peak. T2, duration from start of waveform to 
second peak. TR time to start of reflected wave. ED ejection duration. P1, difference between 
the minimum pressure and the pressure at T1. Augmentation  difference between Systolic 
pressure and P1. AIx Augmentation index augmented pressure divided by pulse pressure 
expressed as a percentage. 
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Figure 3.2 Peripheral AIx in patients with CAD and healthy controls  
 
Figure 3.3 Central AIx in patients with CAD and healthy controls 
 
  
P=NS 
P=NS 
n=63 n=61 
n=63 n=61 
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Figure 3.4. Central AIx corrected for heart rate in patients with CAD and healthy controls 
 
 
  
P=NS 
n=63 n=61 
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Table 3.6 Demographics and clinical characteristics for participants PWV studies 
 CAD (n=60) Control (n=57) P-value 
Age (years) 65.2±9.9 60.1±10.3 0.007 
Male (%) 49(81.7) 30(52.6) 0.001 
Systolic BP, mm Hg 139.4±21.3 138.3±19.4 NS 
Diastolic BP, mm Hg 77.4±11.0 81.7±10.5 0.031 
Pulse Pressure (mmHg) 62.0±15.8 56.5±13.4 0.046 
Heart rate (beats/min) 63.8±11.1 69.2±12.9 0.016 
BMI, kg/m
2
 29.3±4.5 25.8±3.6 <0.0001 
Current smokers (%) 6(10) 4(7) NS 
Type 2 DM (%) 16(26.7) 0 n/a 
Hypertension (%) 32(53.3) 18(31.6) NS 
Myocardial Infarction (%) 34(56.7) 0 n/a 
TIA/CVA (%) 4 (6.7) 1(1.8) NS 
Chronic renal failure (%) 3(5) 0 n/a 
Heart failure (%) 8 (13.3) 0 n/a 
Aspirin (%) 53(88.3) 6(10.5) <0.0001 
Other antiplatelet agent (%) 19 (31.7) 1(1.8) <0.0001 
Statin (%) 56(93.3) 6(10.5) <0.0001 
ACEi/ARB (%) 36(60) 6(10.5) <0.0001 
Beta-blocker (%) 49 (81.7) 5(8.8) <0.0001 
Calcium channel blocker (%) 21(35) 3(5.3) <0.0001 
Nitrate (%) 40 (66.7) 0 <0.0001 
Diuretic (%) 11(18.3) 4(7) NS 
Oral hypoglycaemic agent (%) 12 (20) 0 n/a 
Insulin (%) 4 (6.7) 0 n/a 
Continuous variables are mean ± standard deviation. Discrete variables are absolute numbers 
and percentage (%) BP, blood pressure, TIA; transient ischaemic attack, CVA, cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 3.7 Biochemistry results for healthy controls and patients with CAD in PWV study 
 CAD (n=60) Control (n=57) P-value 
Cholesterol (mmol/L) 4.09±0.93 5.76±1.14 <0.0001 
Triglycerides (mmol/L) 2.03±0.95 1.51±0.84 0.002 
LDL(mmol/L) 2.00±0.73 3.53±1.02 <0.0001 
HDL(mmol/L) 1.15±0.26 1.54±0.40 <0.0001 
CRP (mg/L) 4.33±9.88 1.96±2.23 0.024 
HbA1c (%) 6.19±1.22 5.50±0.30 <0.0001 
Urinary ACR (mg/mmol) 3.15±6.87 1.38±0.99 NS 
All variables mean ± standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C-reactive protein; HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio. 
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Figure 3.5. Aortic PWV in patients with CAD compared to controls 
 
Figure 3.6 Brachial PWV in patients with CAD compared to controls 
  
P=0.003 
P=0.002 
n=42 n=16 
n=57 n=60 
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Figure 3.7 Brachial and aortic PWV 
 
3.5 Discussion 
Arterial stiffness was increased in patients with CAD compared to controls as shown by 
increased aortic PWV, increased brachial and central PP, and shorter time to reflected wave. 
Despite this evidence for increased arterial stiffness in patients with CAD there was no 
significant difference in brachial PWV or AIx between patients with CAD and healthy controls. 
The hypothesis of increased arterial stiffness in patients with type 2 DM and CAD compared to 
patients with CAD alone could not be supported by the available data. There were no significant 
differences in PP (brachial or central) or time to reflected wave in patients with type 2 DM and 
r=0.399 
P=0.005 
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CAD compared to those with CAD alone. AIx was similar in patients with and without type 2 
DM. 
Our finding of increased aortic PWV in patients with established CAD is in keeping with other 
studies. Increased aortic PWV has been found in patients with cardiovascular risk factors and 
established cardiovascular disease 
123
. The difficulties of obtaining aortic PWV recordings have 
been previously discussed and were highlighted in our study by the significant number of 
patients in whom it was not possible to obtain aortic PWV recordings. Brachial PWV with radial 
recordings is simpler to perform and therefore an attractive alternative. The results of previous 
studies question the use of brachial PWV. Cameron et al.
138
 found no correlation between 
brachial PWV and age. Pannier et al.
137
 found that brachial PWV was not predictive of 
cardiovascular events in patients with end stage renal failure whereas aortic PWV was. Although 
there was a correlation between aortic PWV and brachial PWV in all patients studied this 
relationship was not found in patients with CAD when the groups were analysed separately. The 
lack of correlation between PWV measured in peripheral sites is perhaps not surprising as it is 
likely there are different mechanisms contributing to stiffness in different arterial segments. This 
study adds further evidence against the use of peripheral measurement of PWV for the 
assessment of arterial stiffness.  
In addition to aortic PWV a number of other markers of arterial stiffness were significantly 
different in patients with CAD compared to controls. Brachial and central PP was elevated in 
patients with CAD compared to those without. Time to reflected wave was decreased in patients 
with CAD. PP is well established as a marker of arterial stiffness that has previously been shown 
to be elevated in patients with cardiovascular risk factors and predictive of future cardiovascular 
events 
170-172
. Time to reflected wave has been less extensively studied. Time to reflected wave is 
inversely correlated to aortic pulse wave velocity and may be a substitute for PWV
176
. The 
prognostic significance of time to reflected wave compared to aortic PWV is not known.  
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AIx was not significantly different between patients with CAD and controls. There are a number 
of possible explanations for this finding. AIx is affected by a number of physiological variables 
that may account for this finding. There is strong relationship between heart rate and AIx
140
. 
Heart rate was significantly higher in controls compared to patients with CAD. However heart 
rate and AIx are inversely related so a fall in heart rate is associated with an increase in AIx 
140
. 
The faster heart rate in controls therefore should have increased the difference in AIx between 
the two groups. Furthermore when central AIx corrected for heart rate (Central AIx corrected for 
a heart rate of 75 beats per minute by SphygmoCor® software) was analysed there remained no 
significant difference between the two groups. Gender is also an important determinant of AIx, 
with women having higher augmentation index compared to men at all ages 
147
. This is partly a 
reflection of difference in height however there is also an independent effect of sex 
146;149
. Our 
control group contained more females compared to the CAD group which may have resulted in 
increased AIx in this group. When men were analysed alone there was a tendency to increased 
AIx in the CAD group although this was not significant. Age is an important determinant of AIx 
145
. Our control group was significantly younger than patients with CAD, which should again be 
associated with lower AIx. However the mean age in our control group was 60 and CAD group 
65 years. This may account for the high AIx recordings seen in both groups. Weber et 
al.
152
found in patients undergoing diagnostic coronary angiography over 60 years old AIx 
readings were similar in patients with and without CAD and all AIx reading were high. In this 
study AIx recordings were higher in both CAD group and control compared to the study by 
Weber et al.  
Medication use in patients with CAD may have had an impact on AIx. Vasodilators such as 
ACEi/ARBs, CCB and nitrates can reduce AIx and central pressure components to a greater 
extent than brachial blood pressure recordings
38;167
. Therefore despite the similar brachial blood 
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pressure indices between the patients and controls the use of medications such as ACEi and 
CCB in the CAD patients may have lowered AIx in this group.  
There was a trend to increased brachial and central PP and reduced time to reflected wave in 
patients with type 2 DM compared to those without, although these differences were small and 
not statistically significant. It was not possible to assess aortic PWV in patients with type 2 DM 
due to small numbers. It is well established that arterial stiffness is increased in patients with 
type 2 DM 
157-160
. There is less information regarding arterial stiffness in patients with type 2 
DM and established CAD. Lacy et al.
127
 found the time to reflected wave was reduced and aortic 
PWV increased in patients with type 2 DM compared to healthy controls. Time to reflected 
wave was shorter in their patients with type 2 DM 134±1.8 ms compared to our recordings 
139±10ms. Brachial pulse pressure and central pulse pressure were higher in our study in both 
patients with and without diabetes compared to the patients in the study by Lacy et al.
127
. This is 
not surprising given the increased age of patients in this study. There are a number of 
explanations for the findings in this study. The numbers of patients in this study are small and 
this may have been underpowered to detect a difference between the two groups. The recent 
meta-analysis by Cecelja et al.
122
 showed that diabetes status only accounted for a small amount 
of the variability in aortic PWV. The finding of similar AIx in patients with and without type 2 
DM is in keeping with other studies 
127
. The mechanisms underlying this are not fully 
understood.  
Our results highlight the limitations of using simpler surrogates such as augmentation index for 
the assessment of arterial stiffness. Our finding that AIx was not increased in patients with CAD 
whereas other indicators of arterial stiffness were increased adds further evidence to previously 
published studies that question the use of AIx as a surrogate marker of arterial stiffness
127;166
. 
The difficulty of using aortic PWV in certain groups has been highlighted by this study. The use 
of aortic PWV may be more applicable to selected groups with early disease in whom 
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measurement may be more straightforward. TR may be useful parameter that can be easily 
recorded from pulse wave and warrants further investigation.  
Further studies are required to investigate the effect of lowering aortic PWV on cardiovascular 
outcomes. The use of time to reflected wave may be a simpler measure of arterial stiffness 
compared to aortic PWV however the prognostic value of this recording needs further 
evaluation.  
There are clearly a number of limitations with this study. One of the major limitations with this 
study is the composition of the control group. The control group was significantly younger and 
contained more women compared to the CAD group. Age is one of the most important 
determinants of arterial stiffness. Gender has important differences in augmentation index.  
The very small numbers in this study particularly for PWV measurements limits the 
interpretation and analysis of these results. Although can detect differences not able to determine 
whether provide any useful prognostic information. The study design meant patients with CAD 
were seen on the day of admission for surgery. The time available for study tests was limited by 
clinical commitments and this impacted on the number of patients who had aortic PWV 
recordings performed. 
The observational nature of this study clearly limits the conclusions that can be drawn. No 
conclusions can be drawn regarding causation. Vasodilator medications can impact on AIx and 
PWV. Medications were not withheld prior to examinations. Assessing patients on usual 
medications gives probably more clinically relevant information. However it is difficult to 
separate the impact of medications and mechanisms underlying pathological processes. There 
were no differences in markers of arterial stiffness in patients with type 2 DM compared to those 
without.  
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4 Endothelial function 
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4.1 Introduction 
Endothelial dysfunction plays a fundamental role in the development of cardiovascular disease 
(CVD)
82;83
. It is therefore an attractive therapeutic target in the management and prevention of 
CVD.  
4.1.1 Assessment of endothelial dysfunction 
Clinical assessment of endothelial function is important not only to help understand the 
pathophysiology of CVD but also in the evaluation of strategies targeting coronary artery 
disease (CAD). An ideal tool for assessing endothelial function clinically would be non-
invasive, sensitive, reproducible and simple. At present such a test does not exist.  
Currently there are a number of different methods for assessing endothelial function in different 
vascular beds. Although the endothelium has numerous functions, assessment in the mainstay 
concentrates on measurement of endothelium dependent vasodilation. A stimulus known to 
cause nitric oxide (NO) release from endothelial cells such as shear stress or acetylcholine is 
applied. Dilatation of vessel or vessels is then measured as an indicator of endothelium 
dependent vasodilation. In order to show that observed changes are an endothelium dependent 
effect and not due impaired vascular smooth muscle function a stimulus that acts directly on 
vascular smooth muscle cells is tested in parallel.  
4.1.1.1 Ex vivo assessment of endothelial function. 
Segments of vessels can be assessed in organ bath experiments which enable detailed 
pharmacological studies. Clearly the major limitation is the availability of vessels. Furthermore 
the tests are not repeatable over time and results need to be interpreted cautiously as the vessels 
are no longer in situ with ongoing exposure to circulating factors. Patients undergoing coronary 
artery bypass grafting (CABG) for CAD are a good source of vessels
87;177-181
. Short segments of 
the grafts surplus to clinical requirements can be obtained at the time of surgery. Available 
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vessels include left internal mammary arteries, radial arteries and saphenous veins. It is 
saphenous veins that are used most commonly. Although veins are not affected by 
atherosclerotic lesions to the same extent of arteries endothelial dysfunction has been 
demonstrated in both veins and arteries taken from patients with CAD
178
. Given the limited 
availability of arterial samples the use of veins is therefore considered appropriate.  
Control vessels from patients without CVD are even more difficult to obtain. It is possible to 
access saphenous veins from otherwise healthy patients attending for elective varicose vein 
(VV) removal. Endothelial function in these vessels is significantly better than that of patients 
with CAD
179
 
4.1.1.2 In vivo assessment of endothelial function 
There are currently a number of methods for assessing endothelial function in vivo in either 
conduit vessels or the microcirculation. Each method has different disadvantages and as yet no 
method is easily applicable for large scale clinical studies. 
Endothelial function in the coronary arteries can be assessed during cardiac catheterization. 
Acetylcholine is infused and change in arterial diameter measured. With an intact endothelium 
there is vasodilation whereas endothelial dysfunction is associated with vasoconstriction
182
. 
Endothelium independent vasodilation is assessed following sub lingual administration of the 
NO donor glyceryl trinitrate (GTN). Cardiac catherization is attractive as the results provide 
direct assessment of endothelial function in coronary arteries, a major target of the 
atherosclerotic process. However this method of assessment is only applicable to patients with 
established CAD and is not easily repeatable due to the inherent risks associated with cardiac 
catherization. 
Venous plethysmography is a technique that can be used to assess microvascular endothelial 
function
183
. The brachial artery is catheterized and pharmacological agents of interest infused. 
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Blood flow in the forearm is measured non-invasively using strain gauge plethysmography, with 
increases in blood flow being related to vascular reactivity. Although this technique is generally 
considered safe it does involve arterial catheterization and is therefore not completely without 
risk. It is not applicable for large studies or studies requiring repeated assessments of endothelial 
function. 
The current gold standard for non-invasive assessment of endothelial function is flow-mediated 
dilatation (FMD)
112
. FMD measures change in diameter of a conduit vessel following a period of 
ischaemia. The brachial artery is the most commonly studied vessel. A sphygmomanometer cuff 
is placed on the forearm distal to the brachial artery and inflated to suprasystolic blood pressure 
for 4-5 minutes and the cuff is released. The resulting reactive hyperaemia increases shear stress 
leading to NO release and therefore endothelium dependent vasodilation
184
. Endothelium 
independent vasodilation is assessed by response of brachial artery to sublingual GTN. FMD is 
widely used and correlates well with coronary vascular endothelial function
112
.However FMD is 
technically difficult and results are inconsistent when performed by inexperienced operators
185
. 
This together with the expense of equipment currently limits the use of FMD. 
Alternative non-invasive techniques of endothelial function are therefore needed. One of these 
alternatives is the pulse wave analysis based method established by Hayward et al.
109
 and 
validated by Wilkinson et al.
108
. This method assesses changes in pulse wave reflection resulting 
from vascular dilation. Endothelial function can therefore be assessed using agents know to 
cause endothelium dependent vasodilation. Inhaled salbutamol results in endothelial dependent 
vasodilation and a fall in pulse wave reflection
108-110
. Salbutamol directly infused in to the 
brachial artery has no effect on pulse wave reflection. The result is therefore an assessment of 
endothelial function in the microcirculation
110
. Sublingual GTN can be used to assess 
endothelial independent vasodilation. Endothelial function assessed by changes in pulse wave 
reflection following salbutamol correlates well with endothelial function assessed by venous 
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occlusion plethysmography and FMD
108;186
. However currently there are no long term studies 
looking at the prognostic value of this technique or interventional studies.  
4.1.2 Endothelial dysfunction in cardiovascular disease 
Endothelial dysfunction is found in patients with established CAD
87;109;179;182;187;188
. Furthermore 
endothelial dysfunction occurs early in the development of CVD and is present prior to the 
development of overt atherosclerotic plaques
112
. Endothelial dysfunction is therefore an 
attractive therapeutic target early in the cardiovascular continuum. 
In patients with established cardiovascular disease the persisting endothelial dysfunction has 
important implications. Impaired endothelial function as assessed by FMD, during cardiac 
catheterisation or venous plethysmography is an important prognostic factor for future 
cardiovascular events in patients with established disease
187-189
. The increased risk associated 
with endothelial dysfunction appeared to be independent of established CV risk factors
188
. It is 
thought in patients with CAD that persisting endothelial dysfunction continues to drive 
progression of the atherosclerotic process and may contribute to episodes of myocardial 
ischemia, angina and plaque stability
187;190;191
. Currently however there are no prospective 
studies linking improved endothelial function with improved cardiovascular outcomes. 
4.1.3 Endothelial dysfunction in type 2 diabetes mellitus 
Endothelial dysfunction is a key feature of type 2 diabetes mellitus (DM)
110;192-195
. What is less 
clear is whether this is purely an endothelial abnormality. Some groups have reported normal 
endothelium independent vasodilation
110;195
 whereas others have described both impaired 
endothelium dependent and independent vasodilation
193;194
.  
Endothelial dysfunction is also found in patients with insulin resistant states prior to the 
development of overt hyperglycaemia and type 2 DM. For example endothelial dysfunction has 
been described in women with gestational diabetes, obesity and individuals with the metabolic 
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syndrome
196-198
. Suggesting that insulin resistance is important and endothelial dysfunction is 
not simply a consequence of hyperglycaemia. Insulin has important actions on the vasculature 
causing vasodilation through endothelium derived NO
199
. In individuals with insulin resistance 
this effect may be attenuated
197
. Signalling pathways underling the vascular response to insulin 
are similar to those involved in insulin mediated glucose uptake
199
. Therefore there may be a 
common mechanism underlying both the development of endothelial dysfunction and insulin 
resistance. 
The mechanisms underlying endothelial dysfunction in patients with type 2 DM and other 
insulin resistant states are not fully understood. There are a number of proposed mechanisms 
underlying diabetes related endothelial dysfunction these include increased oxidative stress, 
inflammation, dyslipidemia and increased arginase activity
200-202
. However most of the evidence 
points to increased oxidative stress as the predominant underlying cause
91
. 
Endothelial dysfunction is predictive of future cardiovascular events in patients with type 2 
DM
203
. Endothelial dysfunction seen in type 2 DM may in part explain the increased burden of 
cardiovascular disease associated with type 2 DM and is therefore an attractive therapeutic 
target. 
4.1.4 Endothelial dysfunction and dyslipidaemia 
Hypercholesterolaemia has consistently been found to be associated with impaired endothelial 
function
108;204;205
. Elevated cholesterol levels are important across the cardiovascular continuum. 
Endothelial function correlated with low density lipoprotein (LDL) cholesterol levels in both 
children with familial hypercholesterolaemia and patients with severe CAD undergoing 
revascularisation
112;179
. 
Cholesterol lowering by a number of methods either using statins, dietary methods or apheresis 
improves endothelial function
81
. The improvement in endothelial function observed with statins 
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appears to be due to both lipid dependent and independent effects. This is demonstrated by the 
findings from three studies published by John et al.
206-208
 investigating both the short and longer 
term effects of statin therapy on endothelial function. An initial study showed forearm blood 
flow improved after 24 weeks of treatment with fluvastatin compared to placebo
207
. Infusion of 
the NO synthase inhibitor L-NMMA reversed the improvement in endothelial function 
suggesting that increases in NO availability were partly responsible for this finding
207
. A further 
study John el al.
206
 showed that endothelial function is also improved after short term statin 
therapy. Two weeks treatment with cerivastatin was associated with improvements in forearm 
blood flow and this once again was partly mediated by increased NO availability
206
. Furthermore 
these effects of statins on endothelial function appear partly to be independent of lipid lowering 
effects. A subsequent study by John et al.
208
 showed just three days of statin therapy was 
associated with improvements in endothelial function assessed by plethysmography. Assessment 
of endothelial function was repeated after 14 days of statin therapy and there were no further 
improvements seen in endothelial function despite further reduction in LDL levels
208
. The 
improvements in endothelial function appeared to be in part mediated by decreased oxidative 
stress as vitamin C infusion improved endothelial function before but not after statin therapy
208
. 
The effect of high density lipoprotein (HDL) levels on endothelial function can be difficult to 
determine as low HDL levels are usually associated with other lipid abnormalities. However 
HDL levels also appear to be an important determinant of endothelial function. Lupatelli et al.
209
 
measured FMD in 107 patients attending a lipid clinic with either elevated LDL or triglyceride 
levels. When FMD was divided into tertiles HDL was significantly lower in patients with the 
lowest FMD. Triglyceride levels were also elevated in this group whereas LDL levels were 
similar. Strategies to increase HDL levels independently of altering metabolic abnormalities are 
limited. Therefore evidence from interventional studies linking increased HDL levels with 
changes in endothelial function is also limited. In a small study by Spieker et al.
210
 infusion of 
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reconstituted HDL reduced endothelial dysfunction seen in patients with hypercholesterolaemia. 
Kuvin et al.
211
 also showed that treatment with niacin improved FMD in patients with CAD 
compared to controls. The change in FMD was strongly correlated with level of HDL achieved. 
The effect of hypertriglyceridaemia on endothelial function is less clear. Triglyceride levels 
have been shown to be an important determinant of endothelial function. Schnieder et al.
212
 
investigated endothelial function in patients with hypercholesterolaemia. In these patients 
triglyceride levels were an important determinant of endothelial function independent of other 
cardiovascular risk factors
212
. FMD has also been shown to be impaired in men with elevated 
triglyceride levels compared to men with triglyceride levels in the normal range
213
. However in 
the men with hypertriglyceridaemia HDL levels were significantly lower and fasting insulin 
levels higher compared to men with normal triglyceride levels
213
. It may therefore be other 
metabolic abnormalities such as low HDL driving endothelial dysfunction associated with 
hypertriglyceridaemia. In a study by Gudmundsson et al.
214
 no acute impairment in endothelial 
function was observed following triglyceride infusion. Strategies to lower triglyceride levels 
(such as fibrate therapy) alter a number of other metabolic abnormalities therefore direct 
evidence from interventional studies linking elevated triglycerides and endothelial dysfunction is 
lacking. The direct effect of hypertriglyceridaemia on endothelial function is not clear.  
4.1.5 Endothelial dysfunction and hypertension 
The effect of hypertension alone on endothelial function is not clear. Some studies have reported 
endothelial dysfunction in patients with essential hypertension
215;216
. However a number of 
studies have found preserved endothelial function in essential hypertension
217;218
.The conflicting 
results may be partly attributable to different assessment methods or a result of coexisting risk 
factors that tend to cluster in hypertension. Chan et al.
219
 found that endothelial function as 
assessed by forearm blood flow was correlated with other cardiovascular risk factors but not 
blood pressure. However Preik et al.
220
 showed that hypertension when present with other risk 
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factors has an additive detrimental effect on endothelial function. Furthermore endothelial 
function is predictive of future cardiovascular events in patients with hypertension
221
. 
Conflicting results have also been reported regarding the effects of blood pressure treatment on 
endothelial function. In some but not all studies both calcium channel blockers, Angiotensin 
converting enzyme inhibitors (ACEi) and Angiotensin receptor blockers (ARBs) have been 
associated with improvements in endothelial function
81;222
. 
4.1.6 Endothelial function and oxidative stress 
Impaired endothelium dependent vasodilation arises secondary to reduced NO bioavailability
78
. 
This could result from decreased production of NO (reduced eNOS, reduced cofactors for 
eNOS, impaired eNOS signalling) or accelerated NO degradation. Increased NO degradation by 
reactive oxygen species (ROS) is thought to be one of the key mechanisms underlying 
endothelial dysfunction
84
. Hypercholesterolaemia, type 2 DM and hypertension have all been 
associated with increased levels of ROS such as superoxide
87;116;179
. Furthermore administration 
of antioxidants has been shown to improve endothelial function
223;224
.  
4.1.7 Summary 
Endothelial dysfunction is an important step in the development of cardiovascular disease. It is a 
feature found throughout the cardiovascular continuum from patients with single risk factors to 
those with established CVD. Endothelial function is an important predictor of future 
cardiovascular events. Strategies aimed at tackling endothelial function are therefore attractive 
for the management of patients with both established CVD through to those with isolated risk 
factors. The current methods for assessing endothelial function that are available have various 
drawbacks limiting their clinical application. A better understanding of methods underlying 
endothelial dysfunction together with simpler assessment techniques are required. 
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4.2 Aims 
The hypotheses were firstly to confirm that patients with CAD would have impaired endothelial 
function compared to healthy controls. Secondly to confirm that patients with CAD and type 2 
DM would have greater impairment of endothelial function compared to patients with CAD 
alone. It was hypothesised that impairment in endothelial function would remain despite use of 
currently available secondary prevention therapies. 
The aims of the study were:  
 To assess endothelial function using in vivo and ex vivo methods in patients with severe 
CAD undergoing CABG (with and without type 2 DM) compared to healthy controls.  
 To assess the impact of type 2 DM on endothelial function in patients with CAD. 
 To evaluate whether a non invasive pulse wave analysis (PWA) based technique can be 
used to assess endothelial function in patients with established CAD.  
4.3 Methods 
In vivo and Ex vivo endothelial function studies were performed in participants recruited as part 
of the VASCAB study. A detailed description of participant recruitment, clinical examination, 
and methods for in-vivo and ex vivo assessment of endothelial function is given in chapter 2. 
4.4 Results 
4.4.1 Ex vivo vascular function studies in patients with CAD  
Ex vivo vascular function studies were performed in 49 out of a total of 126 CAD patients 
recruited. The reasons for organ bath results not being available for a patient recruited for the 
study were insufficient samples of vein, the vessel not being vital before studies completed, and 
date or location of operation being changed. Sixteen patients attending for elective VV surgery 
were recruited to provide control saphenous vein samples; of these 16 patients, 10 vessels were 
 110 
suitable for organ bath experiments. Reasons for unavailable organ bath studies include 
insufficient size of sample received and vessel not being vital before studies completed. In both 
patients with CAD and patients with VV clinical characteristics (age, sex, history of diabetes 
etc) did not differ from patients in whom vessels were not available. 
Participant characteristics for CAD and control (VV) participants are shown in table 4.1. Table 
10.1 in the supplementary data shows participant characteristics for all patients recruited within 
the study for comparison. Table 10.2 in the supplementary data shows participant characteristics 
for healthy controls compared to all patients with varicose veins. Patients with VV as expected 
are younger than the CAD patients with a lower proportion of males within the group. Although 
49% of CAD patients had a history of hypertension there was no significant difference in blood 
pressure between the two groups. This is probably reflects the universal use of one or more 
antihypertensive agent in the CAD patients. There was high usage of secondary prevention 
therapies (aspirin, statins, ARBs/ACEi and beta-blockers) within the CAD patients.  
The biochemistry results for participants in the ex vivo endothelial function study are shown in 
table 4.2. Total cholesterol and LDL levels were lower in the CAD group compared to VV 
controls, reflecting the high prevalence of statin prescription. HDL levels were lower in the 
CAD group. Table 10.3 in the supplementary data shows biochemistry results for all study 
participants for comparison. Table 10.4 in the supplementary data shows the biochemistry 
results for healthy controls compared to patients with VV. Again the participants in whom 
vessels were available did not differ from all patients recruited for the study.  
Endothelium dependent vasodilation as assessed by maximum relaxation of saphenous veins to 
calcium inophore A23187 is shown in figure 4.2. Maximal relaxation following calcium 
inophore was significantly lower in saphenous veins from patients with CAD compared to 
controls in keeping with impaired endothelial function (43.1±15.7% vs. 61.9±16.3. %, P=0.001). 
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95% Confidence intervals for the difference between mean relaxation to calcium inophore in 
patients with CAD compared to controls was -7.8 to-29.7%. Endothelium independent 
vasodilation as assessed by maximum relaxation of saphenous veins to SNP is shown in figure 
4.3. There was no significant difference in endothelium independent vasodilatation between the 
2 groups, 111.2±15.7 vs 101.3±6.2 in CAD and controls respectively. The 95% confidence 
intervals for the difference in mean relaxation to SNP between patients with CAD compared to 
controls was -6.5 to 26.5%. 
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Table 4.1 Clinical characteristics for patients with CAD and patients with VV in ex vivo 
vascular function study.  
 CAD (n=49) VV control (n=10) P-value 
Age (years) 65.5±9.3 45.9±18.9 0.014 
Male (%) 39(79.6) 4(40) 0.018 
Systolic BP (mm Hg) 138.1±25.9 134.4±24.9 NS 
Diastolic BP (mm Hg) 77.9±12.7 86.2±13.4 NS 
Heart rate (beats/min) 64.2±13.9 68.6±13.3 0.04 
BMI (kg/m
2)
 29.4±4.4 26.9±1.9 NS 
Current smokers (%)  2(4.1) 1(10) NS 
Type 2 DM (%) 14(28.6) 0 n/a 
Hypertension (%) 24(49) 2(20) NS 
Myocardial Infarction (%) 24(49) 0 n/a 
TIA/CVA (%) 3(6.1) 0 n/a 
Chronic renal failure (%) 3(6.1) 0 n/a 
Heart failure (%) 8(16.3) 0 n/a 
Aspirin (%)  43(87.8) 1(10) <0.0001 
Other antiplatelet agent (%) 15(30.6) 0 0.049 
Statin (%) 43(87.8) 1(10) <0.0001 
ACEi/ARB (%) 33(67.3) 1(10) 0.001 
Beta-blocker (%) 36(73.5) 1(10) <0.0001 
Calcium channel blocker (%) 14(28.6) 1(10) NS 
Nitrate (%) 26(53.1) 0 0.001 
Diuretic (%) 14(28.6) 1(10) NS 
Oral hypoglycaemic agent (%) 7(14.3) 0 n/a 
Insulin (%) 3(6.1) 0 n/a 
Continuous variables are mean±standard deviation. Discrete variables are absolute numbers and 
percentage (%) TIA; transient ischaemic attack, CVA, cerebrovascular accident, BP, Blood 
pressure, ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 4.2. Biochemistry results in patients with CAD and patients with VV for ex vivo 
vascular function study  
 CAD (n=49) VV Control 
(n=10) 
P-value 
Cholesterol (mmol/L) 3.99±1.01 5.20±0.82 0.007 
Triglycerides (mmol/L) 2.27±1.48 1.24±0.47 0.016 
LDL (mmol/L) 1.86±0.80 3.00±0.85 0.004 
HDL (mmol/L) 1.15±0.28 1.64±0.20 <0.0001 
CRP (mg/L) 4.36±10.59 3.70±4.54 NS 
HbA1c (%) 6.07±1.11 5.42±0.19 NS 
Urinary ACR (mg/mmol) 2.11±2.16 1.28±0.43 NS 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP C-reactive protein;HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio. 
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Figure 4.1 Maximal relaxation of saphenous veins to calcium inophore A23187 in patients 
with CAD and control patients with VV.  
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Figure 4.2 Maximal relaxation to sodium nitroprusside in saphenous veins from control 
patients with VV and patients with CAD 
 
 
4.4.2 Ex vivo studies in patients with CAD and type 2 DM 
Twenty eight per cent of the CAD patients had type 2 DM. Participant demographics and 
clinical characteristics are shown in table 4.3. Body mass index and prevalence of hypertension 
was higher in the patients with diabetes compared to those without. There were no other 
significant differences between the two groups. Biochemistry results are shown in table 4.4. 
HbA1c was significantly higher in the patients with diabetes compared to those without. There 
P=0.22 
n=4 n=26
910 
 116 
were no significant differences in cholesterol measures between the two groups. Endothelial 
function was worse in patients with CAD and diabetes compared to CAD alone (figure 4.4) 
Maximum relaxation to calcium ionophore was 33.9±10.8% in patients with type 2 DM 
compared to.46.8±15.9% in patients without diabetes (P=0.008).The 95% confidence intervals 
for difference between the means were -22.3 to-3.6%. There was no significant difference in 
endothelium independent vasodilation, 107.6±11.5 vs 119.5±21.3, 95% confidence intervals for 
the difference between the means were -6.17 to 30.1%. Results are shown in figure 4.5. 
Determinants of endothelial function were investigated using stepwise regression. Age, sex, 
CAD status, diabetes status, LDL and HDL levels were entered into a stepwise regression 
model. Of these variables diabetes status was the only significant predictor of endothelial 
function, R
2
=0.157, P=0.003 (table 4.5). 
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Table 4.3 Demographics and clinical characteristics in patients with CAD with and 
without type 2 DM in ex vivo vascular function study. 
 CAD alone 
(n=35) 
CAD and type 2 
DM 
(n=14) 
P-value 
Age (years) 66±8.7 64±11.1 NS 
Male (%) 27 (77%) 12(87.5) NS 
Systolic BP(mm Hg) 137.3±27.15 140.8±22.37 NS 
Diastolic BP (mm Hg) 79.0±11.76 73.9±15.5 NS 
Heart rate (beats/min) 64.3±12.79 63.8±17.79 NS 
BMI, kg/m
2
 28.7±4.11 31.9±4.67 0.047 
Current Smokers (%) 1(2.9) 1(7.1) NS 
Hypertension (%) 12(34.3) 12(85.7) 0.004 
Myocardial Infarction (%) 15(42.9) 9(64.3) NS 
TIA/CVA (%) 2 (5.7) 1(7.1) NS 
Chronic renal failure (%) 2(5.7) 1(7.1) NS 
Heart failure (%) 3(8.6) 5(35.7) NS 
Aspirin (%) 30(85.7) 13(92.9) NS 
Other antiplatelet agent (%) 12(34.3) 3(21.4) NS 
Statin (%) 30(85.7) 13(92.9) NS 
ACEi/ARB (%) 21(60) 12(85.7) NS 
Beta-blocker (%) 25(71.4) 11(78.6) NS 
Calcium channel blocker (%) 9(25.7) 5(35.7) NS 
Nitrate (%) 20(57.1) 6(42.9) NS 
Diuretic (%) 8(22.9) 6(42.9) NS 
Oral hypoglycaemic agent (%) 0 7(50) n/a 
Insulin (%) 0 3(21.4) n/a 
Continuous variables are mean±standard deviation. Discrete variables are absolute numbers and 
percentage (%) TIA; transient ischaemic attack, CVA, cerebrovascular accident, BP, Blood 
pressure, ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 4.4 Biochemical results for patients with CAD alone and patients with CAD and type 
2 DM in ex vivo vascular function study 
 CAD alone 
(n=35) 
CAD and type 2 
DM 
(n=14) 
P- value 
Cholesterol (mmol/L) 4.02±1.07 3.91±0.91 NS 
Triglycerides (mmol/L) 2.04±0.87 2.64±2.32 NS 
LDL (mmol/L) 1.91±0.81 1.78±0.72 NS 
HDL (mmol/L) 1.17±0.30 1.11±0.24 NS 
CRP (mg/L) 5.13±12.58 2.72±3.34 NS 
HbA1c (%) 5.59±0.36 7.41±1.35 <0.0001 
Urinary ACR (mg/mmol) 2.31±6.24 3.79±3.35 NS 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C-reactive protein;HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio. 
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Figure 4.3. Maximal relaxation of saphenous veins to calcium inophore A23187 in patients 
with CAD alone and patients with CAD and type 2 DM 
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Figure 4.4 Maximal relaxation to sodium nitroprusside in saphenous veins from patients 
with CAD alone and patients with CAD and type 2 DM 
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Table 4.5 Determinants of ex vivo endothelial function 
 Full model (R
2
=0.242) Stepwise model (R
2
=0.157) 
 β P-value β P-value 
Age 0.72 0.642 _ _ 
Sex (0=female,1=male) 0.113 0.415 _ _ 
CAD (0=no,1=yes) -0.323 0.073 _ _ 
Type 2 DM (0=no,1=yes) -0.383 0.006 -0.397 0.003 
LDL-cholesterol -0.018 0.907 _ _ 
HDL-cholesterol -0.217 0.196 _ _ 
In the full model all variables were forced into the model. In the stepwise model variables with a 
significance of ≥0.1were removed. Β indicates the partial correlation coefficients. 
4.4.3 In vivo endothelial function studies 
Reproducibility of AIx was assessed in 10 healthy controls. Intra-observer results for AIx 
measurements taken on the same day were -0.034±1.92% and -0.67±3.86% for measurements 
taken 24-48 hours later. In vivo endothelial function studies were performed in 22 patients with 
CAD and 30 healthy controls. Reasons for not performing in vivo vascular function studies 
included insufficient time for studies (74 CAD patients,18 controls) , participant unwilling to 
take either salbutamol or GTN (19 CAD patients and 18 controls) or PWA recording being of 
insufficient quality (33 CAD patients and 19 controls). Table 4.6 shows demographics and 
clinical characteristics for participants in in-vivo vascular function study. Table 4.7 shows 
biochemical analysis. Change in peripheral AIx following inhaled salbutamol was used to assess 
endothelial dependent vasodilation. Table 4.8 shows heart rate, systolic blood pressure, diastolic 
blood pressure and peripheral AIx at 5, 10, 15 and 20 minutes following salbutamol in patients 
with CAD and controls. In view of the variability to peak salbutamol effect between individuals 
the maximum change for each variable was also calculated. There was a significant increase in 
heart rate in both controls and patients with CAD following salbutamol compared to baseline. 
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However there was no difference between the maximum change in heart rate between the two 
groups. Overall there was no trend for change in systolic or diastolic blood pressure following 
salbutamol in either group with no difference in maximum change in either systolic or diastolic 
blood pressure. Peripheral AIx fell at all time points following salbutamol in controls, in CAD 
patients overall there was an increase in peripheral AIx 5 minutes post salbutamol but no other 
significant change. The maximum change in peripheral AIx post salbutamol was significantly 
greater in the control group indicating improved endothelial function compared to CAD,-
7.32±8.1 vs -0.6±9.4 in controls and patients with CAD respectively. The 95% confidence 
intervals for the difference between the mean response of peripheral AIx to salbutamol in 
controls compared to patients with CAD were 1.80 to 11.65% (figure 4.6). 
Heart rate, systolic blood pressure, diastolic blood pressure and peripheral augmentation index 
following GTN administration are shown in table 4.9. There was a significant increase in heart 
rate following GTN in both groups but the maximum change in heart rate was not different 
between the 2 groups. There were no significant changes in blood pressure following GTN. 
Peripheral augmentation index fell significantly following GTN administration. Healthy controls 
showed a greater response to GTN compared to patients with CAD; this was of borderline 
significance -16.8±8.65 vs -11.9±7.1, P=0.05. 95% confidence intervals for the difference 
between the mean change in AIx following GTN between healthy controls and patients with 
CAD was 2.4 to 4.85% (Figure 4.7).  
In vivo endothelial function was assessed in 5 patients with type 2 DM and CAD compared to 17 
patients with CAD alone. Peripheral AIx fell to a lesser degree in the patients with type 2 DM 
compared to those without diabetes however in view of the small numbers detailed analysis is 
not appropriate.  
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Twelve patients (8 with CAD and 4 VV controls) had both in-vivo and ex vivo measures of 
endothelial function. In these 12 participants there was no relationship between the two different 
assessments of endothelial function, r=-0.27, P=0.4 (figure 4.8). 
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Table 4.6 Demographics and clinical characteristics for patients with CAD and healthy 
controls in in vivo vascular function study 
 CAD (n=22) Control (n=30) P-value 
Age (years) 66.6±10.8 60.8±12.8 NS 
Male (%) 18(81.8) 17(56.7) NS 
Systolic BP (mm Hg) 139.8±19.8 142.0±20.5 NS 
Diastolic BP (mm Hg) 76.8±8.6 82.4±12.2 NS 
Pulse pressure (mm Hg) 63.0±17.3 59.6±13.8 NS 
Heart rate (beats/min) 64.4±8.7 72.0±13.2 0.015 
BMI, kg/m
2
 30.0±3.2 26.0±3.3 <0.0001 
Current Smokers (%) 1(4.5) 2(6.7) NS 
Type 2 DM (%) 5(22.7) 0 n/a 
Hypertension (%) 17(77.3) 8(26.7) 0.002 
Myocardial Infarction (%) 11(50) 0 n/a 
TIA/CVA (%) 1(4.5) 1 (3.3) NS 
Chronic renal failure (%) 1(4.5) 0 n/a 
Heart failure (%) 1(4.5) 0 n/a 
Aspirin (%) 19(86.4) 3(10) <0.0001 
Other antiplatelet agent (%) 7(31.8) 1(3.3) 0.007 
Statin (%) 22(100) 5(16.7) <0.0001 
ACEi/ARB (%) 15(68.5) 2(6.7) <0.0001 
Beta-blocker (%) 16(72.7) 2 (6.7) <0.0001 
Calcium channel blocker (%) 9(40.9) 1 (3.3) 0.001 
Nitrate (%) 16(72.7) 0 <0.0001 
Diuretic (%) 5(22.7) 4(13.3) NS 
Oral hypoglycaemic agent (%) 2(9.1) 0 n/a 
Insulin (%) 1(4.5) 0 n/a 
Continuous variables are mean±standard deviation. Discrete variables are absolute numbers and 
percentage (%) TIA; transient ischaemic attack, CVA, cerebrovascular accident, BP, Blood 
pressure, ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 4.7 Biochemical results for patients with CAD and healthy controls in in vivo 
vascular function study 
 CAD (n=22) Control (n=30) P-value 
Cholesterol (mmol/L) 4.01±0.84 5.69±1.09 <0.0001 
Triglycerides (mmol/L) 1.96±0.75 1.68±0.83 NS 
LDL (mmol/L) 1.93±0.71 3.36±1.04 <0.0001 
HDL (mmol/L) 1.18±0.29 1.53±0.37 0.001 
CRP (mg/L) 3.15±4.42 1.96±2.67 0.039 
HbA1c (%) 5.95±0.84 5.55±0.33 0.027 
Urinary ACR (mg/mmol) 4.14±10.7 1.40±0.84 NS 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C reactive protein;HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio. 
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Table 4.8 Response to salbutamol in patients with CAD and healthy controls 
 Healthy Control 
(n=30) 
P-value CAD (n=22) P-value  
Heart rate 
(beat/min) 
    
0 63.9±10.5  58.5±6.9  
5 66.3±10.8 0.001 59.6±7.2 0.006 
10 66.4±10.6 0.01 60.5±7.4 0.03 
15 64.7±10.1 0.013 60.2±7.4 0.018 
20 66.2±10.3 0.005 60.0±7.4 NS 
Max. change in 
Heart rate  
2.6±3.8  2.0±5.2  
SBP (mmHg)     
0 136.4±17.9  134.9±18.4  
5 139.3±20.9 NS 139.7±17.3 0.006 
10 137.0±18.1 NS 137.0±18.0 NS 
15 136.1±20.5 NS 138.6±19.6 NS 
20 135.6±18.5 NS 134.8±19.3 NS 
Max. change in 
SBP 
3.3±14.9  2.9±15.3  
DBP (mmHg)     
0 80.1±11.5  73.0±8.0  
5 82.7±11.4 NS 75.3±7.4 0.01 
10 76.2±17.5 NS 74.5±8.2 NS 
15 78.7±9.7 NS 76.8±8.2 0.01 
20 78.1±10.1 NS 74.4±7.9 NS 
Max change in 
DBP 
2.2±14.9  4.5±8.2  
Peripheral AIx (%)     
0 85.7±18.5  84.7±12.7  
5 82.7±17.7 0.005 86.3±12.7 0.032 
10 81.3±18.8 <0.0001 82.7±11.3 NS 
15 80.9±19.0 0.001 86.0±14.1 NS 
20 80.7±17.9 <0.0001 83.8±16.2 NS 
Max change 
peripheral AIx(%) 
-7.32±8.1  -0.6±9.4*  
BP, blood pressure; AIx, augmentation index, P-values indicate significant change from 
baseline. *Significant difference between CAD and controls (P=0.008). 
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Table 4.9. Response following GTN in healthy controls and patients with CAD 
 Healthy Control 
(n=30) 
P-value CAD (n=22) P-value 
Heart rate 
(beats/min)  
    
0 65.2±9.8  59.5±7.8  
5 68.3±9.7 <0.0001 63.3±7.1 <0.0001 
Change in heart rate 3.2±3.5  3.9±2.6  
SBP(mmHg)     
0 138.6±21.3  136.7±19.0  
5 138.1±18.4 NS 134.7±19.3 NS 
Change in SBP -0.5±9.5  -3.2±8.0  
Diastolic BP(mmHg)     
0 80.3±9.7  75.1±8.4  
5 78.1±13.0 NS 74.6±7.9 NS 
Change in DBP -2.1±10.2  -0.8±5.5  
Peripheral Aix (%)     
0 81.8±20.9  84.1±10.9  
5 64.6±20.2 <0.0001 70.2±19.6 <0.0001 
Change in peripheral 
AIx 
-16.8±8.7  -11.9±7.1*  
BP, blood pressure; AIx, augmentation index, P-values indicate significant change from baseline 
*Significant difference between CAD and controls (P=0.05). 
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Figure 4.5. Maximum change in peripheral AIx post salbutamol in patients with CAD and 
controls 
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Figure 4.6. Maximum change in peripheral AIx post GTN in patients with CAD and 
controls 
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Figure 4.7. Scatter plot of maximum change in peripheral AIx post salbutamol and 
maximum relaxation to calcium inophore 
 
4.5 Discussion 
Using an ex vivo method the presence of endothelial dysfunction was confirmed in patients with 
CAD compared to healthy controls. There was no impairment in endothelium independent 
vasodilation. These results are consistent with a plethora of published data
87;109;179;182;187;188
. 
Twenty eight per cent of the CAD patients had type 2 DM; this is representative of all patients 
undergoing CABG in Scotland
99
. Endothelial function was significantly impaired in patients 
P=NS 
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with type 2 DM and CAD compared to patients with CAD alone. There was no difference in 
endothelium independent vasodilation. These findings are in keeping with a number of 
previously published studies
110;195
. Endothelial function has been found to be an important 
prognostic factor in patients with established CAD
187;188
. The greater degree of endothelial 
impairment in patients with type 2 DM may explain the worse cardiovascular outcomes seen in 
these patients. 
Despite a number of interventions that have been associated with improved endothelial function, 
endothelial dysfunction persisted in patients with CAD, with and without type 2 DM. Previous 
studies have shown LDL levels to be one of the major determinants of endothelial function
179
. 
LDL levels were significantly lower in the CAD group compared to controls. LDL levels were 
also well controlled in patients with type 2 DM, indeed there was a trend to lower LDL levels 
although this was not statistically significant. Statin therapy was widespread in all patients with 
CAD. Statins therapy has been shown to improve endothelial function through both a reduction 
in LDL levels and lipid independent effects
206-208
. In some studies ACEi/ARBs have been 
associated with improvements in endothelial function
222
. Use of ACEi/ARB was unsurprisingly 
high in patients with CAD compared to controls. In addition a higher proportion of patients with 
type 2 DM were on ACEi/ARBs although this was not statistically significant. 
Interestingly diabetes status was the only significant determinant of ex vivo endothelial function. 
Although this only accounted for approximately 16% of the variability observed, suggesting that 
factors other than those commonly known to alter endothelial function (Age, CAD status, LDL 
and HDL) are important. A number of mechanisms could account for the endothelial 
dysfunction seen in patients with type 2 DM, including insulin resistance, hyperglycaemia, 
increased oxidative stress and dyslipidaemia. These same mechanisms may also partly 
contribute to the endothelial dysfunction observed in patients with CAD alone.  
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Hyperglycaemia as assessed by HbA1c was significantly higher in patients with type 2 DM 
compared to controls. Hyperglycaemia may contribute to endothelial dysfunction through a 
number of mechanisms including increased oxidative stress, advanced glycation end products 
and increased flux through the hexosamine biosynthetic pathway
91;225;226
. Blood glucose levels 
may have also partly contributed to the impaired endothelial function observed in CAD patients 
without type 2 DM. Blood glucose is continuous variable therefore dividing in to diabetes 
yes/no somewhat arbitrary. It is likely that a proportion of CAD patients without diabetes will 
have had impaired glucose tolerance. HbA1c with a cut off of 6.5% was accepted in January 
2011 by the WHO for the diagnosis of diabetes 
3
. At present the use of HbA1c for the diagnosis 
of impaired glucose tolerance is not recommended
3
. Although HbA1c was higher in patients with 
type 2 DM compared to controls, glycaemic control was reasonable in patients with type 2 DM 
(mean HbA1c 7.4±1.35%) and as highlighted by recent clinical trials tight glycaemic control may 
actually be harmful in some groups of patients 
3;27
. Therefore even if hyperglycaemia is 
contributing to endothelial dysfunction further reductions in blood glucose levels may not be 
appropriate in this group of patients. 
Insulin resistance has also be shown to be associated with endothelial dysfunction and may 
partly explain the worse endothelial function in patients with type 2 DM
197
. Insulin resistance 
like blood glucose levels is a continuous variable therefore may have also contributed to 
endothelial dysfunction seen in CAD patients without type 2 DM. Insulin resistance was not 
assessed in this study however type 2 DM is by definition an insulin resistant state. It has been 
shown in patients with established CAD without diabetes insulin resistance is also common, 
illustrated by the high prevalence of the metabolic syndrome
227
. A similar pattern is likely in this 
study. Previous studies have shown that insulin resistance is associated with endothelial function 
228;229
. What degree this is a direct consequence of insulin resistance and how much can is the 
result of coexisting factors such as dyslipidaemia is not clear. Some but not all studies have 
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shown that insulin resistance is an independent predictor of endothelial function. In healthy 
individuals without diabetes or other cardiovascular risk factors fasting insulin levels as a 
surrogate for insulin resistance were related to brachial FMD
229
. However Hamburg et al.
228
 
showed that the impaired brachial FMD associated with insulin resistance was due to 
components of the metabolic syndrome rather than independent effect of insulin resistance. 
Further evidence for the role of insulin resistance in the development of endothelial dysfunction 
comes from studies looking at the effects of improving insulin sensitivity. Insulin sensitizing 
agents have been shown to improve endothelial function. Rosiglitazone improves endothelial 
function assessed during venous plethysmography in patients with type 2 DM
230
. Metformin also 
improves endothelial function in patients with type 2 DM and in individuals with the metabolic 
syndrome but normal glucose tolerance
231;232
 Metformin was used in 47% of patients with type 2 
DM in this study, glitazones in 11%. Ongoing use of glitazones and in particular rosiglitazone in 
patients with CVD is not recommended due to studies suggesting increased CV events 
32
. Indeed 
since October 2010 rosiglitazone has been withdrawn in Europe and has restrictions placed on 
its use within the USA. Metformin is however safe and well tolerated. Other strategies that are 
known to improve insulin sensitivity including weight loss and increased physical activity have 
also been shown to improve endothelial function
233-235
. 
Lipid abnormalities in addition to LDL levels may also contribute to endothelial dysfunction. 
HDL levels have been shown to be correlated with endothelial function
209
. HDL was 
significantly lower in patients with CAD compared to controls furthermore there was a trend 
towards lower HDL levels in the patients with type 2 DM although this was not significant. 
However in multivariate analysis HDL was not a significant determinant of endothelial function. 
Insulin resistant states are associated with changes in LDL subfractions with increased levels of 
small dense LDL particles
236
. Small dense LDL has been associated with endothelial 
dysfunction
237
. 
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Increased oxidative stress has been reported in patients with type 2 DM
177
. Increased oxidative 
stress is thought to be one of the major mechanisms underlying endothelial dysfunction in 
patients with CAD
84
. Antioxidants such as vitamin C improves endothelial function in patients 
with type 2 DM, however large clinical trials have not shown improved cardiovascular outcomes 
with anti-oxidants
238-240
. The role of oxidative stress in the development of endothelial 
dysfunction warrants further investigation.  
Using a non-invasive pulse wave analysis technique for assessing in vivo endothelial function 
the presence of endothelial dysfunction in patients with CAD compared to healthy controls was 
confirmed. In this method there was also evidence for impaired endothelial independent 
vasodilation. Previous reports using this PWA technique in patients with CAD have reported 
normal responses to GTN
109
. Our results may simply be due to small numbers in this study. 
There were insufficient numbers of patients in the PWA endothelial function group to assess the 
effect of type 2 DM although there was a trend to worse endothelial function in this group. 
Use of the PWA based technique for assessment of endothelial function has not been widely 
reported to date. Endothelial dysfunction using the PWA based technique was found in patients 
with established CVD and patients with hypercholesterolaemia 
108;109
. Wilkinson et al 
108
 have 
shown that response to salbutamol is consistent in healthy volunteers examined over a week 
with a mean difference of -2.3±3.0%. Repeatability of response to salbutamol was not further 
examined in this study however the within observer reproducibility of AIx index measurement 
in this study was similar to previously reported data 
241
.  
The two methods for assessing endothelial function both detected endothelial dysfunction in 
patients with CAD compared to controls. There was however no correlation between the two 
methods. This is not surprising given the small numbers of patients in whom both methods were 
performed. Furthermore the two methods assess endothelial function in different vascular beds. 
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Rambaran et al.
186
 compared endothelial function assessed by change in wave reflection 
following salbutamol and FMD. They found that although endothelial function as assessed by 
these two methods was correlated this relationship was not particularly strong. Only a subgroup 
of the all the participants recruited for the study had endothelial function data available 
reflecting some of the difficulties with the two methods. Organ bath data was limited by the 
availability of vessels which cannot be easily controlled for. More disappointing were the 
number of patients in whom in vivo endothelial function data was available. The PWA technique 
was relatively easy to perform and well tolerated by participants. The major factor limiting 
completion of in vivo endothelial function studies was time. The protocol took approximately 1 
hour which was excessive for many of the CAD patients and was a major limitation of the 
technique. Patients were seen immediately prior to admission to hospital and time was limited 
due to admission procedures and distance many of the patients had to travel. This was a 
deficiency of the study design. 
The presence of impaired endothelial function in patients with type 2 DM and CAD despite well 
controlled LDL levels, widespread use of statins and ACEi/ARBs and reasonable glycaemic 
control highlights the need for further cardiovascular management strategies specifically 
targeted at improving endothelial function. Insulin resistance, increased oxidative stress, 
inflammation and dyslipidaemia may all contribute to endothelial dysfunction seen in patients 
with CAD with and without overt diabetes. Elucidating the relative contribution of these 
mechanisms should help identify novel strategies for tackling endothelial dysfunction in these 
patients. Since endothelial dysfunction is an important prognostic factor in patients with 
established CAD it is hoped that improved endothelial function would lead to improved 
cardiovascular outcomes. Large prospective studies are required to confirm this hypothesis. To 
date large trials assessing endothelial function have been limited by the availability of simple 
non-invasive techniques. The PWA technique used in this study would be suitable for larger 
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trials. It was simple to perform and well tolerated by the majority of patients. The major 
drawback was the time required for completion of the protocol. Furthermore it is unclear as to 
the sensitivity of this test and the ability to detect the small changes in endothelial function that 
might be expected in an intervention study. 
There are a number of limitations to this study. The design of the study limited the time 
available to examine patients and therefore reduced the numbers of patients who had in vivo 
assessment of endothelial function performed. The small number of patients in the study, 
particularly with in vivo results limited the further analysis of the results. The cross-sectional 
design, limits the conclusions that can be drawn from this study. The VV control group was 
significantly younger than patients with CAD and contained more women. Age has previously 
been shown to be an important determinant of endothelial function and results need to be 
interpreted in the context of the age difference 
81
. However the results of the ex vivo endothelial 
function studies were confirmed using an in vivo method in a healthy control group that was 
more closely matched for age to the patients with CAD.  
4.6 Chapter summary 
This study has shown patients with established CAD have impaired endothelial function 
compared to healthy controls. Type 2 DM is associated with significantly impaired endothelial 
function compared to patients with CAD alone. The impairment in endothelial function persists 
despite good control of cardiovascular risk factors and widespread use of secondary prevention 
therapies. Novel strategies targeting endothelial dysfunction are therefore required. A non-
invasive PWA technique for assessing endothelial function is feasible for use in larger clinical 
trials however a major limitation is the time for required to complete studies.  
  
 137 
5 Oxidative stress 
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5.1 Introduction  
Increased production of reactive oxygen species (ROS) and in particular superoxide (O2
-
)is 
understood to be pivotal the development of endothelial dysfunction and cardiovascular disease 
(CVD)
84
. Sources of O2
-
 include both vascular cells and circulating cells such as 
phagocytes
92;178
. Within the vasculature there are a number of enzymatic sources of O2
-
. These 
include NAD(P)H oxidase, xanthine oxidase, endothelial nitric oxide synthase (eNOS) and the 
mitochondrial electron transport system
84
. Of these NAD(P)H oxidase is understood to be one of 
the principle sources
87
. The enzyme eNOS under normal conditions produces nitric oxide (NO). 
However under certain circumstances the enzyme becomes uncoupled and can switch to being a 
net producer of O2
-177
. This may occur when the availability of the cofactor tetrahydrobiopterin 
is limited
177
. Circulating cells such as phagocytes also contribute to the burden of oxidative 
stress both whilst in circulation and as they infiltrate atherosclerotic plaques
92
. Phagocytes 
produce O2
-
 via NAD(P)H oxidase system
242
.  
5.1.1 Assessing oxidative stress 
The term oxidative stress refers to complex interactions between ROS and antioxidant systems. 
Levels of ROS can be measured directly or assessed using indirect markers. Direct measurement 
of ROS in the mainstay focuses on measurement of superoxide as this is considered to be the 
principle ROS. O2
-
 is highly reactive and unstable making assessment difficult. O2
-
 production 
can be measured directly in tissues affected by the CVD process for example vascular tissue, 
cardiac tissue and also in cells that are involved in the pathogenesis of CVD such as 
mononuclear cells or endothelial progenitor cells
116;178;243;244
. Primary cells such as vascular 
smooth muscle cells can also be cultured and ROS species measured
245
. Using the above 
methods for assessing oxidative stress in humans is clearly limited by the availability of suitable 
samples. Furthermore the results need to be interpreted cautiously as due the ex vivo nature of 
the methods processes involved may differ from those occurring in situ. Techniques suitable for 
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direct measurement of O2
-
 include chemiluminescence-based techniques and electron spin 
resonance spectroscopy
113
.  
Indirect methods involve the quantification of products produced as a result of oxidative 
damage. These include oxidised low density lipoprotein (LDL), isoprostanes and thiobarbituric 
acid-reacting substances. These indirect measures are attractive as samples of blood or urine are 
easily obtained. In addition the techniques required for these assays tend to be more 
straightforward than those employed for the direct measurement of ROS. The sensitivity and 
specificity of these techniques has been questioned however
246
. Oxidised LDL can be measured 
using enzyme linked immunosorbant assays. There are a number of different assays that 
measure slightly different changes in LDL particles that comprise the oxidised LDL entity. The 
results are therefore not necessarily comparable between different assays
247
. Oxidised LDL has 
been shown to be a predictor of severity of coronary artery disease (CAD)
248;249
. However some 
assays are not independent of LDL levels
247
 There are as yet no prospective studies of oxidised 
LDL and cardiovascular outcomes. Isoprostanes are stable compounds formed following the 
reaction of ROS with the phospholipid domain of cell membranes and can be measured in urine 
or plasma 
250
.Urinary isoprostanes have been shown to be an independent predictor of CAD
251
. 
Prospective studies are once again needed. Thiobarbituric acid reacting substances are products 
of lipid peroxidation and had previously been used in a number of studies
246
. However ongoing 
use of these in the assessment of oxidative stress has been questioned due to low accuracy of 
these methods
246;250
. 
An ideal tool for assessing oxidative stress would be simple, specific, non-invasive and 
repeatable. At present such a test does not exist restricting the detailed assessment of oxidative 
stress in humans to ex vivo experiments.  
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5.1.2 Oxidative stress and CAD 
There is a wealth of data implicating increased oxidative stress, and in particular increased O2
-
 
levels, as a major underlying mechanism underlying cardiovascular disease in animal models
79
. 
This is supported by evidence from studies in humans although this is more limited due to the 
inherent difficulties with assessing oxidative stress in vivo. 
Vascular O2
-
 is increased in saphenous veins of patients with CAD compared to controls
179
. In 
patients with CAD NAD(P)H oxidase is thought to be the predominant source of O2
-87
. There is 
evidence that hypertension, hypercholesterolemia and diabetes mellitus (DM) all contribute to 
the increased levels of oxidative stress observed in patients with CAD. Diabetes status and 
hypercholesterolaemia are both independently associated with levels of NAD(P)H oxidase 
activity
87
. Levels of O2
-
 are increased in circulating phagocytes in patients with hypertension and 
cardiovascular risk factors
116;252
. Levels of mononuclear O2
-
 production has been shown to be 
associated with carotid–intima media thickness, a surrogate marker of atherosclerosis253. Less is 
known regarding mononuclear O2
-
 production in vivo in patients with established CAD. 
Mononuclear cell O2
-
 production was increased in patients with stable angina and these cells 
exhibited greater adhesiveness in ex vivo studies
254
. 
5.1.3 Oxidative stress and DM 
The role of oxidative stress in patients with type 2 DM is of particular interest. Increased 
oxidative stress has been implicated as a key mechanism underlying many of the complications 
of diabetes including CVD
255
. In addition increased oxidative stress may contribute to insulin 
resistance and β-cell dysfunction driving the development of type 2 DM225. Increased oxidative 
stress in patients with type 2 DM may partly explain the endothelial dysfunction and increased 
cardiovascular risk associated with DM.  
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Vascular O2
-
 is increased in vessels of patients with CAD and type 2 DM compared to patients 
with CAD alone
177
.In these patients important sources included NAD(P)H oxidase and 
uncoupled eNOS
177
. Mononuclear NAD(P)H oxidase O2
-
 production is increased in phagocytes 
of patients with metabolic syndrome and this appeared to be related to hyperinsulinaemia
252
. 
Mononuclear cells from patients with type 2 DM secrete increased levels of O2
-
 compared to 
controls
256
. Mononuclear cells incubated in hyperglycaemic conditions also produce increased 
O2
-257
 Other markers of increased oxidative stress such as increased circulating markers and 
decreased antioxidant capacity abnormal in patients with type 2 DM 
91
.  
The mechanisms underlying increased oxidative stress in type 2 DM are not fully understood. 
Hyperglycaemia appears to be one of the driving factors. Hyperglycaemia can cause increased 
oxidative stress through a number of mechanisms including glucose autoxidation, through the 
formation of advanced glycation end products (AGE) and activation of polyol pathway
91
. 
Important enzymes are thought to include NAD(P)H oxidases, mitochondrial electron transport 
chain and uncoupled eNOS 
177;258
.  
5.1.4 Strategies to reduce oxidative stress 
Increased intake of fruit and vegetables protects against CVD 
259
. The epidemiological data 
together with evidence implicating increased oxidative stress in the pathogenesis of CVD 
disease led to the hope that oral antioxidants would be beneficial in reducing CVD. Both vitamin 
C and vitamin E improve endothelial dysfunction in patients with cardiovascular risk 
factors
223;224
. Large randomised control trials have however shown no improvement in 
cardiovascular outcomes. The HOPE trial randomised patients to either vitamin E or placebo 
and showed no reduction in cardiovascular events after 5 years
260
. Furthermore subgroup 
analysis showed no benefit of vitamin E in terms of CVD in patients with type 2 DM
239
. This is 
despite evidence that patients with type 2 DM are thought to have higher levels of oxidative 
stress. Similar results were found in the heart protection study
240
. The heart protection study 
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showed no improvement in cardiovascular outcomes with a combination of vitamin E, vitamin C 
and β carotene240 It is not clear why the use of antioxidants failed to improve cardiovascular 
outcomes in these large trials. Due to the inherent difficulties of assessing oxidative stress these 
trials did not quantify the changes in levels of oxidative stress. Therefore it is unknown whether 
the administration of oral antioxidants had the desired effect on oxidative stress. The negative 
results seen in large clinical trials do not refute the importance of oxidative stress in the 
development of cardiovascular disease. Various explanations have been proposed for the failure 
of antioxidants to improve cardiovascular outcomes. Possible reasons include selection of the 
wrong antioxidants, the wrong dose of antioxidants and targeting patients too far along the 
cardiovascular continuum
261
. 
In view of the disappointing results with oral vitamins and antioxidants other strategies for 
reducing oxidative stress have been considered. There is evidence that use of Angiotensin 
converting enzyme inhibitors (ACEi) and Angiotensin receptor blockers (ARBs) can reduce 
vascular NAD(P)H oxidase O2
-
 production
262
. Statins have been shown in improve both 
endothelial dependent vasodilation and reduce endothelial O2
-
 production
263
. Exercise training 
has also been shown to reduce oxidative stress in patients with CAD
264
. 
5.1.5 Summary  
Increased oxidative stress appears to be pivotal in the development of cardiovascular disease. 
Increased oxidative stress can contribute to endothelial dysfunction by reducing the 
bioavailability of NO. Increased oxidative stress may be particularly important in the 
development of cardiovascular disease in patients with type 2 DM. However the failure of oral 
antioxidants in large clinical trials highlights the need for further understanding of the 
mechanisms underlying oxidative stress in CVD and diabetes and better tools for assessing 
oxidative stress clinically. 
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5.2 Aims 
The hypotheses were firstly that patients with CAD would have increased oxidative stress 
compared to healthy controls. Secondly patients with CAD and type 2 DM would have further 
elevations in oxidative stress compared to patients with CAD alone.  
The aims of this study were: 
1. To assess O2
-
 levels in the vasculature, mononuclear cell and whole blood of patients 
with CAD compare to healthy controls 
2. To assess the impact of type 2 DM on O2
-
 levels in patients with CAD 
3. To assess the use of whole blood O2
-
 production as a simple marker of oxidative stress. 
5.3 Methods 
Vascular O2
- 
production was assessed in saphenous veins in patients with CAD and VV controls 
recruited as part of the VASCAB study. Mononuclear and whole blood O2
-  
levels were 
 
assessed 
using EPR spectroscopy in patients with CAD and controls recruited as part of the VASCAB 
study. Detailed methods are provided in chapter 2. 
5.4 Results 
5.4.1 Vascular O2- studies 
5.4.1.1 Vascular O2- studies in patients with CAD 
Vascular O2
-
 measurements were performed in saphenous veins from 71 patients with CAD 
undergoing CABG and in 13 control veins from patients undergoing VV surgery. Participant 
characteristics and demographics are shown in table 5.1. VV controls were significantly younger 
than CAD group with greater proportion of females. There was no significant difference in 
blood pressure. As expected there was high usage of cardiovascular secondary prevention 
therapies in the CAD group. Biochemistry results are shown in table 5.2. Lipid profiles reflect 
the widespread use of statins in the patients with CAD with lower total cholesterol and LDL 
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cholesterol levels compared to controls. HDL was significantly lower in patients with CAD 
compared to controls. Triglyceride levels were significantly higher in patients with CAD. The 
patients in whom vascular O2
-
 levels were available did not differ from the whole study cohort in 
terms of clinical examination and biochemistry results (see supplementary data tables 10.1 to 
10.4). 
Levels of O2
-
 in saphenous veins from patients with CAD were significantly higher compared to 
varicose vein controls, 0.75±0.48 vs.0.43±0.33 nmol/mg/min P=0.012 (figure 5.1).The 95% 
confidence intervals for the difference in mean vascular O2
- 
in patients with CAD compared to 
controls was 0.09 to 0.54 nmol/mg/min.  
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Table 5.1 Demographics and clinical characteristics for patients with CAD and control 
patients with VV in vascular O2
-
 studies 
 CAD 
 (n=71) 
VV Controls  
(n=13) 
P-value 
Age (years) 64.8±10.1 47.3±18.0 <0.0001 
Male (%) 58(81.7) 5(38.5) 0.003 
Systolic BP (mm Hg) 139.4±25.2 134.8±22.8 NS 
Diastolic BP(mm Hg) 78.2±11.8 85.3±12.4 NS 
Heart rate (beats/min) 63.6±12.7 73.5±17.7 NS  
Body Mass Index (kg/m
2
) 29.6±5.0 26.5±2.0 NS 
Current Smoker (%) 3(4.2) 2(15.4) NS 
Type 2 diabetes mellitus (%) 22(31) 0 n/a 
Hypertension (%) 41(57.7) 3(23.1) 0.015 
Myocardial Infarction (%) 38(53.5) 0 n/a 
TIA/CVA (%) 4(5.6) 1(7.7) NS 
Chronic renal failure (%) 3(4.2) 0 NS 
Heart failure (%) 12(16.9) 0 n/a 
Aspirin (%) 61(85.9) 2(15.4) <0.0001 
Other antiplatelet agent (%) 20(28.2) 1(7.7) NS 
Statin (%) 63(88.7) 2(15.4) <0.0001 
ACEi/ARB (%) 45(63.4) 1(7.7) <0.0001 
Beta-blocker (%) 53(74.6) 1(7.7) <0.0001 
Calcium channel blocker (%) 22(31.0) 1(7.7) NS 
Nitrate (%) 36(50.7) 0 <0.0001 
Diuretic (%) 21(29.6) 2(15.4) NS 
Oral hypoglycaemic agent (%) 11(15.5) 0 n/a 
Insulin (%) 4(5.6) 0 n/a 
Continuous variables are mean± standard deviation. Discrete variables are absolute numbers and 
percentage (%) BP, blood pressure, TIA; transient ischaemic attack, CVA, cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 5.2. Biochemistry results in patients with CAD and control patients with VV for 
vascular O2
- studies 
 CAD 
(n=71) 
VV controls 
(n=13) 
P-value 
Cholesterol (mmol/L) 4.07±1.04 4.96±0.99 0.034 
Triglycerides (mmol/L) 2.22±1.37 1.17±0.47 0.005 
LDL (mmol/L) 1.95±0.82 2.69±1.11 0.03 
HDL (mmol/L) 1.14±0.26 1.72±0.30 <0.0001 
CRP(mg/L) 4.45±9.27 3.55±4.17 NS 
HbA1c (%) 6.08±1.07 5.42±0.17 <0.0001 
Urinary ACR(mg/mmol) 3.06±7.50 1.19±0.46 NS 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C-reactive protein; HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio. 
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Figure 5.1 Vascular O2
- production in saphenous veins from patients with CAD and 
control patients with VV. 
 
5.4.1.2 Vascular O2- in patients with CAD with and without type 2 DM 
Twenty two (31%) of the CAD patients had type 2 DM. Demographics and clinical 
characteristics for CAD patients with and without type 2 DM are shown in table 5.3. Body mass 
index was significantly higher in the patients with type 2 DM compared to those without. There 
was a higher prevalence of hypertension in the patients with type 2 DM. There was significantly 
higher usage of diuretics in the patients with diabetes. Use of modifiers of renin-angiotensin 
P=0.012 
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system (ARB/ACEi) was also more widespread in patients with type 2 DM although this was 
not statistically significant.  
Biochemistry results are shown in table 5.4. HbA1c was significantly higher in the patients with 
Type 2 DM. There was a trend to lower levels of both LDL and HDL in patients with type 2 DM 
although this was not statistically significant. 
There was no significant difference in vascular O2
-
 production in patients with CAD and type 2 
DM compared to patients with CAD alone, 0.64±0.43 vs 0.79±0.50 nmol/mg/min, P=0.164 
(Figure 5.2).The 95% confidence intervals for the difference in mean vascular O2
- 
production in 
patients with and without type 2 DM was -0.39 to 0.09 nmol/mg/min. 
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Table 5.3 Demographics and clinical characteristics in CAD patients with and without type 
2 DM in vascular O2
- study. 
 CAD alone 
(n=49) 
CAD and type 2 
DM 
(n=22) 
P-value 
Age (years) 64.8±9.6 64.9±11.3 NS 
Male (%) 39(79.6) 19(86.4) NS 
Systolic BP(mm Hg) 139.7±26.5 138.8±22.2 NS 
Diastolic BP(mm Hg) 79.7±11.0 74.4±13.2 NS 
Heart rate (beats/min) 63.0±12.1 64.9±14.2 NS 
Body Mass Index, kg/m
2
 28.7±4.7 32.2±5.1 0.023 
Current smokers (%) 2(4.1) 1(4.5) NS 
Hypertension (%) 20(40.8) 21(95.5) <0.0001 
Myocardial Infarction (%) 24(49) 14(63.6) NS 
TIA/CVA (%) 2(4.1) 2(9.1) NS 
Chronic renal failure (%) 2(4.1) 1(4.5) NS 
Heart failure (%) 5(10.2) 7(31.8) NS 
Aspirin (%) 41(83.7) 20(90.2) NS 
Other antiplatelet agent (%) 16(32.7) 4(18.2) NS 
Statin (%) 43(87.8) 20(90.9) NS 
ACEi/ARB (%) 28(57.1) 17(77.3) NS 
Beta-blocker (%) 35(71.4) 18(81.8) NS 
Calcium channel blocker (%) 15(30.6) 7(31.8) NS 
Nitrate (%) 27(55.1) 9(40.9) NS 
Diuretic (%) 10(20.4) 11(50) 0.026 
Oral hypoglycaemic agent (%) 
Meformin 
Glitazones 
Sulphonylureas 
n/a 11(50) 
8(36) 
2(9) 
6(27) 
n/a 
Insulin (%) n/a 4(18.2) n/a 
Continuous variables are mean± standard deviation. Discrete variables are absolute numbers and 
percentage (%) BP, blood pressure, TIA; transient ischaemic attack, CVA, cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 5.4. Biochemistry results for vascular O2
- studies in CAD patients with and without 
type 2 DM 
 CAD alone 
(n=49) 
CAD and type 2 
DM (n=22) 
P-value 
Cholesterol (mmol/L) 4.10±1.01 3.99±1.11 NS 
Triglycerides (mmol/L) 2.04±0.98 2.63±1.97 NS 
LDL (mmol/L) 2.01±0.80 1.81±0.85 NS 
HDL (mmol/L) 1.16±0.28 1.10±0.22 NS 
CRP(mg/L) 5.27±10.9 2.59±2.91 NS 
HbA1c (%) 5.6±0.42 7.2±1.26 <0.0001 
Urinary ACR (mg/mmol) 3.19±8.95 2.79±2.69 NS 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C-reactive protein; HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio. 
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Figure 5.2. Vascular O2
-
 production in saphenous veins in patients with CAD alone and 
CAD with type 2 DM. 
 
5.4.2 EPR spectroscopy studies 
5.4.2.1 EPR spectroscopy studies in patients with CAD 
O2
-
 release from mononuclear cell and whole blood was assessed in 89 patients with CAD and 
68 healthy controls. Participant demographics and clinical characteristics are shown in table 5.5. 
Controls were younger than patients with CAD and included more women. Diastolic blood 
pressure was lower in patients with CAD compared to controls there was no significant 
P=0.164 
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difference in systolic blood pressure. There was widespread use of cardiovascular secondary 
prevention strategies in patients with CAD. 
Biochemistry results are shown in table 5.6. As would be expected given the prevalence of statin 
therapy total cholesterol and LDL cholesterol levels were lower in patients with CAD. HDL was 
lower in and triglyceride levels higher in patients with CAD. HbA1c, CRP and urinary ACR 
were all higher in the CAD group. 
Mononuclear cell O2
-
 release is shown in figure 5.3. Basal O2
-
 release from mononuclear cells 
was significantly greater in patients with CAD compared to controls 70.0±52.68 vs. 49.7±30.98 
AU, P=0.01. In addition PMA stimulated O2
-
 levels were also higher in CAD patients compared 
to controls (773.4±371.5 vs. 416.6±189.4 AU, P<0.0001).  
O2
-
 levels in whole blood were also increased in CAD patients compared to controls 54.7±57 x 
10
3 
AU vs. 31.4±14 x10
3
AU, P=0.043 (figure 5.4).The 95% confidence intervals for the 
difference in mean whole blood O2
-
 between patients with CAD compared to controls were 14.3 
to 45.8 x10
3
 AU.  
  
 153 
Table 5.5. Demographics and clinical characteristics in patients with CAD and controls in 
EPR spectroscopy studies 
 CAD 
(n=89) 
Controls 
(n=68) 
P-value 
Age (years) 67.0±9.1 60.8±10.5 <0.0001 
Male (%) 69(77.5) 41(60.3) 0.023 
Systolic BP, mm Hg 139.2±23.6 137.6±18.8 NS 
Diastolic BP, mm Hg 77.4±11.3 81.3±10.6 0.03 
Heart rate (beats/min) 63.2±11.1 68.2±12.7 0.01 
Body Mass Index, kg/m
2
 29.2±4.8 26.0±3.6 NS 
Current Smokers (%) 8(9.0) 4(5.9) NS 
Type 2 diabetes mellitus (%) 25(28.1) 0 n/a 
Hypertension 49(55.1) 18(27.3) 0.001 
Myocardial Infarction 42(47.2) 0 n/a 
TIA/CVA 6(6.7) 1(1.5) NS 
Chronic renal failure 5(5.6) 0 NS 
Heart failure 14(15.7) 0 n/a 
Aspirin 76(85.4) 9(13.2) <0.0001 
Other antiplatelet agent 23(25.8) 1(1.5) <0.0001 
Statin 80(89.9) 8(11.8) <0.0001 
ACEi/ARB 52(58.4) (8.8) <0.0001 
Beta-blocker 68(76.4) 5(7.4) <0.0001 
Calcium channel blocker 32(36.0) 4(5.9) <0.0001 
Nitrate 56(62.9) 0 <0.0001 
Diuretic 21(23.6) 5(7.4) 0.008 
Oral hypoglycaemic agent 16(18.0) 0 n/a 
Insulin 5(5.6) 0 n/a 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C-reactive protein; HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio. 
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Table 5.6.Biochemistry results in patients with CAD and controls in EPR spectroscopy 
studies 
 CAD 
(n=89) 
Controls 
 (n=68) 
P-value 
Cholesterol (mmol/L) 4.04±0.86 5.67±1.16 <0.0001 
Triglycerides (mmol/L) 1.99±0.72 1.51±0.79 0.001 
LDL(mmol/L) 1.96±0.72 3.45±1.04 <0.0001 
HDL(mmol/L) 1.17±0.27 1.53±0.40 <0.0001 
CRP(mg/L) 4.25±8.94 1.96±2.37 0.002 
HbA1c(%) 6.19±1.09 5.52±0.32 <0.0001 
Urinary ACR(mg/mmol) 2.79±6.03 1.34±0.94 0.046 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C-reactive protein; HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio. 
Figure 5.3. Basal and stimulated mononuclear cell O2
-
 production in patients with CAD 
and controls (mean+standard deviation)  
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Figure 5.4. Whole blood O2
-
 production in patients with CAD compared to controls  
 
5.4.2.2 EPR spectroscopy studies in patients with CAD, with and without type 2 DM 
EPR spectroscopy O2
-
 studies were performed in 25 patients with CAD and type 2 DM and 64 
patients with CAD alone. Demographics and clinical characteristics are shown in table 5.7.There 
was a higher prevalence of hypertension in the patients with type 2 DM. Blood pressure was not 
difference between the two groups there was however higher usage of ARB/ACEi, calcium 
channel blockers and diuretics in patients with type 2 DM. 
Biochemistry results are shown in table 5.8.Unsurprisingly patients with type 2 DM had higher 
HbA1c levels compared to patients with CAD alone. There were no other significant differences 
between the two groups. 
P=0.043 
n=68 n=89 
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Basal mononuclear cell O2
-
 was not increased in patients with type 2 DM compared to those 
without diabetes, rate 53.7±32.5 vs. 75.7±57.3 AU, P=0.12. In fact there was a trend towards 
lower O2
-
 levels in patients with type 2 DM. There was no difference in stimulated mononuclear 
cell O2
-
 release between patients with and without type 2 DM, 30.2±21.5 vs.34.7±21.4 AU 
p=0.38 (Figure 5.5). There was also no difference in whole blood O2
-
 release between the 2 
groups. 60.8±68.2 x 10
3
 AU in patients with type 2 DM vs 52.4±53 x10
3
 AU in patients without 
diabetes P=0.8 (figure 5.6).The 95% confidence intervals for the difference in mean whole 
blood superoxide between patients with and without type 2 DM were -35.2 to 33.3 x10
3
 AU. 
There was a strong correlation between whole blood O2
-
 release and basal mononuclear cell O2
-
release, r=0.689, P<0.0001 (figure 5.7). 
 157 
Table 5.7. Demographics and clinical characteristics for patients with CAD with and 
without type 2 DM in the EPR spectroscopy study 
 CAD alone 
(n=64) 
CAD and type 2 
DM  
(n=25) 
P-value 
Age (years) 66.1±9.8 69.1±6.8 NS 
Male (%) 48(75) 21(84) NS 
Systolic BP (mm Hg) 138.5±25.4 141.1±18.2 NS 
Diastolic BP(mm Hg) 78.5±11.6 74.7±9.9 NS 
Heart rate (beats/min) 63.5±12.2 62.4±7.9 NS 
Body Mass Index (kg/m
2
) 28.8±4.9 30.5±4.2 NS 
Current Smoker (%) 5(7.8) 3(12) NS 
Hypertension (%) 28(43.8) 21(84) 0.004 
Myocardial Infarction (%) 28(43.8) 14(56) NS 
TIA/CVA (%) 2(3.1) 4(16) NS 
Chronic renal failure (%) 3(4.7) 2(8) NS 
Heart failure (%) 8(12.5) 6(24) NS 
Aspirin (%) 53(82.8) 23(92) NS 
Other antiplatelet agent (%) 16(25) 7(28) NS 
Statin (%) 57(89.1) 23(92) NS 
ACEi/ARB (%) 33(51.6) 19(76) 0.042 
Beta-blocker (%) 48(75) 20(80) NS 
Calcium channel blocker (%) 18(28.1) 14(56) 0.026 
Nitrate (%) 42(65.6) 14(56) NS 
Diuretic (%) 11(17.2) 10(40) 0.05 
Oral hypoglycaemic agent (%) 0 15(60) n/a 
Insulin (%) 0 5(20) n/a 
Continuous variables are mean± standard deviation. Discrete variables are absolute numbers and 
percentage (%) BP, blood pressure, TIA; transient ischaemic attack, CVA, cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
  
 158 
Table 5.8 Biochemical analysis for patients with CAD, with and without type 2 DM in the 
EPR spectroscopy study 
 CAD alone 
(n=64) 
CAD and type 2 
DM 
 (n=25) 
P-value 
Cholesterol (mmol/L) 4.07±0.87 3.95±0.87 NS 
Triglycerides (mmol/L) 1.89±0.82 2.22±1.23 NS 
LDL(mmol/L) 2.00±0.74 1.83±0.66 NS 
HDL(mmol/L) 1.20±0.28 1.10±0.24 NS 
CRP(mg/L) 4.16±9.4 4.45±7.78 NS 
HbA1c (%) 5.7±0.35 7.4±1.3 <0.0001 
Urinary ACR (mg/mmol) 2.46±6.61 3.6±4.3 NS 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C-reactive protein; HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio. 
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Figure 5.5 Mononuclear cell O2
-
 prodction in patients with CAD, with and without type 2 
DM (mean+standard deviation) 
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Figure 5.6. Whole blood O2
-
 release in patients with CAD with and without type 2 DM.  
 
  
P=0.8 
n=64 n=25 
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Figure 5.7. Basal mononuclear cell O2
-
 release and whole blood O2
-
 release.  
 
 
  
Y=0.75x-1.69 
R2=0.55 
P<0.0001 
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5.5 Discussion 
In this study vascular, mononuclear and whole blood O2
-
 was increased in patients with CAD 
compared to healthy controls. However patients with type 2 DM had similar levels of oxidative 
stress compared to those without diabetes. Whole blood O2
-
 levels are a simple measure of 
oxidative stress and were strongly correlated with mononuclear O2
-
 production. Whole blood O2
-
 
levels may therefore be a measure of oxidative stress that can be applied to larger studies in the 
future. 
The finding of increased vascular O2
-
 production in patients with CAD is in keeping with 
previous other studies
87;179
. It is understood this is the first study to use EPR spectroscopy 
techniques to assess mononuclear cell O2
-
 production in patients with established CAD. Basal 
mononuclear cell O2
-
 levels may modify oxidative status of blood as it circulates and in addition 
reduce NO bioavailability contributing to endothelial dysfunction
116
. Stimulated mononuclear 
cell O2
-
 production indicates the responsiveness of the cells to stimuli. Mononuclear cells have 
been shown to have higher stimulated levels of O2
-
 in patients with cardiovascular risk factors
252
. 
Increased responsiveness may contribute to increased ROS production in vascular tissues. Little 
was previously known regarding mononuclear production of O2
-
 in patients with established 
CAD. However our finding of increased levels compared to controls is in keeping with other 
studies that have shown increased phagocyte O2
-
 in patients with cardiovascular risk 
factors
116;252;253
. To the best of knowledge this is the first study to show that whole blood O2
-
levels are increased in patients with CAD and that these levels correlate with phagocyte O2
-
 
levels. Whole blood O2
-
 production may provide information about both systemic levels of 
oxidative stress and white cell O2
-
 release.  
It is of interest that patients with CAD have increased levels of oxidative stress despite the use 
of ACEi/ARBs and statins which have been shown to reduce O2
-
 production
262;263
. Elevated 
levels of oxidative stress are thought to be pivotal in the development of cardiovascular disease 
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and in particular the development of endothelial dysfunction
84
. The endothelial dysfunction 
observed in patients with CAD may be partly a consequence of these elevated O2
-
 levels. 
Increased O2
-
 levels seen in patients with CAD may be a target for therapy but larger studies are 
needed to show the prognostic significance of O2
-
 and whether lowering these improves 
cardiovascular outcomes. 
Both hyperglycaemia and diabetes have previously been shown to be associated with increased 
levels of oxidative stress
91;177
 However in contrast to other studies the presence of type 2 DM 
was not associated with increased O2
-
 in the vasculature, mononuclear cells or whole blood. 
There are a number of possible explanations for these findings. Pharmacological management of 
patients with type 2 DM may be one explanation. ACEi/ARBs, statins and metformin have all 
been shown to reduce O2
-
 production
262;263;265
. In this study a high proportion of patients with 
type 2 DM were on ACEi/ARBs, in contrast in the study by Guzik et al.
87
 where use of 
ACEi/ARBs was similar between patients with and without diabetes. In this study 36% of 
patients were taking metformin. It is possible that the patients with type 2 DM had higher levels 
of vascular superoxide that were controlled by medication. 
As has been previously discussed the categorisation of patients in to diabetes or no diabetes is 
somewhat arbitrary. Hyperglycaemia and insulin resistance are continuous variables. Impaired 
glucose tolerance and insulin resistance were not assessed formally in our study; however given 
the elevated body mass index in the control group it is likely that a proportion of these patients 
had impaired glucose tolerance and insulin resistance. Fortuno et al.
252
 showed that in patients 
with metabolic syndrome mononuclear O2
-
 production was related to insulin resistance Patients 
with CAD without diabetes but with insulin resistance may have attenuated the difference 
between the two groups.  
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In chapter 4 it was shown that patients with type 2 DM and CAD had greater degrees of 
endothelial impairment compared to patients with CAD alone. Increased oxidative stress in 
patients with type 2 DM was previously believed to explain the impairment in endothelial 
function
84
. However in this study increased oxidative stress does not explain the greater degrees 
of endothelial dysfunction found in patients with type 2 DM. This data does not refute the 
importance of oxidative stress in the development of cardiovascular disease and endothelial 
dysfunction in patients with type 2 DM. These results do however show that patients with CAD 
and type 2 DM, on secondary prevention therapies with well controlled cardiovascular risk 
factors and reasonable glycaemic control do not have elevated oxidative stress. The finding that 
patients with type 2 DM have greater degree of endothelial dysfunction despite comparable 
levels of oxidative stress suggests that other mechanisms underlying endothelial dysfunction in 
this group of patients are important. Furthermore these mechanisms are not being addressed by 
current cardiovascular management strategies.  
Future studies are required to further understand the role of oxidative stress in cardiovascular 
disease. This includes the prognostic value of O2
-
 levels and the impact of decreasing superoxide 
levels on surrogate endpoints such as endothelial dysfunction but more importantly on 
cardiovascular outcomes. The use of whole blood O2
-
 levels could be applied to larger studies to 
try and answer these questions. In patients with type 2 DM further studies are required to 
identify mechanisms underlying impaired endothelial function.  
This study clearly has a number of limitations. It is an observational study so although O2
-
 levels 
are elevated in patients with CAD this gives use no information on the consequences of this 
effect. Furthermore results are only available for a small group of patients making further 
subgroup analysis limited. Our control groups were not well matched in terms of sex or age. 
This was partly a consequence of using patients with VV as controls. Healthy controls were 
recruited form health clubs and this may have biased us to recruiting more female patients. Age 
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has been associated with increased levels of oxidative stress
266;267
. Gender may also have effects 
on levels of oxidative stress
79
. This study focused only on one ROS and although O2
- 
is felt to be 
the key ROS others may also be important.  
5.6 Chapter summary 
This study has found increased levels of oxidative stress in patients with CAD compared to 
controls. Levels of oxidative stress are however similar between patients with type 2 DM 
compared to those without. Although oxidative stress may be important in the development of 
endothelial function and CVD, increased levels of oxidative stress do not explain the greater 
degree of endothelial impairment seen in patients with CAD and type 2 DM. Whole blood O2
-
 
levels may be a simple direct measure of ROS suitable for large scale clinical studies. 
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6 Dyslipidaemia in type 2 diabetes mellitus 
  
 167 
6.1 Introduction 
Abnormal lipids are a major risk factor for cardiovascular disease (CVD). Type 2 diabetes 
mellitus (DM) and other insulin resistant states are associated with a characteristic 
dyslipidaemia. This dyslipidaemia may partly explain the increased endothelial dysfunction in 
patients with type 2 DM described in chapter 4. 
6.1.1 Diabetic dyslipidaemia 
In insulin resistant states and type 2 DM abnormalities in lipoprotein metabolism result in a 
dyslipidemia characterised by high triglyceride levels and low, high density lipoprotein 
cholesterol (HDL)
40
. Low density lipoprotein cholesterol (LDL) levels are not significantly 
increased; there is however a preponderance of small dense LDL particles
268
. This has been 
called the atherogenic lipoprotein phenotype
269
. This phenotype may be partly genetically 
determined, however insulin resistance appears to play a key role
236
. 
6.1.2 Hypertriglyceridaemia 
The role of elevated triglycerides in the development of CVD is complex. Triglyceride levels are 
associated with increased risk of CVD
270
. The risks associated with hypertriglyceridaemia 
decrease after adjustment for HDL levels but remain significant
270
. Much of the increased risk 
associated with elevated triglycerides appears to be due to various effects and interactions with 
other lipoproteins
268
. Hypertriglyceridemia and altered metabolism of triglyceride rich 
lipoproteins is pivotal in the development of the dyslipidemia seen in insulin resistant states
236
. 
Triglycerides are transported in the circulation as chylomicrons and very low density lipoprotein 
(VLDL). Type 2 DM and insulin resistance is associated with increased levels of VLDL
40
. 
Insulin resistance increases three main sources of triglycerides for VLDL assembly in the liver. 
These are increased mobilisation of fatty acids from the adipose tissue, increased hepatic uptake 
of VLDL, intermediate LDL (ILDL) and chylomicron remnants, and increased de novo 
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lipogenesis
271
. Overproduction of VLDL results in low levels of HDL and generation of small 
dense LDL. This arises through in part to cholesterol transfer protein (CETP)-mediated 
triglyceride enrichment of LDL and HDL particles and the action of hepatic lipase on these 
particles
271
. 
6.1.3 Small dense LDL particles 
The structure of LDL is not homogenous. Usually 3 peaks are seen in the LDL density profile 
termed LDL-I, LDL-II and LDL-III
272
. LDL-I has lowest density and LDL-III, also called small, 
dense LDL has the highest density. In humans LDL shows a bimodal distribution and can be 
separated in to two phenotypes. Phenotype A consists of larger more buoyant LDL and pattern B 
where smaller denser LDL predominates
272
. An increase in small dense LDL particles is a 
feature of insulin resistance
273
. LDL size correlates positively with HDL levels and negatively 
with triglyceride levels
274
. Triglyceride is a major determinant of appearance of small, dense 
LDL particles. Small dense LDL is seen infrequently in patients with plasma triglyceride levels 
of less than 1.3mmol/L
275
. When triglyceride levels increase above this level small dense LDL 
increases in proportion to rise in triglycerides. The formation of small dense LDL particles in 
patients with hypertriglyceridaemia appears in part to be related to hepatic lipase activity
236
. 
Hepatic lipase activity is increased in insulin resistant states
271
. Hepatic lipase converts 
triglyceride enriched LDL to small dense LDL It is suggested that raised triglyceride levels are a 
key determinant of hepatic lipase activity
236
.  
A number of studies have shown an increased risk of CVD with small dense LDL
276;277
. 
However in many of these studies after multivariate adjustment small dense LDL is no longer an 
independent predictor of cardiovascular risk
277
. Small dense LDL may simply be a marker of a 
cluster of a broader pathology occurring as part of insulin resistant states rather than the driving 
factor underlying increased atherosclerosis. 
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Despite the above concerns small dense LDL exhibits a number of features that are 
proatherogenic. The susceptibility to oxidation increases with decreasing LDL size
278
. Small 
dense LDL is taken into arterial tissues more readily than larger LDL and resides in the sub-
endothelial space for longer due to increased proteoglycan
279
. Small dense LDL is also 
associated with impaired endothelial function
237
.  
6.1.4 HDL 
HDL levels are low in type 2 DM and other insulin resistant states
40
. Like LDL, HDL is 
heterogeneous with multiple subclasses of different diameter and density existing
280
. In type 2 
DM and other insulin resistant states there are reductions in the larger less dense species of HDL 
with relative increases in levels of smaller denser HDL 
268
. The causes of low HDL in type 2 
DM are likely to be multiple. One major factor appears to be transfer of cholesterol from HDL 
to triglyceride rich lipoproteins and transfer of triglyceride to HDL. Triglyceride rich HDL is 
hydrolysed by hepatic lipase and cleared from the plasma 
268
. As has already been discussed 
hepatic lipase is increased in insulin resistance 
236
. 
HDL levels are inversely correlated with cardiovascular risk 
49;50
. HDL mediates reverse 
transport of cholesterol. In addition HDL activates eNOS and may be associated with improved 
endothelial function 
211;281
. 
6.1.5 Managing dyslipidaemia in DM 
To date much of the focus on lipid management for CV prevention in type 2 DM has 
concentrated on the management of LDL. Levels of LDL are an important risk factor for CVD 
and statin therapy is generally safe and well tolerated 
44
. Concentrating on LDL alone will 
neglect to address important lipid disorders in type 2 DM and may hinder the further prevention 
of cardiovascular disease in patients with type 2 DM. 
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6.1.6 Lifestyle interventions 
Weight loss through calorie restriction has a beneficial effect on dyslipidaemia in type 2 DM 
282
. 
Low carbohydrate diets may be more effective than other weight loss diets. In a small 
randomised control study a low carbohydrate diet was associated with greater reductions in 
triglyceride levels and increase in HDL levels compared to a conventional low calorie, high 
carbohydrate diet. At 12 months there was no significant difference in weight loss achieved or 
LDL levels 
283
 . 
Dietary modification with increased intake of omega -3 fatty acids may also be beneficial. Fish 
oil increased HDL and reduced triglycerides but had no effect on levels of small dense LDL in 
patients with type 2 DM 
53
. 
Exercise can improve lipoprotein profiles in patients with insulin resistance. In a study of 111 
overweight individuals increasing the amount and intensity of exercise increased LDL particle 
size, HDL levels and reduced triglyceride levels. There were no changes in LDL levels 
284
 . 
6.1.7 Statins 
The evidence for the use of statins in the prevention of CVD is extensive 
44
. Statin therapy is 
therefore the mainstay of treatment for the management of dyslipidaemia in patients with type 2 
DM. Statins predominantly lower LDL levels through the inhibition of hepatic cholesterol 
synthesis and up-regulation of LDL receptors. Statins have a lesser effect on triglyceride levels 
and HDL levels 
44
. The effect of statins on levels of small dense LDL is variable with some 
classes increasing LDL size to a greater degree although results have been variable 
277
.  
6.1.8 Fibrates 
The mechanism of action of fibrates is not fully understood however one effect of fibrates is to 
decrease VLDL levels by increasing lipoprotein lipase activity 
271
. Fibrate therapy is therefore 
associated with increased HDL levels, decreased triglyceride levels and a decrease in small 
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dense LDL 
285
. There have been a number of fibrate studies assessing surrogate markers of 
atherosclerosis progression that showed promising results. The Diabetes Atherosclerosis study 
assessed the effect of fenofibrate on atherosclerosis progression as assessed by angiography 
286
. 
Fibrate therapy was associated with a reduction in the progression of angiographic markers of 
atherosclerosis. This effect appears to be partly mediated by changes in LDL size associated 
with fenofibrate 
287
.  
The results from large prospective clinical outcome trials of fibrates have been mixed however. 
The Veterans Affairs High-Density Lipoprotein Intervention study trial (VA-HIT) showed that 
in men with established coronary artery disease (CAD) and low HDL levels gemfibrozil reduced 
the risk of major cardiovascular events 
288
. The use of other lipid lowering medication in 
particular statins were extremely low in this study. The Fenofibrate Intervention and Event 
Lowering in Diabetes (FIELD) study looked at fenofibrate in over 9000 patients with type 2 DM 
289
. Compared to placebo fenofibrate did not reduce the primary endpoint of cardiovascular 
events there was however a significant reduction in non-fatal myocardial infarction and 
revascularisation 
289
. In the FIELD study a significantly higher proportion of patients in the 
placebo group commenced statin therapy compared to those in the treatment group. This may 
account for the apparent lack of benefit seen with fenofibrate. Most recently the lipid arm of the 
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial aimed to address whether 
intensive lipid management would be associated with further cardiovascular risk reduction 
290
. 
Over 5000 patients were randomised to either simvastatin and fenofibrate or simvastatin alone. 
There were no significant differences in LDL or HDL cholesterol between the two groups. 
Fibrate therapy was associated with a significant reduction in triglyceride levels. Combination 
therapy was not associated with a reduction in cardiovascular risk compared to statin therapy 
alone. Subgroup analysis however showed there appeared to be benefit in patients with a high 
baseline triglyceride and low baseline HDL levels
290
. At present there is no evidence supporting 
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the widespread use of fibrates in patients with type 2 DM. Fibrate therapy may however be 
beneficial in selected groups, and further research is required. 
6.1.9 Nicotinic acid 
Nicotinic acid predominantly raises HDL levels but in addition reduces triglyceride, LDL and 
small dense LDL levels 
285
. Nicotinic acid is associated with reduction of atherosclerosis 
assessed during angiography and significant regression of carotid intima media thickness 
291;292
. 
There is however only one cardiovascular outcome study, Coronary Drug Project 
293
. This study 
showed a reduction in myocardial infarction with niacin. Results of large clinical trials with 
niacin are awaited. There is concern regarding the use of niacin in patients with type 2 DM as it 
is associated with impaired glycaemic control. This effect however appears to be minimal when 
niacin is used in low doses. 
6.1.10 Summary 
Type 2 DM is commonly associated with a mixed dyslipidaemia of raised triglycerides, low 
HDL and increased small dense LDL levels. This dyslipidaemia appears to be a consequence of 
insulin resistance and may explain the increased cardiovascular risk. These lipid abnormalities 
may also partly account for the impaired endothelial function seen in patients with type 2 DM 
and other insulin resistant states. Strategies that specifically tackle these lipid abnormalities may 
be beneficial in preventing CVD in these groups, although evidence from clinical trials to 
support this hypothesis is limited at present.  
6.2 Aims 
In chapter 4 patients with type 2 DM and CAD were shown to have impaired endothelial 
function compared to patients with CAD alone. In this cohort oxidative stress does not appear to 
account for this difference in endothelial function. Type 2 DM is associated with a typical 
dyslipidaemia. These lipid abnormalities may persist in patients with type 2 DM and established 
 173 
CAD and may partially account for the greater impairment in endothelial function. The 
hypothesis was therefore that patients with type 2 DM and CAD would continue to have 
elevated triglyceride levels, low HDL and a preponderance of small dense LDL particles 
compared to patients without diabetes. Furthermore that this lipid abnormality may explain the 
greater endothelial dysfunction found in patients with CAD and diabetes compared to patients 
with CAD alone.  
The aims of this study were to perform detailed lipid analysis including LDL and HDL 
subfraction analysis in patients with CAD undergoing CABG with and without type 2 DM to try 
and explain the difference in endothelial function that had previously been observed. 
6.3 Methods 
Patients with established CAD with and without diabetes were recruited as part of the VASCAB 
study. Detailed lipid analysis was performed in these patient according to the methods described 
in chapter 2. 
6.4 Results 
In total 90 patients with CAD alone and 36 patients with type 2 DM and CAD were recruited as 
part of the VASCAB study. Demographics and clinical characteristics are shown in table 6.1. 
Patients with type 2 DM had significantly higher body mass index (BMI) compared to those 
without diabetes. In patients with type 2 DM prevalence of hypertension was significantly 
higher as was the use of modifiers of the renin-angiotensin system and diuretics.  
There was no difference in LDL levels in patients with type 2 DM compared to those without. 
There was however a preponderance of small dense LDL particles in patients with type 2 DM. 
LDL peak particle diameter (25.6±2.24 vs 25.8±0.53 nm; P=0.010) and mean particle diameter 
(25.8±2.24 vs 26.0±0.44 nm, P=0.035) were significantly smaller (table 6.2). The proportion of 
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LDL present in fraction 3 (small LDL-III) was greater in subjects with diabetes (53±2 vs. 
47±1%, P=0.041) (Figure 6.1). Levels of HDL were significantly lower in patients with diabetes 
compared to those without diabetes (1.07±0.05 vs. 1.27±0.04 mmol/L, P=0.015, table 6.2). 
There was a trend towards smaller dense particles (measured as mean particle diameter) 
although this was not significant. There was a trend to greater triglyceride levels in patients with 
type 2 DM although this was not statistically significant (Table 6.2). 
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Table 6.1. Demographics and clinical characteristics of patients with CAD and type 2 DM 
compared to CAD alone 
 CAD alone 
(n=90) 
CAD and Type 
2 DM (n=36) 
P-value 
Age (years) 65.7±9.2 66.9±10.0 NS 
Male (%) 67(77) 31 (83.8) NS 
Systolic BP (mm Hg) 139.0±24.8 140.3±19.7 NS 
Diastolic BP (mm Hg) 78.8±11.3 74.7±12.7 NS 
Heart rate (beats/min) 64.0±12.6 64.6±11.6 NS 
Body Mass Index, kg/m
2
 28.7±4.8 31.3±4.6 0.014 
Current smokers (%) 8(9.2) 3(8.1) NS 
Hypertension (%) 36(41.4) 33(89.2) 0.0001 
Myocardial Infarction (%) 41(47.1) 22(59.5) NS 
TIA/CVA (%) 5(5.7) 4(10.8) NS 
Chronic renal failure (%) 5(5.7) 2(5.4) NS 
Heart failure (%) 11(12.6) 11(29.7) NS 
Aspirin (%) 72(82.8) 33(89.2) NS 
Other antiplatelet agent (%) 26(29.9) 9(24.3) NS 
Statin (%) 76(87.4) 35(94.6) NS 
ACEi/ARB (%) 45(51.7) 30(81.1) 0.007 
Beta-blocker (%) 64(73.6) 31(83.8) NS 
Calcium channel blocker (%) 25(28.7) 17(45.9) NS 
Nitrate (%) 51(58.6) 19(51.4) NS 
Diuretic (%) 14(16.1) 18(48.6) 0.001 
Oral hypoglycaemic agent (%) 0 23(62.2) n/a 
Insulin (%) 0 8(21.6) n/a 
Continuous variables are mean± standard deviation. Discrete variables are absolute numbers and 
percentage (%) BP, blood pressure, TIA; transient ischaemic attack, CVA, cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 6.2 Lipid results for patients with type 2 DM and CAD compared to CAD alone 
  
n 
Type 2 diabetes 
mean±SEM  
 
n 
No diabetes 
mean±SEM 
P-value 
Total Cholesterol (mmol/L) 36 3.83±0.17 90 4.09±0.10 NS 
LDL-cholesterol (mmol/L) 34 1.79±0.12 90 2.00±0.08 NS 
LDL MPD (nm) 28 25.78±0.08 79 25.98±0.05 0.035 
LDL PPD(nm) 28 25.56±0.08 79 25.83±0.06 0.010 
HDL-cholesterol (mmol/L) 36 1.07±0.05 90 1.21±0.04 0.015 
HDL MPD (nm) 27 9.57±0.03 80 9.65±0.02 0.075 
Triglycerides (mmol/L) 36 2.38±0.29 84 1.92±0.10 NS 
SEM standard error of the mean; LDL low density lipoprotein; HDL, high density lipoprotein; 
MPD, mean particle diameter; PPD, peak particle diameter. 
Figure 6.1. LDL particle size in patients with CAD and type 2 DM compared to CAD alone 
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6.5 Discussion 
This study has shown that LDL levels are similar in patients with and without type 2 DM but 
there was a preponderance of small dense LDL particles. In addition HDL levels were lower in 
patients with type 2 DM. Triglyceride levels were increased in patients with type 2 DM but were 
not significantly different from levels in patients without diabetes.  
Low HDL levels and increased small dense LDL particles have been reported by other groups as 
a feature of type 2 DM and other insulin resistant states 
117;273
. Hypertriglyceridaemia is thought 
to be an important factor driving this abnormality 
271
. Although triglyceride levels were elevated 
in patients with type 2 DM, the difference was only moderate and not statistically significant. 
Other groups have reported that triglyceride levels above 1.3mmol/L are associated with 
increase in small dense LDL particles; triglyceride levels that are within the range seen in 
patients with type 2 DM in this study 
275
. 
Small dense LDL particles are associated with endothelial dysfunction 
237
. The finding of 
increased small dense LDL in this study may explain the greater endothelial dysfunction 
associated with type 2 DM described in chapter 2. The precise mechanisms underlying small 
dense LDL and endothelial dysfunction are not fully understood. However small dense LDL has 
greater susceptibility to oxidation and oxidised LDL reduces endothelium dependent 
vasodilation 
278;294
. Although small dense LDL is associated with increased CV risk the effect of 
LDL size as a predictor is often lost during multivariate adjustment further more at present the 
effect of modifying LDL particle size is unclear 
277
. 
The finding of significantly lower HDL levels in patients with type 2 DM may also explain the 
greater impairment of endothelial function described in patients with type 2 DM. HDL levels are 
a determinant of endothelial function and may be more important than LDL particle size 
193;209
. 
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HDL can activate and increase expression of eNOS which may partly account for the association 
between HDL levels and endothelial function 
211;281
.  
The patients in this study all had established CAD and were undergoing elective CABG. These 
patients should therefore be on optimal secondary prevention therapies. Use of statins was high 
in patients with and without diabetes reflected by the low LDL levels found in both groups. 
Indeed patients with type 2 DM had a trend towards lower LDL levels. The fact that patients 
with type 2 DM in this study continued to have low HDL levels and a preponderance of small 
dense LDL highlights the limitations of current secondary prevention strategies. Statin therapy 
will only have some impact on LDL particle size and HDL levels 
44;236
. This study was not 
powered to analyse the effect of different statins on lipid profiles although other studies have 
suggested that different statins may have different effects on LDL particle size 
277
. Currently 
there is no evidence from clinical trials to support the use of one statin above another 
independent of LDL levels 
44
. More information on the effect of modifying LDL size on clinical 
outcomes is needed.  
The dyslipidemia found in patients with type 2 DM compared to those without may partly 
explain the impaired endothelial dysfunction found in these patients. Future studies are needed 
to show whether addressing LDL particle size and HDL levels improves endothelial function 
and cardiovascular outcomes. Current management strategies are limited. There is currently no 
evidence to support the widespread use of fibrates in patients with type 2 DM, although the use 
in selected groups may be beneficial 
290
. Other options for improving dyslipidaemia associated 
with insulin resistant states include weight loss, dietary modification and increasing levels of 
physical activity. However with all of these interventions it will be difficult to separate whether 
modifying LDL size or increasing HDL levels are most important as the two variables are so 
inextricably linked. 
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This study has a number of limitations. Patient with type 2 DM were found to have both 
impaired endothelial function and increased small dense LDL and low HDL but since this is a 
cross-sectional study conclusions regarding causation cannot be made. The small numbers of the 
study limited subgroup analysis. The impact of addressing the specific lipid abnormalities in 
patients with type 2 DM on endothelial function is not known. The relative importance on the 
different aspects of diabetes related dyslipidaemia can also not be determined. 
6.6 Chapter summary 
In patients with type 2 DM and CAD there is a preponderance of small dense LDL particles and 
low HDL levels compared to patients with CAD alone. These lipid abnormalities may account 
for the impaired endothelial function associated with type 2 DM. Strategies to specifically 
address these abnormalities may improve endothelial function and cardiovascular outcomes in 
patients with type 2 DM. 
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7 Strategies for managing cardiovascular disease in type 2 
diabetes mellitus; the role of low density lipoprotein lowering 
 181 
7.1 Introduction 
7.1.1 Low density lipoprotein and cardiovascular disease 
Low density Lipoprotein (LDL) cholesterol is an important risk factor for cardiovascular disease 
(CVD) 
41
. Lowering LDL significantly reduces rates of CVD. Although lowering LDL by any 
means, including surgical methods is effective in reducing CVD the majority of the evidence 
comes from statin trials 
42;43
. The Cholesterol trialists collaboration showed a 20% reduction in 
cardiovascular events per mmol/L reduction in LDL 
44
. This benefit was seen across the range of 
LDL concentrations. Guidelines for the management of cardiovascular disease in high risk 
patients are therefore recommending increasingly low LDL-cholesterol targets in patients at 
high cardiovascular risk 
22-24
. Although patients with type 2 diabetes mellitus (DM) do not have 
elevated LDL levels compared to those without diabetes, considering the increased 
cardiovascular risk in patients with type 2 DM aggressive LDL lowering is one strategy for 
reducing CVD in these patients.  
LDL-cholesterol contributes to the development of CVD through a number of mechanisms. 
LDL-cholesterol is a key component of atherosclerotic plaques; however the role in the 
development of CVD is much more complex than simple accumulation of lipid within the vessel 
wall. LDL-cholesterol contributes to oxidative stress and endothelial dysfunction that underlie 
the atherosclerotic process 
87;179
. 
LDL-cholesterol levels are an important determinant of endothelial function
179
. Lowering LDL 
improves endothelial function. This is seen in statin therapy and by removal of LDL by 
apheresis 
207;295;296
. LDL can impair endothelial function through a number of mechanisms. 
LDL-cholesterol levels are an important determinant of oxidative stress 
87;179
. Furthermore 
Oxidised LDL-cholesterol can impair endothelial nitric oxide synthase (eNOS) activity by a 
 182 
depletion of caveolae cholesterol, a redistribution of eNOS away from caveolae and a 
diminished capacity to activate eNOS 
297;298
. 
7.1.2 Statin therapy 
Statins are effective at lowering LDL levels, are generally safe and well tolerated and therefore 
provide the mainstay of cholesterol lowering therapy. It can be difficult to differentiate between 
lipid effects and statin effects. Clearly achieving lower LDL targets will usually require more 
intensive statin therapy so LDL levels may be a surrogate marker for the intensity of statin 
therapy. Previous studies have shown that lipid lowering with statins is associated with 
improvements in endothelial function 
207
. Endothelial function improves rapidly following the 
initiation of statin therapy and is not related to the degree of LDL lowering 
208
. Statins have a 
number of effects that can contribute to improved endothelial function independent of lipid 
effects. Statins can increase eNOS expression; phosphorylation and activation 
299
. Arginase 
competes with eNOS for L-arginine and has been implicated in development of endothelial 
dysfunction 
202
. Statins inhibit a number of small signalling molecules for example inhibition of 
RhoA with consequent inhibition of arginase activity 
299
. Statins also reduce superoxide 
production through inhibition of vascular NAD(P)H oxidise expression and recoupling of eNOS 
263;300
. 
The clinical significance of the apparent lipid independent effects of statins is not certain. Meta-
analysis of the large statin trials shows no evidence that statins either as a class or individually 
provided additional cardiovascular risk reduction above that expected from degree of LDL 
lowering achieved 
301
. Indeed lowering LDL surgically by ileocecal bypass associated with 
similar risk reductions to those seen in statin prevention trials 
43
.  
Statin therapy is generally safe and well tolerated. Statin therapy can be associated with 
rhabdomyolysis although this is rare. The cholesterol trialists collaboration showed there was no 
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significant difference in rhabdomyolysis in patients on long term statins compared to controls 
44
. 
This analysis did not contain many high dose statin trials; and as rate of rhabdomyolysis is dose 
dependent high dose statin therapy may alter this risk. More recently concerns were raised 
regarding risk of DM with statin therapy. A meta-analysis by Sattar et al.
302
 found an increased 
risk of newly diagnosed DM with statin therapy. The risk of diabetes was small and the clinical 
significance is unclear. Furthermore the possible mechanisms underlying this association are not 
known. The lower LDL targets that are increasingly recommended are likely to increase the use 
of higher doses of statin therapy. It is therefore important as with all preventative therapy to 
reconsider both the risks and benefits of this strategy. 
There is a limit to the reduction in LDL levels that can be achieved with statin therapy alone. 
Combining other lipid lowering agents with statins are therefore of interest. Recent studies 
however have questioned the benefit of achieving lower LDL levels with combination therapy. 
In patients with familial hypercholesterolaemia there was no additional benefit on carotid intima 
media thickness with the addition of ezetimibe despite lower LDL levels 
303
 . More recently the 
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial showed no additional 
benefit on cardiovascular outcomes in patients with type 2 DM following the addition of fibrates 
to statin therapy, although LDL levels were not different between the two groups 
290
. The value 
of intensive lipid lowering and the choice of drugs to achieve this are still under debate. 
7.1.3 Summary 
In summary LDL cholesterol is an important factor in the development of CVD and a key 
determinant of endothelial function. Lowering cholesterol levels by any means improves 
cardiovascular outcomes. Statin therapy appears to have a number of lipid independent effects 
that may further contribute to the improvements in cardiovascular outcomes, however the 
clinical significance of these effects are uncertain. More intensive lipid lowering is 
recommended for high risk groups. The effect of these recommendations on the processes 
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underlying cardiovascular disease, such as endothelial function and oxidative stress is currently 
uncertain.  
7.2 Aims  
The hypothesis was that aggressive control of LDL cholesterol levels in patients with 
established coronary artery disease (CAD) in line with current secondary prevention protocols 
will lead to improvement in endothelial function and reduced oxidative stress. 
The aims of this study were therefore to compare lipid profiles, endothelial function, and levels 
of vascular superoxide (O2
-
) in a group of patients who underwent coronary artery bypass graft 
surgery in 2003 with patients who underwent surgery in 2007.  
7.3 Methods 
Patients undergoing CABG for severe CAD were recruited as part of the VASCAB study and 
comprised the 2007 CAD cohort. The 2007 cohort of patients was compared to a cohort 
undergoing CABG in 2003. Clinical examination, routine biochemistry, vascular O2
- 
and ex vivo 
endothelial function was performed in both 2003 and 2007 cohorts. VV control patients 
recruited in 2003 and 2007 were recruited to confirm consistency of assessments for vascular 
O2
- 
and ex vivo endothelial function. Detailed methods are provided in chapter 2. 
7.4 Results 
7.4.1 Clinical characteristics and cholesterol levels 
The 2007 group was slightly older and contained more males than the 2003. Diastolic blood 
pressure was lower in the 2007 group (Table.7.1). Control subjects undergoing VV surgery were 
similar between 2003 (n=19; age 48±13 years) and 2007 (n=19; age 48±13 years). In patients 
with CAD, statin use increased from 88% in 2003 to 94% in 2007 (P=0.038). Average statin 
dose increased from 26±16 mg/d in 2003 to 37±17 mg/d in 2007 (P<0.001). Lower total 
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(4.0±0.9 vs. 4.8±1.0 mmol/L; P<0.001) and LDL cholesterol levels (2.0±0.7 vs. 3.0±0.9 
mmol/L; P<0.001) in 2007 reflect this increased statin usage (figure 7.1). HDL cholesterol 
levels were unchanged between 2007 and 2003 (1.1 [0.9: 1.3] vs. 1.2 [1.0; 1.4] mmol/L; 
P=0.124; Figure 7.1).  
7.4.2 Endothelial function 
In patients with CAD endothelium dependent vasodilation, measured as the maximum relaxation 
of saphenous veins to calcium ionophore A23187, was significantly greater in the 2007 
compared to the 2003 group (44±15% vs. 28±12%, P<0.001, n=36 each; Figure 7.2). 
Endothelium-dependent vasodilation remained unchanged in saphenous vein from control 
subjects between 2003 and 2007(maximum response to calcium ionophore A23187 in 2003: 
60±11 %, in 2007: 65±15 %; P=0.252; n=14). 
There was an inverse correlation between LDL cholesterol and endothelial function (r=-0.482, 
P<0.0001 figure 7.3) Linear regression analysis was performed with endothelial function 
(vasodilatory response to calcium inophore) as the dependent variable and characteristics that 
were different between 2003 and 2007 groups (age, sex, diabetes status, smoking status, LDL-C 
levels, diastolic blood pressure, statin dose and ACEI/ARB usage) together with a variable 
indicating year of study as predictors (table 7.2). Only LDL cholesterol contributed significantly 
to endothelial function explaining 15.6% of its variability. 
7.4.3 Vascular O2- generation 
Levels of total vascular O2
-
 were not significantly different between the 2003 and 2007 groups 
(0.77 [0.53; 1.08] vs. 0.50 [0.37; 0.85] nmol/mg/min; P=0.053; n=33 each) although there was a 
trend towards lower levels in the 2007 group (Figure 7.4). Vascular O2
-
 production remained 
unchanged in control subjects between 2003 and 2007 (0.47±0.26 vs. 0.43±0.32 nmol/mg/min, 
P=0.697; n=14). 
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Table 7.1 Demographics and clinical characteristics for patients with CAD in 2003 and 
2007 
 
2003 
n=121 
2007 
n=105 
P-value 
Age (years) 62 ± 9 65 ± 10 0.028 
Male (%) 77 (64%) 84 (80%) 0.003 
BMI (kg/m²) 28.7 ± 4.9 29.5 ± 5.0 0.243 
Systolic BP (mmHg) 140 ± 14 140 ± 24 0.999 
Diastolic BP (mmHg) 82 ±11 78 ± 12 0.009 
Type 2 DM (%) 27 (22%) 28 (27%) 0.092 
Active smokers* (%) 28 (23%) 18 (17%) 0.071 
Aspirin (%) 103 (85%) 88 (84%) 0.140 
Beta blocker (%) 75 (62%) 67 (64%) 0.106 
ACEI or ARB (%) 58 (48%) 55 (52%) 0.085 
Statin (%) 107 (88%) 99 (94%) 0.038 
Simvastatin 68 58 0.148 
Atorvastatin 19 30 0.073 
Pravastatin 11 4 0.069 
Rosuvastatin 0 2 n/a 
Fluvastatin 0 1 n/a 
*Current smokers and recent history of smoking. Continuous variables are mean± standard 
deviation. Discrete variables are absolute numbers and percentage (%) BP, blood pressure, 
ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 7.2 Determinants of endothelial function in the combined 2003 and 2007 cohort 
 Full model (R
2
=0.275) Stepwise model (R
2
=0.156) 
 β P-value β P-value 
Age 0.062 0.558 _ _ 
Sex (0=female;1=male) 0.005 0.965 _ _ 
Type 2 DM 
(0=no;1=yes) 
-0.061 0.562 _ _ 
Active smoking 
(0=no,1=yes) 
0.128 0.245 _ _ 
Diastolic BP  -0.163 0.140 _ _ 
LDL cholesterol -0.0286 0.022 -0.395 <0.001 
ACEI/ARB 
(0=no,1=yes) 
-0.025 0.856 _ _ 
Statin dose -0.058 0.597 _ _ 
Year of study 0.343 0.027 _ _ 
 
In the full model all variables were forced into the model. The stepwise model was developed 
using probabilities of F to enter and remove variables of ≤0.05 and ≥0.10 respectively. β 
indicates the partial correlation coefficients, ACEI, Angiotensin-converting enzyme inhibitor; 
ARB, Angiotensin receptor blocker. 
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Figure 7.1 Total cholesterol, LDL and HDL in patients with CAD in 2003 and 2007 
 
  
2003 n=90 
2007 n=90 
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Figure 7.2 Endothelial function in patients with CAD in 2003 and 2007 
 
  
n=36 n=36 
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Figure 7.3 Scatterplot of maximum response to calcium ionophore and LDL-cholesterol 
levels  
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Figure 7.4.Vascular O2
-
 levels in patients with CAD in 2003 and 2007 
 
 
7.5 Discussion 
The results of this study show that between 2003 and 2007 statin use increased and LDL levels 
decreased. This was paralleled by improved endothelial function in patients with CAD. 
Endothelial function did not change in control subjects between 2003 and 2007. Endothelial 
function is an independent predictor of morbidity and mortality in patients with cardiovascular 
disease 
187-189
. The improvement in endothelial function may provide surrogate evidence for 
improved cardiovascular outcomes as a result of increased targeting of LDL-cholesterol levels. 
LDL was a significant determinant of endothelial function. This is in keeping with previous 
studies 
108;204;205
. LDL levels can contribute to endothelial dysfunction through a number of 
different mechanisms. LDL-cholesterol can impair functioning of eNOS and increase oxidative 
P=NS 
n=33 n=33 
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stress 
297;298
. This will reduce the bioavailability of NO and result in impaired endothelium 
dependent vasodilation.  
LDL levels only accounted for 16% of the variability in endothelial function. Clearly other 
factors in addition to LDL are important in determining endothelial function. Increased 
oxidative stress has frequently been implicated as a major mechanism underlying endothelial 
dysfunction. Both LDL and oxidised LDL increase superoxide production through xanthine 
oxidase, NAD(P)H oxidase and uncoupling of eNOS 
304-306
. Interestingly, despite improvements 
in endothelial function and reduced levels of LDL-cholesterol there were no changes in levels of 
O2
-
 between 2007 and 2003. In this study changes in levels of oxidative stress do not account for 
the improvement in endothelial function seen in the 2007 group. Other determinants of 
endothelial function that differed between 2003 and 2007 included use of ACEi/ARBs, and 
diastolic blood pressure. However these were not significant predictors of endothelial function 
in this cohort of patients. 
Statin dose and the choice of statins differed between the two groups. Statins may have a lipid 
independent effect on endothelial function 
208
. This effect may be different between different 
statins. Statin dose was significantly different between the two groups but was not a predictor of 
endothelial function. The study was too small to analyse the effects of different statins.  
A number of other factors that have been associated with endothelial function were not analysed 
in this study. LDL particle size may be of particular relevance. LDL particle size is associated 
with endothelial function, with small dense LDL being associated with greater impairment of 
endothelial function 
237
. Statin therapy can modulate LDL size causing a shift to larger less 
dense species 
307
. There is however wide variation between the different statins. Fluvastatin and 
atorvastatin are reported most frequently as having the greatest beneficial effect on LDL size, 
pravastatin the least 
277
. 
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Although lower LDL levels in this study were associated with improved endothelial function 
there is clearly other factors that are important in determining endothelial function. Targeting 
LDL levels can only therefore partly correct endothelial dysfunction. Future studies to identify 
these other determinants are required if further improvements in endothelial function and 
cardiovascular outcomes are to be achieved. It would be of interest to see how LDL-cholesterol 
particle size compared between the 2003 and 2007 groups. With regards to statin and LDL 
lowering future studies are required to try and distinguish between statin and LDL effects. 
Finally outcome studies are required to assess whether the improvements in endothelial function 
are associated with improvements in cardiovascular outcomes.  
In chapter 4 diabetes status was the major determinant of endothelial function. Lack of HbA1c 
measurement in the 2003 cohort limited the direct comparison of endothelial function in patients 
with diabetes in 2007 cohorts. From case note review HbA1c was available for a proportion of 
the patients recruited in 2003. The HbA1c levels were however not taken at similar time prior to 
surgery. Although HbA1c gives an indication of blood glucose levels over the preceding 3 
months, HbA1c is a weighted average of blood glucose levels over this time. This means that 
blood glucose levels over the preceding 30 days contribute significantly more to HbA1c levels 
compared to blood glucose levels over days 90-120. It was therefore felt that using HbA1c levels 
that had been obtained over a range of weeks and months was not appropriate. Although the 
effects of LDL lowering would not be expected to be any less in patients with type 2 DM the 
specific effect on patients with type 2 DM remains unclear and cannot be addressed by this 
study. 
Clearly the major limitation of this study is that it is observational rather than a randomised 
controlled trial. It is therefore not possible to make any conclusions as to whether LDL levels 
and statin therapy cause the differences in endothelial function observed or are merely a markers 
for other changes that exist between the two groups. Furthermore this study cannot distinguish 
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relative contributions between LDL levels and statin dose and individual statins. The study 
initially aimed to investigate the effect of aggressive management of LDL-cholesterol levels in 
patients with and with type 2 DM. A number of features of the study design prevented this 
analysis. The small numbers in this study limited sub group analysis. Furthermore as already 
discussed measures of hyperglycaemia such as HbA1c were not available for the 2003 cohort. 
7.6 Chapter summary 
In summary this study has found a significant improvement in endothelial function in patients 
with established CAD in 2007 compared to 2003. This is paralleled by lower LDL cholesterol 
levels and increased statin usage. This improvement in endothelial function was not associated 
with a reduction in levels of oxidative stress. Endothelial function is an independent predictor of 
morbidity and mortality and may provide surrogate evidence for improved survival of patients 
with CAD as a consequence of current secondary prevention guidelines. LDL-cholesterol levels 
however only explain a small proportion of the variability in endothelial function. Further 
studies are therefore required to elucidate the other mechanisms underlying endothelial 
dysfunction in patients with CAD. 
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8 Strategies for managing cardiovascular disease; the role of 
physical activity 
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8.1 Introduction 
8.1.1 Sedentary lifestyles and cardiovascular disease 
For over 50 years it has been recognised that sedentary lifestyles are an important risk factor for 
cardiovascular disease (CVD). In 1953 the now classic epidemiological study by Morris et al.
58
 
showed that bus conductors compared to bus drivers had lower rates of coronary artery (CAD). 
Furthermore when conductors were diagnosed with CAD it tended to be later in life with a lower 
mortality. This difference was partly attributed to the conductors being more physically active at 
work compared to bus drivers. Since then numerous studies have confirmed a reduction in levels 
of CVD with increased levels of physical activity 
69;71
. Increased levels of physical activity also 
reduce the risk of further cardiovascular events in patients with established CVD 
71
. For the 
prevention of CVD it is recommended that individuals take 30 minutes of regular physical 
activity most days of the week 
22
  
Part of the reduction in cardiovascular events can be explained by the effect on conventional risk 
factors. Increasing levels of physical activity increased high density lipoprotein (HDL) levels by 
approximately 3% in both men and women in Heritage study 
51
. Meta-analysis of exercise 
studies on total cholesterol and low density lipoprotein (LDL) levels showed more variable 
results with some but not all studies reporting moderate reductions of total and LDL cholesterol 
following interventions aimed at increasing physical activity 
308
. Increasing physical activity 
reduces blood pressure on average by 3.4/2.4 mmHg however greater reductions can be 
achieved in hypertensive individuals 
309
 Not all the risk reduction can be explained by reductions 
in conventional risk factors, there appears to be an independent effect of exercise 
69
. Other 
mechanisms that may contribute to the beneficial effects of increased physical activity include 
reduced levels of oxidative stress, improved endothelial function, reduced insulin resistance, 
reduced inflammation and improved lipoprotein subclass distribution 
310.  
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8.1.2 Sedentary lifestyles and type 2 diabetes mellitus  
Increasing physical activity is important in both the prevention and management of type 2 
diabetes mellitus (DM). Three large studies the Diabetes Prevention Study (DPS) Diabetes 
prevention project (DPP) and The Da Qing IGT and Diabetes study looked at the role of 
physical activity in the prevention of type 2 DM in high risk populations 
311-313
. All studies 
showed a large and significant reduction in the progression to type 2 DM in individuals 
randomised to exercise programmes. In patients with established type 2 DM meta-analysis has 
shown that increasing physical activity reduces HbA1c by approximately 0.66% 
314
. This is a 
clinically significant result with HbA1c reductions comparable to those achieved in UKPDS and 
of a magnitude that would be expected to result in a reduction of diabetes related complications. 
8.1.3 Physical activity as a strategy for tackling CVD in patients with type 2 DM 
Physical activity may reduce the excess cardiovascular risk associated with insulin resistant 
states such as type 2 DM. The Whitehall study looked at the relationship between levels of 
physical activity and CAD mortality in men with impaired glucose tolerance/diabetes and 
normal glycaemia 
315
. In men with impaired glucose tolerance/diabetes the relationship between 
levels of physical activity and CAD mortality was steeper compared to the normoglycaemic 
men. The risk reduction associated with increased physical activity was therefore greater in 
patients with impaired glucose tolerance/diabetes compared to normoglycaemic individuals 
315
. 
Similar results have been observed in other studies. The aerobic centre longitudinal study found 
unfit men with the metabolic syndrome had cardiovascular mortality rates of 31.0/10000 years 
of observation compared to 11.9/10000 years of observation in fit men with the metabolic 
syndrome
316
. Rates in unfit and fit men without the metabolic syndrome were 19.0 and 5.0 
deaths/10 000 years respectively
316
. 
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8.1.4 Cardiac rehabilitation; a strategy for increasing physical activity  
Across the general population levels of activity are low. In Scotland only 38% of men and 27% 
of women met the recommended weekly levels of physical activity 
72
. There is evidence that 
levels of activity in individuals with type 2 DM may be even lower 
317
. Cardiac rehabilitation is 
defined as a “programme that aims to enable patients with established cardiovascular disease 
maintain optimal physical and psychosocial health” 318. One of the key aspects of cardiac 
rehabilitation is a structured 10-12 week exercise programme. The typical comprehensive 
cardiac rehabilitation programme consists of 4 phases, phase 1 starting whilst the person is 
inpatient, phase 2 immediately following discharge. Phase 3 takes the form of a structured 
exercise programme together with advice and support on risk factors. Phase 4 is the long term 
maintenance of physical activity and lifestyle change e.g. membership of a local gym. In some 
instances exercise only cardiac rehabilitation may be offered. 
A Cochrane review of 32 trials found that exercise only cardiac rehabilitation reduced all cause 
mortality by 27%, cardiac death by 31% and the combined end point of mortality, non fatal MI 
and revascularization by 19% 
319
. There was no additional benefit from comprehensive 
programmes; indeed comprehensive cardiac rehabilitation had a smaller effect on all cause 
mortality. It was unclear why there was the discrepancy between the exercise only programmes 
and comprehensive cardiac rehabilitation and this may simply be a reflection of study design.  
There are few large randomised trials looking at the impact of cardiac rehabilitation programmes 
on cardiac risk factors. In the Cochrane review only a minority of studies analysed lipid levels 
319
. In the studies of exercise only cardiac rehabilitation there was no effect on total cholesterol, 
LDL, HDL or triglycerides. In the comprehensive cardiac rehabilitation studies there was a 
significant reduction in total cholesterol and LDL with no significant changes in HDL and 
inconsistent effects on triglyceride levels. Of the minority of studies that reported blood pressure 
as an outcome there were no significant changes following rehabilitation 
319
. There is little 
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information regarding cardiac rehabilitation in patients with type 2 DM or the effects on 
glycaemic control. 
8.1.5 Cardiac rehabilitation and endothelial function 
Exercise programmes have been shown to improve endothelial function in patients with CAD 
233;235;264
. Edwards et al.
233
 measured endothelial function using brachial FMD before and after 
12 weeks of exercise only cardiac rehabilitation. A control group were patients who did not have 
access to cardiac rehabilitation due to lack of insurance or distance from the rehabilitation class. 
Patients attending cardiac rehabilitation had improved endothelial function compared to the 
control group. This was a small study with only 9 patients in each group, no comment was made 
on diabetes status of patients and there was no assessment of conventional risk factors before 
and after cardiac rehabilitation. Hambrecht et al.
235
 also reported improvements in endothelial 
function in patients with established CVD following increased physical activity. Endothelial 
function assessed during coronary artery angiography improved following 4 weeks of exercise 
training. The mechanisms underlying this improvement were not clear. The patients in this 
group were highly selected, both diabetes and hypercholesterolaemia were exclusion factors. 
Finally Adams et al.
264
 randomized patients either to an exercise group or control group prior to 
surgical revascularisation. Segments of left internal mammary artery obtained at time of bypass 
showed improved endothelial function in the exercise group. This study looked at the effects of 
an in hospital exercise training program rather than more standard cardiac rehabilitation 
programme  and excluded patients with type 2 DM and hypercholesterolaemia. Blood pressure 
fell significantly in the training group but there were no significant differences in lipids or other 
cardiovascular risk factors.  
8.1.6 Cardiac rehabilitation and oxidative stress 
Physical activity may modify levels of oxidative stress. In patients following surgical 
revascularisation circulating markers of oxidative stress; lipid peroxidation products 
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(thiobarbituric acid reactive substances, diene conjugates and lipid hydroperoxide) and markers 
of blood antioxidant levels (total antioxidative capacity and glutathione markers ) were reduced 
following a 12 week exercise programme 
320
. In this study the greatest improvements were seen 
in the patients with lowest levels of fitness. 
In both the studies by Edwards et al.
233
 and Adams et al.
264
 the improvements in endothelial 
function were associated with improvements in markers of oxidative stress. Edwards et al.
233
. 
assessed levels of oxidative stress using total plasma SOD activity, glutathione peroxidase 
activity and levels of isoprostanes. In the cardiac rehabilitation group there was a reduction in 
the levels of oxidative stress. Adams et al.
264
 showed that exercise training was associated with 
reduced expression of NAD(P)H oxidase subunits and NAD(P)H oxidase activity and ROS 
(total superoxide production as measured by SOD inhibitable reduction of ferricytochrome C in 
segments of internal mammary artery obtained at the time of surgery.  
8.2 Aims  
The hypothesis was that phase 3 of the cardiac rehabilitation programme would improve 
endothelial function, reduce oxidative stress and improve HDL levels in patients with 
established CAD. In patients with type 2 DM who have more marked endothelial dysfunction it 
was hypothesised that increasing physical activity would be of greater benefit.  
The aims of this study were using cardiac rehabilitation as a strategy for increasing levels of 
physical activity:  
1. To investigate the effect of phase 3 cardiac rehabilitation on conventional 
cardiovascular risk factors. 
2. To investigate the effect of phase 3 cardiac rehabilitation on endothelial function. 
3. To measure mononuclear and whole blood superoxide (O2
-
) levels as an indicator of 
degree of oxidative stress before and after cardiac rehabilitation. 
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8.3 Methods 
Patients who had undergone CABG and were attending cardiac rehabilitation were recruited to 
assess the effect of increased exercise on endothelial function and levels of O2
-
. Patients were 
assessed before and after a 10 week programme of education and exercise classes provided as 
part of phase 3 of cardiac rehabilitation. Detailed clinical examination and routine biochemistry 
was performed at both visits. Endothelial function was assessed using a PWA based technique. 
Whole blood and mononuclear cell O2
- 
was assessed using EPR. A detailed description of the 
methods used is provided in chapter 2.  
8.4 Results 
Thirty four patients attending cardiac rehabilitation following coronary artery by-pass were 
recruited. Of these patients 29 completed the study and attended for visits both before and after 
cardiac rehabilitation. Demographics for these patients are shown in table 8.1. Three patients 
were unable to attend for the second visit. Reasons included moving from the area, ill health and 
not being available to attend the unit due to a return to work. Two participants were not willing 
to attend for a second visit. 
Clinical examination recordings pre and post cardiac rehabilitation are shown in table 8.2. 
Diastolic blood pressure and heart rate fell significantly following cardiac rehabilitation. There 
was a trend to reduced body mass index and waist circumference but this was not significant. 
Levels of physical activity were assessed by taking total leisure time activity recorded in the 
SPAQ. Levels of physical activity increased significantly following cardiac rehabilitation from 
317.5 [207.5; 567.5] minutes per week to 540[362.5; 1316.3] minutes per week, P<0.0001. 
Functional capacity significantly increased following cardiac rehabilitation from 4.87±0.92 
Metabolic Equivalent of Task (METS) to 5.93±0.98 METS, P<0.0001. 
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Biochemistry results are shown in table 8.3. Total cholesterol and HDL cholesterol increased 
following cardiac rehabilitation. There was a small but significant rise in HbA1c. There were no 
other significant changes. 
Endothelium dependent vasodilation was improved following cardiac rehabilitation. Maximum 
change in peripheral AIx following salbutamol was -8.3±8.2% at visit 2 compared to -1.1±7.5% 
at visit 1, P=0.003(figure 8.1). In 4 patients endothelial function was worse at visit 2. No clear 
reason for this finding could be identified. This aberrant response following exercise did not 
appear to be accounted for by number of exercise classes attended, change in weight, HDL, 
HbA1c or blood pressure. There was no significant difference in endothelium independent 
vasodilation between the two visits; -18.1±8.8% vs.-19.9±8.7% P=NS (figure 8.2).  
There were no significant changes in basal mononuclear cell superoxide release (66.6 
[35.3;102.2] AU vs 53.5 [38.3;102.7] AU P=0.93, figure 8.3), stimulated mononuclear cell 
superoxide release (529.3 [422.2;1056.6] AU vs 441.6 [340.3,829.9] AU, P=0.094,figure 8.4) or 
whole blood superoxide release following cardiac rehabilitation (61.4[30.0;80.8] x 10
3
AU vs 
37[22.8;58.6] x 10
3
 AU, P=0.44,figure 8.5). 
  
 203 
Table 8.1. Demographics of patients attending for cardiac rehabilitation 
 Recruited  
(n=34) 
Completed study 
(n=29) 
Age (years) 66.4±8.4 67.0±8.6 
Male (%)  30(81.1) 25(86.2) 
Current smokers (%) 2(5.4) 0 
Type 2 DM (%) 5(13.5) 4(13.8) 
Hypertension (%) 19(51.4) 15(51.7) 
Myocardial Infarction (%) 20(54.1) 16(55.2) 
Cerebrovascular disease (%) 3(8.1) 2(6.9) 
Chronic renal failure (%) 1(2.7) 0 
Heart failure (%) 3(8.1) 3(10.3) 
Aspirin (%) 36(97.3) 29(100) 
Other antiplatelet agent (%) 4(10.8) 1(3.4) 
Statin (%) 32(86.5) 25(86.2) 
ACEi/ARB (%) 22(59.5) 17(58.6) 
Beta-blocker (%) 27(73.0) 22(75.9) 
Calcium channel blocker (%) 1(2.7) 0 
Nitrate (%) 3(8.1) 2(6.9) 
Diuretic (%) 9(24.3) 6(20.7) 
Oral hypoglycaemic agent (%) 2(5.4) 1(3.4) 
Insulin (%) 0 0 
Continuous variables are mean± standard deviation. Discrete variables are absolute numbers and 
percentage (%) BP, blood pressure, TIA; transient ischaemic attack, CVA, cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 8.2 Clinical examination before and after phase 3 cardiac rehabilitation 
 Pre rehabilitation  
(n=29) 
Post 
rehabilitation 
(n=29) 
P-value 
Systolic BP (mm Hg) 137.8±21.8 135.8±22.2 NS 
Diastolic BP (mm Hg) 81.2±12.5 76.6.3±10.8 0.007 
Heart rate (beats/min) 72.3±10.8 64.9±8.9 0.008 
Body Mass Index (kg/m
2
)
 
 29.3±6.39 28.4±3.80 NS 
Waist circumference (cm) 100.9±9.8 99.5±7.8 NS 
Mean±Standard deviation, BP, blood pressure. 
 
Table 8.3 Basic biochemistry and white cell count results before and after phase 3 cardiac 
rehabilitation 
 Pre rehabilitation  
(n=29) 
Post 
rehabilitation 
(n=29) 
P-value 
Cholesterol (mmol/l) 3.54±0.74 3.84±0.8 0.016 
Triglycerides (mmol/l) 1.38±0.54 1.48±1.0 NS 
LDL (mmol/l) 1.79±0.69 1.93±0.78 NS 
HDL(mmol/l) 1.11±0.3 1.23±0.34 0.004 
CRP(mg/L) 6.21±8.8 4.68±7.0 NS 
HbA1c (%) 5.52±0.38 5.86±0.46 0.04 
Urinary ACR(mmol/l) 4.25±6.21 3.85±6.52 NS 
Fasting Glucose(mmol/l)  5.51±0.17 5.75±0.15 NS 
Total white cell count 
(10
9
/L) 
7.03±1.88 6.48±1.38 NS 
Lymphocytes(%) 31.4±8.2 33.7±8.1 NS 
Mononuclear cell (%) 8.2±2.9 5.9±2.3 NS 
Granulocytes(%) 60.3±9.1 60.4±9.1 NS 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP C-reactive protein; HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio. 
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Figure 8.1. Endothelium dependent vasodilation pre and post cardiac rehabilitation 
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Figure 8.2. Endothelium independent vasodilation following cardiac rehabilitation 
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Figure 8.3 Basal mononuclear cell O2
-
 production before and after cardiac rehabilitation 
 
  
P=NS 
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Figure 8.4 Stimulated mononuclear cell O2
-
 production before and after cardiac 
rehabilitation 
 
  
P=NS 
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Figure 8.5 Whole blood O2
- 
production before and after cardiac rehabilitation 
 
 
8.5 Discussion 
Endothelial function improved significantly following completion of the phase 3 stage of cardiac 
rehabilitation. Levels of oxidative stress as assessed by mononuclear and whole blood O2
-
 levels 
were not altered by cardiac rehabilitation program. There was a significant increase HDL-
cholesterol following cardiac rehabilitation. 
The finding of improved endothelial function following cardiac rehabilitation is in keeping with 
a number of other studies
233;235;264
. Endothelial function is an important predictor of 
P=NS 
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cardiovascular morbidity and mortality. The improvements in endothelial function seen in this 
study may result in improved cardiovascular outcomes. In the studies by Adams et al.
264
 and 
Edwards et al.
233
 reductions in levels of oxidative stress occurred alongside the improvements in 
endothelial function. Reduced levels of oxidative stress were therefore thought to be the 
mechanism underlying improved endothelial function. In this study there were no changes in 
mononuclear cell or whole blood O2
-
 levels in our patients following cardiac rehabilitation, 
suggesting that reduced levels of oxidative stress did not underlie the improvements in 
endothelial function observed.  
Low HDL levels are a strong risk factor for CVD 
48-50
. Previous studies have shown HDL 
cholesterol levels are correlated with endothelial function 
209
. It is well established that HDL can 
be increased by increasing levels of physical activity 
51
. Some but not all previous studies have 
shown an improvement in levels of HDL following cardiac rehabilitation 
319
. In this study there 
was a significant increase in HDL cholesterol following 10 weeks of exercise training as part of 
cardiac rehabilitation. The increase in HDL levels in our study may partly account for the 
improvement in endothelial function observed. HDL can contribute to improvements in 
endothelial function through a number of mechanisms including activation of endothelial nitric 
oxide synthase (eNOS) 
281
. 
HDL levels may simply be a marker for increased levels of physical activity with other 
mechanisms driving the improvements in endothelial function observed. In addition to 
increasing HDL cholesterol levels increased physical activity can alter lipoprotein composition. 
Exercise increases the mean size of HDL and LDL particles 
284
 . Small dense LDL particles have 
a number of features that are atherogenic and are associated with endothelial dysfunction 
237
.  
Increased insulin sensitivity is likely to partly account for the reduction in cardiovascular 
mortality associated with increased levels of physical activity 
321
. Insulin resistance is associated 
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with endothelial dysfunction 
197
. Insulin resistance may contribute to impaired endothelial 
function through impairment of insulin stimulated nitric oxide (NO) production 
197;199
. 
Improving insulin sensitivity pharmacologically with thiazolidinediones or metformin has been 
shown in small studies to improve endothelial function 
230;231
. Insulin resistance was not 
formally assessed in this study. There was a small although non-significant reduction in waist 
circumference measurements. Even small reductions in central obesity may be associated with 
improvements in insulin sensitivity 
60
. 
Increasing levels of physical activity may be a strategy for tackling endothelial dysfunction in 
patients with established CVD. This strategy may be particularly beneficial in patients with type 
2 DM who have a greater degree of endothelial impairment and higher cardiovascular risk 
compared to patients without diabetes. In these patients insulin resistance is thought to be a key 
mechanism underlying increased cardiovascular risk and endothelial dysfunction 
15;18;199
. The 
improvements in endothelial function seen following cardiac rehabilitation in this study may be 
partly mediated by improvements in HDL levels. There are currently no pharmacological agents 
that specifically increase HDL, lifestyle changes such as increasing physical activity are 
therefore the main strategy for addressing low HDL levels. Four patients in this study had worse 
endothelial function following exercise. The reasons for this aberrant response were not clear. 
Future studies are required to assess the frequency and intensity of exercise required for 
improvements in endothelial function. In addition long term follow-up studies are required to 
assess whether improved endothelial function is associated with improved cardiovascular 
outcomes. It will also be important to investigate the role of other mechanisms such as LDL 
particle size and insulin resistance that may contribute to improved endothelial function 
following increased physical activity. 
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There are a number of limitations to this study. This study was a cross-sectional observational 
study. The lack of a control group clearly limits the conclusions that can be drawn from this 
study with regard to the causal link between increased physical activity and improvements in 
endothelial function. When designing the study the lack of a control group was of concern. 
Cardiac rehabilitation is a standard part of a patients management post cardiac events that is 
known to reduce morbidity and mortality. It would therefore have been unethical to recruit a 
control group who were not offered cardiac rehabilitation. When designing the study it had been 
hoped to partially compensate for a lack of control group by looking at the number of exercise 
classes attended however the final number of patients recruited made this analysis impossible. 
One of the aims of this study was to assess the effect of increased physical activity on 
endothelial function in patients with type 2 DM however due to the small numbers of patients 
recruited were not able to look at this group separately. Increased insulin sensitivity is thought to 
be an important mechanism of the improved endothelial function and reduced cardiovascular 
risk associated with increased physical activity. Insulin sensitivity was not formally assessed in 
this study so it is not possible to comment on this mechanism.  
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9 Final discussion 
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9.1 Discussion 
Type 2 diabetes mellitus (DM) is associated with 2-4 fold increase in risk of cardiovascular 
disease (CVD) compared to patients without diabetes 
9
. Type 2 DM is dramatically increasing in 
prevalence due to a combination of an ageing population, obesity epidemic and increasingly 
sedentary lifestyles
4
. Currently management of cardiovascular risk in patients with type 2 DM 
focuses on control of blood pressure, low density lipoprotein (LDL) and hyperglycaemia. Recent 
studies such as ADVANCE and ACCORD have highlighted the limitations of this approach
26;27
. 
New strategies are needed particularly in light of the predicted worldwide rise in cases of type 2 
DM. Changes in the mechanical and functional properties of arteries are key in the development 
of atherosclerotic plaques that cause coronary artery disease (CAD) 
74;82;93
. Understanding these 
process and the underlying mechanisms should help identify new management strategies.  
I have shown using ex vivo and in vivo techniques that endothelial function is impaired in 
patients with CAD compared to healthy controls. This finding is in keeping with a plethora of 
previously published work 
87;109;179;182;187;188
. Furthermore using ex vivo techniques I have 
confirmed that endothelial function is significantly worse in patients with CAD and type 2 DM 
compared to patients with CAD alone 
110;194;195
. Endothelial dysfunction is an important 
prognostic factor in patients with established CVD 
187;188
. It is hoped that improving endothelial 
function will improve cardiovascular outcomes. The majority of patients in this study were well 
treated with established cardiovascular secondary prevention therapies. Cardiovascular risk 
factors including blood pressure, LDL levels and hyperglycaemia were also well controlled. 
That endothelial dysfunction persists in these patients highlights the need for novel therapeutic 
strategies. Type 2 DM was the only significant determinant of endothelial dysfunction. The 
mechanisms underlying endothelial dysfunction are not fully understood but may include 
hypergylcaemia, insulin resistance, dyslipidaemia and oxidative stress 
84;87;89;108;197;204;205
. 
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Understanding the development of endothelial dysfunction in patients with type 2 DM may 
identify novel cardiovascular prevention strategies.  
Previous evidence supported increased oxidative stress as the major mechanism underlying 
endothelial dysfunction in type 2 DM 
87
. In my study superoxide (O2
-
) levels were similar in 
patients with and without type 2 DM, suggesting that increased oxidative stress did not account 
for the increased endothelial dysfunction associated with type 2 DM. The reasons underlying the 
different findings in this study compared to earlier reports of elevated oxidative stress in type 2 
DM are not clear. It is hypothesised that the pharmacological management of the patients with 
type 2 DM may have lowered O2
-
 levels to those of patients without diabetes. Use of 
Angiotenisn-converting enzyme inhibitors (ACEi) and Angiotensin receptor blockers (ARBs) 
are more widespread in patients with CAD and type 2 DM compared to CAD alone. These 
agents have been shown to lower NAD(P)H oxidase vascular O2
- 
production
262
. Statins have also 
been shown to reduce O2
-
 production
263
. The use of statins was high in patients with and without 
type 2 DM. Finally approximately half of patients with type 2 DM were taking metformin. 
Metformin has been shown to reduce oxidative stress in cultured cells 
265
. The results of this 
study do not refute the role of oxidative stress in the development of endothelial dysfunction but 
does suggest that oxidative stress does not explain endothelial dysfunction associated with type 
2 DM in this group of patients.  
Type 2 DM and other insulin resistant states are associated with low high density lipoprotein 
(HDL) levels and a preponderance of small dense LDL particles
40;268
. This pattern of 
dyslipidaemia was confirmed in patients with type 2 DM and CAD in this study. Small dense 
LDL particles have been associated with increased cardiovascular risk and endothelial 
dysfunction
237;276
. Low HDL levels are also an important cardiovascular risk factor and 
associated with endothelial dysfunction
49;50;209
. It is proposed that the persisting dyslipidaemia 
seen in patients with type 2 DM may partly explain the endothelial dysfunction that was 
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observed. The optimal treatment for the specific lipid abnormalities associated with insulin 
resistance is complex. Fibrates reduced triglyceride levels increase HDL and increase LDL 
particle size. In theory fibrates are an optimal therapy however results from the ACCORD study 
question this approach 
290
 . In ACCORD fenofibrate added to statin therapy was not associated 
with improved cardiovascular outcomes. Whether fibrate therapy may be of benefit in selected 
patients is currently unclear. Insulin resistance is understood to be the major process driving 
lipid abnormalities associated with type 2 DM 
268;271
. Strategies that improve insulin sensitivity 
such as increased physical activity are therefore of interest in the management of the 
dyslipidaemia associated with type 2 DM.  
Structural changes in the vasculature such as increased arterial stiffness are understood to play 
an important role in the development of cardiovascular disease
80;93;119
. Age and hypertension are 
the key determinants of arterial stiffness
122
. The relative contribution of other factors such as 
type 2 DM and hypercholesterolaemia is currently uncertain
122
. Furthermore the optimal 
methods for assessing arterial stiffness in routine clinical care unclear. Aortic pulse wave 
velocity (PWV) is currently the gold standard method for assessing arterial stiffness although 
this method is associated with a number of limitations
121
. This study has shown increased aortic 
PWV in patients with CAD compared to control in keeping with other studies. The problems 
associated with measurement of aortic PWV are well recognised and were highlighted in this 
study. The difficulties associated with recording aortic PWV make simpler methods attractive. 
Other surrogate markers of arterial stiffness including augmentation index (AIx), and brachial 
PWV were not increased in this cohort of patients with CAD. The use of these surrogate 
markers of arterial stiffness has been previously called in to question by the results of other 
studies 
127;137;155
. This study adds further weight to the evidence against these other measures of 
arterial stiffness in preference to aortic PWV. Time to reflected wave (TR) assessed by PWA is 
a simple measure that correlates with PWV
176
. TR was significantly reduced in patients with 
 217 
CAD compared to controls. The use of TR as a simple surrogate measure of arterial stiffness 
warrants further investigation. Although there is a wealth of evidence for increased arterial 
stiffness in patients with type 2 DM this study was unable to confirm this observation. This 
finding is in keeping with the meta-analysis by Cecelja et al.
122
. showing diabetes status 
accounts for only a small proportion of variability in arterial stiffness. The role of assessing 
arterial stiffness and the optimal techniques for doing this in routine clinical care remain unclear.  
Intensive cholesterol lowering has increasingly been a strategy for preventing CVD in high risk 
patients such as those with diabetes or established CVD. Intensive statin therapy may improve 
endothelial function through both reductions in LDL levels and lipid independent effects
206-208
. 
This study found that in 2007 compared to 2003 LDL levels were significantly lower, statin 
usage increased and endothelial function improved. Endothelial function is an important 
prognostic factor in patients with established CVD 
187;188
. The increased endothelial function 
seen in this study may therefore provide indirect evidence for improved cardiovascular 
outcomes as the result of intensive lipid lowering strategies. Oxidative stress has been proposed 
as one mechanism by which LDL levels contribute to endothelial dysfunction 
87;179
. The reduced 
LDL levels and improved endothelial function observed in the 2007 cohort of patients was not 
associated with reduced levels of oxidative stress. This finding adds further weight to the 
findings of chapter 3 that suggest oxidative stress may not be a key contributor to the endothelial 
dysfunction in this group of patients. LDL levels only accounted for less than a fifth of the 
variability in endothelial function. Other mechanisms are clearly important and remain to be 
elucidated. The specific effect of intensive LDL lowering in patients with type 2 DM could not 
be determined by this study. 
Insulin resistance is also thought to be an important factor underlying both development of CVD 
and endothelial dysfunction
15;197
. Type 2 DM is by definition an insulin resistant state. Insulin 
resistance is also common in patients with established CAD without overt diabetes
227
. Increased 
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physical activity is associated with reduced cardiovascular risk and this is likely to be in part due 
to improved insulin sensitivity 
69
. This study showed increased physical activity following the 
cardiac rehabilitation programme improved endothelial function in patients with type 2 DM, 
possibly mediated through increased HDL levels. A “prescription” of regular supervised 
exercise classes, similar to the cardiac rehabilitation programme may be a strategy for reducing 
the cardiovascular risk associated with type 2 DM. Exercise classes as a cardiovascular 
management strategy are attractive as the risks/side effects are low and there are likely to be 
multiple additional benefits. Increased physical activity may help to address a number of 
cardiovascular risk factors such as HDL levels, LDL particle size, insulin resistance that are not 
well controlled with currently available drugs
51;310
. 
9.2 Study limitations  
Clearly there are a number of limitations with this study. The major limitations are discussed 
below. 
Firstly the number of patients and controls recruited in to this study was relatively small. This 
may have been of particular importance when comparing the differences between patients with 
and without type 2 DM in whom the numbers were further still. The effect of type 2 DM on 
arterial stiffness in a group of patients with established CAD are likely to be small. This study is 
likely to have been under powered to detect such small differences within groups of patients. 
However despite the small numbers of patients within this study a number of clearly significant 
differences such as endothelial function were identified between patients with and without type 
2 DM.  
One of the major themes of this study was to assess the effect of type 2 DM on cardiovascular 
phenotypes. In a number of the sub-studies in particular the arterial stiffness and cardiac 
rehabilitation studies that number of patients with diabetes was smaller than expected. This 
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limited the conclusions that can be drawn specifically regarding the impact of diabetes and will 
further studies are required to address this shortcoming.  
All the sub-studies that form this thesis are observational. Although a number of important 
associations have been identified as part of this study causation cannot clearly be attributed. For 
example prospective interventional studies would be required to ascertain whether there is a 
direct causative role between low HDL levels and endothelial dysfunction.   
The main technique employed to assess endothelial dysfunction was an ex vivo technique. Ex 
vivo techniques are clearly limited by the availability of tissue but the results also need to be 
interpreted carefully as the samples may behave differently compared to when in vivo. 
Alternative in vivo measures of endothelial function were used when possible and confirmed the 
ex vivo results. 
Due to the nature of the ex vivo tests used (endothelial function testing and vascular O2
-
 
assessment) the characteristics of the control group was significantly different to the patient 
group in terms of age and gender. This limits some of the conclusions that can be drawn with 
regards to mechanisms underlying differences between the two groups. A further control group 
for in vivo studies was recruited that was better matched in terms of age and sex and partially 
compensated for the limitations of the ex vivo control group.  
9.3 Future directions 
One of the key findings of this study is that endothelial dysfunction remains a major problem in 
patients with type 2 DM which is not adequately addressed by current cardiovascular prevention 
strategies. This endothelial dysfunction may partly account for the worse cardiovascular 
outcomes associated with type 2 DM. Results from this study have shown some potential 
therapeutic targets that may result in improved endothelial function. Correcting the specific lipid 
abnormalities associated with insulin resistant states, namely low HDL and small dense LDL, 
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may be of particular benefit. Furthermore use of structured exercise programmes to increase 
levels of physical activity may be beneficial by targeting cardiovascular risk factors such as low 
HDL levels that are not presently well addressed by currently available cardiovascular 
prevention therapies. Future studies to assess the impact on cardiovascular outcomes in addition 
to surrogate markers such as endothelial function are required. 
A large proportion of the variability in endothelial function found was not explained by factors 
measured as part of this study. Understanding these mechanisms may identify more targeted 
approaches than those discussed above. The role of mitochondrial dysfunction in the 
development of insulin resistant states such as type 2 DM and complications of diabetes is of 
particular interest. Mitochondrial function has been shown to be impaired in insulin resistant 
states
322
. This impairment in mitochondrial function is thought to be due to smaller and fewer 
mitochondria
322
. Mitochondrial dysfunction is thought to be an important mechanism underlying 
insulin resistance in skeletal muscle
322
. Mitochondrial dysfunction is also thought to play an 
important role in the development of atherosclerotic lesions and endothelial dysfunction
323;324
. 
Endothelial mitochondrial dysfunction may contribute to endothelial dysfunction through a 
number of mechanisms including increased oxidative stress, altered intracellular calcium 
signalling and endothelial cell apoptosis amongst others
323;325
. Factors thought to contribute to 
mitochondrial dysfunction include aging, genetic factors, oxidative stress
322-324
. Strategies that 
improve mitochondrial function may therefore reduce insulin resistance and improve 
cardiovascular outcomes. Both thiazolidinediones and metformin have been shown to increase 
mitochondrial biogenesis 
265
. Aerobic exercise has also been shown to increase mitochondrial 
biogenesis
322
. Novel agents that target mitochondrial oxidative stress are of particular interest. 
Ongoing work in the VASCAB cohort of patients by Dr Ruth Mackenzie has suggested 
increased levels of mitochondrial oxidative stress in patients with CAD and type 2 DM 
compared to patients with CAD alone (data submitted for PhD thesis to University of Glasgow, 
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2010). MitoQ10 is a mitochondrial targeted antioxidant that is currently the focus of the 
cardiovascular research group lead by Professor Dominiczak. Work from this group has shown 
MitoQ10 is associated with improved endothelial function in animal studies 
326
.  
In summary based on the work in this thesis future directions should include studies to 
investigate the effect of improving endothelial function (through the management of 
dyslipidaemia and insulin resistance) on cardiovascular outcomes in patients with type 2 DM. 
Further studies are also required to elucidate the additional mechanisms that are contributing to 
endothelial dysfunction in patients with type 2 DM as only a proportion of the variability to be 
explained by conventional cardiovascular risk factors. 
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10 Supplementary data 
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10.1 Participant questionnaire 
All participants recruited to the VASCAB study completed a questionnaire to provide detailed 
information regarding lifestyle and medical history.  
Figure 10.1. Participant questionnaire 
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10.2 Scottish physical activity questionnaire 
Participants recruited to the exercise study were asked to complete the Scottish physical activity 
questionnaire at visits 1 and 2. 
Figure 10.2 Scottish physical activity questionnaire. 
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Figure 10.3 Letter of ethical approval for VASCAB study 
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Figure 10.4 Letter of ethical approval for exercise study. 
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10.3 VASCAB study participants 
10.3.1 All participants  
In total 126 patients with coronary artery disease (CAD) undergoing elective coronary artery 
bypass grafting (CABG) were recruited for the VASCAB study. Eighty control subjects were 
recruited in total. Table 10.1 shows demographics and clinical characteristics for patients with 
CAD compared to all controls. Control patients were younger than CAD patients. A higher 
proportion of the patients with CAD were male. There was no difference in systolic blood 
pressure between the two groups however patients with CAD had significantly lower diastolic 
blood pressure. Body mass index was significantly higher in patients with CAD compared to 
controls. As would be expected the use of secondary cardiovascular prevention therapies such as 
aspirin, statins and modifiers of rennin-angiotensin system was widespread in patients with 
CAD.  
The control group consisted of 64 healthy controls and 16 patients attending for elective 
varicose vein surgery. The patients undergoing varicose vein (VV) surgery were significantly 
younger than the healthy controls otherwise the group were similar. Table 10.2 shows the 
participant characteristics for the healthy controls compared to VV controls. 
Table 10.3 shows the biochemistry results for patients with CAD compared to all controls. Total 
cholesterol and low density lipoprotein (LDL) levels were significantly lower in the patients 
with CAD reflecting the widespread use of statins in this group. Triglyceride levels were 
significantly higher and high density lipoprotein (HDL) levels significantly lower in the CAD 
group. C-reactive protein (CRP), glycated haemoglobin (HbA1c) and urinary albumin to 
creatinine ratio (ACR) were all significantly higher in the patients with CAD.  
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Table 10.4 shows the biochemistry results for healthy controls compared to VV controls. 
Healthy controls had higher LDL levels compared to the patients undergoing VV surgery there 
were no other significant differences. 
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Table 10.1. Participant characteristics for patients with CAD and all controls in the 
VASCAB study 
 CAD 
(n=126) 
All controls (n=80) P-value 
Age (years) 66.1 ±9.34 59.6±11.6 <0.0001 
Male (%) 100(79.4) 43(53.8) <0.0001 
Systolic Blood pressure (mm Hg) 138.7±23.6 137.2±18.6 NS 
Diastolic Blood pressure (mm Hg) 77.8±11.8 81.4±10.4 0.028 
Heart rate (beats/min) 64.4±12.3 68.6±12.6 0.022 
Body Mass Index (kg/m
2 
) 29.4±4.84 25.9±3.5 <0.0001 
Current smokers (%) 11 (8.7)  5(6.3) NS 
Type 2 diabetes mellitus (%) 36(28.6) 0 n/a 
Hypertension (%) 69(54.8) 21(26.3) <0.0001 
Myocardial Infarction (%) 63(50) 0 n/a 
TIA/CVA (%) 9(7.1) 1(1.3) NS 
Chronic renal failure (%) 7(5.6) 0 NS 
Heart failure (%) 22(17.5) 0 n/a 
Aspirin (%) 105(83.3) 10(13) <0.0001 
Other antiplatelet agent (%) 34(27.0) 1(1.3) <0.0001 
Statin (%) 109(86.5) 9(11.3) <0.0001 
ACEi/ARB (%) 74(58.7) 6(7.5) <0.0001 
Beta-blocker (%) 94(74.6) 5(6.3) <0.0001 
Calcium channel blocker (%) 41(32.5) 5(6.3) <0.0001 
Nitrate (%) 68(54) 0 <0.0001 
Diuretic (%) 31(24.6) 6(7.5) 0.001 
Oral hypoglycaemic agent (%) 24(19) 0 n/a 
Insulin (%) 8(6.3) 0 n/a 
Continuous variables are mean ± standard deviation. Discrete variables are absolute numbers 
and percentage (%) TIA; transient ischaemic attack, CVA, cerebrovascular accident. ACEi, 
Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 10.2 Participant characteristics for healthy controls and patients with VV recruited 
for the VASCAB study 
 Healthy 
controls 
(n=64) 
Varicose vein 
controls (n=16) 
Age (years) 61.6±8.23 52.8±18.6 
Male (%) 37(57.8) 7(43.8)* 
Systolic Blood pressure (mm Hg) 137.2±18.4 137.3±22.2 
Diastolic Blood pressure (mm Hg) 81.0±10.20 84.1±11 
Heart rate (beats/min) 67.8±11.76 75.2±15.6 
Body Mass Index (kg/m
2 
) 25.9±3.68 26.5±1.8 
Current smokers (%) 3(4.7) 2(12.5) 
Type 2 diabetes mellitus (%) 0 0 
Hypertension (%) 18(28.1)  2(12.5) 
Myocardial Infarction (%) 0 0 
TIA/CVA (%) 0 1(6.3)** 
Chronic renal failure (%) 0 0 
Heart failure (%) 0 0 
Aspirin (%) 8(12.5) 2(12.5) 
Other antiplatelet agent (%) 0 1(6.3) 
Statin (%) 7(10.9) 2(12.5) 
ACEi/ARB (%) 5(7.8) 2(12.5) 
Beta-blocker (%) 4(6.3) 2(12.5) 
Calcium channel blocker (%) 4(6.3) 0 
Nitrate (%) 0 0 
Diuretic (%) 4(6.3) 1(6.3) 
Continuous variables are mean ± standard deviation. Discrete variables are absolute numbers 
and percentage (%) TIA; transient ischaemic attack, CVA, cerebrovascular accident. ACEi, 
Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker.*P=0.038, 
**P=0.01. 
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Table 10.3 Biochemistry results for all CAD participants compared to all controls.  
 CAD  
 (n=126) 
All controls 
(n=80) 
P-value 
Cholesterol (mmol/L) 4.00±0.94 5.70±1.14 <0.0001 
Triglycerides (mmol/L) 2.04±1.21 1.51±0.78 0.001 
LDL(mmol/L) 1.92±0.74 3.46±1.01 <0.0001 
HDL(mmol/L) 1.17±0.31 1.55±0.41 <0.0001 
CRP(mg/L) 4.09±8.08 2.00±2.33 0.003 
HbA1c (%) 6.16±1.12 5.52±0.31 <0.0001 
Urinary ACR (mg/mmol) 4.58±17.6 1.30±0.92 0.019 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C-reactive protein;HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio. 
Table 10.4 Biochemistry results for healthy controls compared to VV controls. 
 Healthy 
controls(n=64) 
VV control (n=16) 
Cholesterol (mmol/L) 5.81±1.14 4.99±0.92 
Triglycerides (mmol/L) 1.54±0.81 1.29±0.55 
LDL(mmol/L) 3.57±0.98 2.75±1.04* 
HDL(mmol/L) 1.53±0.42 1.64±0.36 
CRP(mg/L) 1.78±1.96 3.42±3.87 
HbA1c (%) 5.53±0.33 5.41±0.15 
Urinary ACR (mg/mmol) 1.31±0.97 1.22±0.44 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C-reactive protein;HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio.*P=0.034. 
10.3.2 Patients with type 2 diabetes mellitus 
Thirty seven (28.6%) of the participants with CAD had type 2 diabetes mellitus (DM). 
Participant characteristics for participants with CAD and type 2 DM compared to those with 
CAD alone are shown in 10.5.The patients with type 2 DM had significantly higher body mass 
index (BMI) compared to those with CAD alone. There was higher prevalence of hypertension 
in the patients with type 2 DM. Use of both diuretics and ACEi/ARB was higher in patients with 
type 2 DM. 
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Patients with type 2 DM and CAD had significantly lower HDL levels compared to patients 
with CAD alone (table 10.6). As would be expected HbA1c levels were higher in patients with 
type 2 DM.  
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Table 10.5 Participant characteristics for patients with CAD and type 2 DM and patients 
with CAD alone 
 CAD alone 
(n=90) 
CAD and type 2 
DM (n=36) 
P-value 
Age (years) 65.7±9.2 66.9±10.0 NS 
Male (%) 67(77) 31 (83.8) NS 
Systolic BP (mm Hg) 139.0±24.8 140.3±19.7 NS 
Diastolic BP (mm Hg) 78.8±11.3 74.7±12.7 NS 
Heart rate (beats/min) 64.0±12.6 64.6±11.6 NS 
Body Mass Index, kg/m
2
 28.7±4.8 31.3±4.6 0.014 
Current smokers (%) 8(9.2) 3(8.1) NS 
Hypertension (%) 36(41.4) 33(89.2) 0.0001 
Myocardial Infarction (%) 41(47.1) 22(59.5) NS 
TIA/CVA (%) 5(5.7) 4(10.8) NS 
Chronic renal failure (%) 5(5.7) 2(5.4) NS 
Heart failure (%) 11(12.6) 11(29.7) NS 
Aspirin (%) 72(82.8) 33(89.2) NS 
Other antiplatelet agent (%) 26(29.9) 9(24.3) NS 
Statin (%) 76(87.4) 35(94.6) NS 
ACEi/ARB (%) 45(51.7) 30(81.1) 0.007 
Beta-blocker (%) 64(73.6) 31(83.8) NS 
Calcium channel blocker (%) 25(28.7) 17(45.9) NS 
Nitrate (%) 51(58.6) 19(51.4) NS 
Diuretic (%) 14(16.1) 18(48.6) 0.001 
Oral hypoglycaemic agent (%) 
Metformin 
Sulphonylurea  
Thiazolidinediones 
0 23(62.2) 
17 (47.2) 
13 (36) 
4 (11) 
n/a 
Insulin (%) 0 8(21.6) n/a 
Continuous variables are mean ± standard deviation. Discrete variables are absolute numbers 
and percentage (%) TIA; transient ischaemic attack, CVA, cerebrovascular accident. ACEi, 
Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 10.6 Biochemistry results in patients with CAD alone compared to patients with 
CAD and type 2 DM 
 CAD alone 
(n=90) 
CAD and type 2 
DM 
(n=36) 
P-value 
Cholesterol (mmol/L) 4.09±0.91 3.82±0.99 NS 
Triglycerides (mmol/L) 1.92±0.89 2.38±1.71 NS 
LDL (mmol/L) 2.00±0.73 1.74±0.74 NS 
HDL (mmol/L) 1.21±0.33 1.07±0.24 P=0.030 
CRP(mg/L) 4.29±8.75 3.78±6.60 NS 
HbA1c (%) 5.62±0.37 7.39±1.29 <0.0001 
Urinary ACR(mg/mmol) 2.31±6.24 3.59±4.17 0.021 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C-reactive protein; HbA1c, glycated haemoglobin; urinary ACR, urinary 
albumin:creatinine ratio. 
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